Arthritis, Rheumatoid
Conditions
Keywords
DMARD therapy
Brief summary
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid arthritis.
Interventions
DRUGCP-690,550
4 blinded tablets administered BID
OTHERplacebo
Placebo
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Active rheumatoid arthritis * Inadequate response to stably dosed methotrexate
Exclusion criteria
* Current therapy with any DMARD or biologic other than methotrexate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | Week 12 | ACR20 response: \>= 20% improvement in tender joints count (TJC); \>= 20% improvement in swollen joints count (SJC); and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad. |
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2, 4, 6, 8, 16, 20, 24/Early Termination (ET) | ACR20 response: \>= 20% improvement in TJC; \>= 20% improvement in SJC; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP. |
| Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 2, 4, 6, 8, 12, 16, 20, 24/ET | ACR50 response: \>= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP. |
| Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2, 4, 6, 8, 12, 16, 20, 24/ET | ACR70 response: \>= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP. |
| Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Baseline up to Week 2, 4, 6, 8, 12 | ACR-n: calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The area under the curve (AUC) for ACR-n is the measure of the area under the curve of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC. |
| Tender Joints Count (TJC) | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. |
| Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement. |
| Swollen Joints Count (SJC) | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. |
| Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement. |
| Patient Assessment of Arthritis Pain | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain. |
| Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain. |
| Patient Global Assessment (PtGA) of Arthritis | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | Participants answered: Considering all the ways your arthritis affects you, how are you feeling today? Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly. |
| Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | Participants answered: Considering all the ways your arthritis affects you, how are you feeling today? Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly. |
| Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. |
| Physician Global Assessment of Arthritis | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad. |
| C-Reactive Protein (CRP) | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per deciliter (mg/dL) to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. |
| Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultra-sensitive assay. Normal range of CRP is 0 mg/dL to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. |
| Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (\<=) 3.2 implied low disease activity and more than (\>) 3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) less than (\<) 2.6 = remission. |
| Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission. |
| Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2, 4, 6, 8, 12, 16, 20, 24/ET | Disease improvement was classified as good, moderate, and none based on improvement in DAS 28-3 (CRP) from baseline and present DAS 28-3 (CRP) score. Good: an improvement from baseline of \>1.2 and a present score of \<=3.2; none: an improvement of \<=0.6 or \>0.6 to \<=1.2 with a present score of \>5.1; remaining participants were classified as having moderate (Mod) improvement. Scores of good and moderate were considered to have therapeutic response. |
| Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2, 4, 6, 8, 12, 16, 20, 24/ET | DAS28-3 (CRP) defined remission was classified as a score of \<2.6. |
| 36-Item Short-Form Health Survey (SF-36) | Baseline, Week 12, 24/ET | SF-36 is a standardized survey evaluating 8 domains (of 2 components \[C\]; physical \[Ph\] and mental \[Mn\]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \[R-P\], role-emotional \[R-E\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). |
| Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Baseline, Week 12, 24/ET | SF-36 is a standardized survey evaluating 8 domains (of 2 components \[C\]; physical \[Ph\] and mental \[Mn\]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \[R-P\], role-emotional \[R-E\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). |
| Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Baseline, Week 12, 24/ET | EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. |
| Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Baseline, Week 12, 24/ET | EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. |
| Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline, Week 2, 12, 24/ET | Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0)and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range\* 100); total score range: 0 to 100; higher score = greater intensity of attribute. |
| Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Baseline, Week 2, 12, 24/ET | Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range: 0-100); sleep quantity (Qua) (range: 0-24), and optimal (Opt) sleep (yes: 1, no: 0) and 9 item index measures of sleep disturbance were constructed to provide 2 composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range\*100); total score range: 0 to 100; higher score = greater intensity of attribute. |
| Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline, Week 2, 12, 24/ET | FACIT-Fatigue scale (FS) is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status. |
| Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Baseline, Week 2, 12, 24/ET | FACIT-FS is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status. |
| Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET | HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Change = scores at observation minus score at Baseline, and total possible score ranged from -3 to 3. A negative value in change from baseline indicates an improvement. |
Countries
Argentina, Brazil, Bulgaria, Chile, Czechia, Hungary, Mexico, Poland, Slovakia, Spain, Sweden, Turkey (Türkiye), United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| CP-690,550 1 mg CP-690,550 1 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 1 mg to 5 mg (R) treatment arm for next 12 weeks. | 70 |
| CP-690,550 3 mg CP-690,550 3 mg tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 3 mg to 5 mg (R) treatment arm for next 12 weeks. | 68 |
| CP-690,550 5 mg CP-690,550 5 mg tablet orally twice daily for 24 weeks. | 71 |
| CP-690,550 10 mg CP-690,550 10 mg tablet orally twice daily for 24 weeks. | 74 |
| CP-690,550 15 mg CP-690,550 15 mg tablet orally twice daily for 24 weeks. | 75 |
| CP-690,550 20 mg CP-690,550 20 mg tablet orally once daily as morning dose and matching placebo tablet orally once daily as evening dose for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to CP-690,550 20 mg to 5 mg (R) treatment arm for next 12 weeks. | 80 |
| Placebo Matching placebo tablet orally twice daily for 24 weeks. Participants who failed to achieve a minimum improvement of at least 20 % reduction in both swollen and tender joint counts over baseline at Week 12 visit were reassigned to Placebo to CP-690,550 5 mg (R) treatment arm for next 12 weeks. | 69 |
| Total | 507 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Post Week 12 | Adverse Event | 2 | 0 | 2 | 1 | 4 | 2 | 2 | 0 | 0 | 0 | 0 |
| Post Week 12 | Lack of Efficacy | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Post Week 12 | Lost to Follow-up | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Post Week 12 | Other | 1 | 2 | 3 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Post Week 12 | Withdrawal by Subject | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Up To Week 12 | Adverse Event | 1 | 3 | 1 | 4 | 6 | 4 | 1 | 0 | 0 | 0 | 0 |
| Up To Week 12 | Lack of Efficacy | 2 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 |
| Up To Week 12 | Lost to Follow-up | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Up To Week 12 | Other | 3 | 1 | 6 | 1 | 2 | 4 | 3 | 0 | 0 | 0 | 0 |
| Up To Week 12 | Randomized, Not Treated | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Up To Week 12 | Withdrawal by Subject | 0 | 2 | 0 | 2 | 0 | 2 | 2 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | CP-690,550 1 mg | CP-690,550 3 mg | CP-690,550 5 mg | CP-690,550 10 mg | CP-690,550 15 mg | CP-690,550 20 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Age, Customized 18 to 44 Years | 15 participants | 23 participants | 19 participants | 9 participants | 14 participants | 15 participants | 17 participants | 112 participants |
| Age, Customized 45 to 64 Years | 47 participants | 31 participants | 42 participants | 49 participants | 49 participants | 49 participants | 40 participants | 307 participants |
| Age, Customized Greater Than or Equal to (>=) 65 Years | 8 participants | 14 participants | 10 participants | 16 participants | 12 participants | 16 participants | 12 participants | 88 participants |
| Sex: Female, Male Female | 57 Participants | 52 Participants | 57 Participants | 55 Participants | 66 Participants | 63 Participants | 56 Participants | 406 Participants |
| Sex: Female, Male Male | 13 Participants | 16 Participants | 14 Participants | 19 Participants | 9 Participants | 17 Participants | 13 Participants | 101 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 28 / 49 | 14 / 21 | 30 / 55 | 10 / 13 | 40 / 71 | 45 / 74 | 46 / 75 | 37 / 67 | 6 / 13 | 29 / 51 | 12 / 18 |
| serious Total, serious adverse events | 1 / 49 | 1 / 21 | 4 / 55 | 0 / 13 | 4 / 71 | 1 / 74 | 6 / 75 | 4 / 67 | 0 / 13 | 0 / 51 | 0 / 18 |
Outcome results
Primary
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12
ACR20 response: \>= 20% improvement in tender joints count (TJC); \>= 20% improvement in swollen joints count (SJC); and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
Time frame: Week 12
Population: Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using Baseline Observation Carried Forward (BOCF).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 47.14 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 55.88 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 56.34 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 58.11 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 56.00 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 56.25 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 | 36.23 percentage of participants |
Secondary
36-Item Short-Form Health Survey (SF-36)
SF-36 is a standardized survey evaluating 8 domains (of 2 components \[C\]; physical \[Ph\] and mental \[Mn\]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \[R-P\], role-emotional \[R-E\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Time frame: Baseline, Week 12, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=40,20,44,13,55,64,60,53,12,36,17) | 39.94 units on a scale | Standard Deviation 8.41 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=40,20,44,13,55,64,60,53,12,36,17) | 40.51 units on a scale | Standard Deviation 8.53 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 37.41 units on a scale | Standard Deviation 10.35 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=70,0,68,0,71,73,75,80,0,69,0) | 40.32 units on a scale | Standard Deviation 9.95 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=40,20,44,13,55,64,60,53,12,36,17) | 40.23 units on a scale | Standard Deviation 11.08 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=70,0,68,0,71,73,75,80,0,69,0) | 34.72 units on a scale | Standard Deviation 11.55 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=70,0,68,0,71,73,75,80,0,69,0) | 37.76 units on a scale | Standard Deviation 10.41 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=63,0,59,0,64,65,65,70,0,61,0) | 37.24 units on a scale | Standard Deviation 8.19 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=40,20,44,13,55,64,60,53,12,36,17) | 49.05 units on a scale | Standard Deviation 10.69 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=70,0,68,0,71,73,75,80,0,69,0) | 34.14 units on a scale | Standard Deviation 6.6 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C(n=40,20,44,13,55,64,60,53,12,36,17) | 46.62 units on a scale | Standard Deviation 12.04 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=63,0,59,0,64,65,65,70,0,61,0) | 45.45 units on a scale | Standard Deviation 9.82 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=40,20,44,13,55,64,60,53,12,36,17) | 44.17 units on a scale | Standard Deviation 8.68 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=40,20,44,13,55,64,60,53,12,36,17) | 40.65 units on a scale | Standard Deviation 7.4 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=70,0,68,0,71,73,75,80,0,69,0) | 34.53 units on a scale | Standard Deviation 8.52 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=70,0,68,0,71,73,75,80,0,69,0) | 31.48 units on a scale | Standard Deviation 10.33 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=63,0,59,0,64,65,65,70,0,61,0) | 41.62 units on a scale | Standard Deviation 8.02 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=70,0,68,0,71,73,75,80,0,69,0) | 40.39 units on a scale | Standard Deviation 11.42 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=63,0,59,0,64,65,65,70,0,61,0) | 38.47 units on a scale | Standard Deviation 8.77 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=63,0,59,0,64,65,65,70,0,61,0) | 44.86 units on a scale | Standard Deviation 11.45 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=63,0,59,0,64,65,65,70,0,61,0) | 35.05 units on a scale | Standard Deviation 10.73 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=63,0,59,0,64,65,65,70,0,61,0) | 37.85 units on a scale | Standard Deviation 8.1 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=63,0,59,0,64,65,65,70,0,61,0) | 41.18 units on a scale | Standard Deviation 11.32 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 43.62 units on a scale | Standard Deviation 10.4 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=63,0,59,0,64,65,65,70,0,61,0) | 39.47 units on a scale | Standard Deviation 12.12 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=70,0,68,0,71,73,75,80,0,69,0) | 35.08 units on a scale | Standard Deviation 6.77 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=40,20,44,13,55,64,60,53,12,36,17) | 45.92 units on a scale | Standard Deviation 11.1 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=70,0,68,0,71,73,75,80,0,69,0) | 33.13 units on a scale | Standard Deviation 6.72 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=63,0,59,0,64,65,65,70,0,61,0) | 43.84 units on a scale | Standard Deviation 10.95 |
| CP-690,550 1 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=70,0,68,0,71,73,75,80,0,69,0) | 38.98 units on a scale | Standard Deviation 11.58 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=40,20,44,13,55,64,60,53,12,36,17) | 39.60 units on a scale | Standard Deviation 9.23 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 34.30 units on a scale | Standard Deviation 10.72 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 39.40 units on a scale | Standard Deviation 10.26 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=40,20,44,13,55,64,60,53,12,36,17) | 39.57 units on a scale | Standard Deviation 11.54 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=40,20,44,13,55,64,60,53,12,36,17) | 35.06 units on a scale | Standard Deviation 9.36 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C(n=40,20,44,13,55,64,60,53,12,36,17) | 39.10 units on a scale | Standard Deviation 11.18 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=40,20,44,13,55,64,60,53,12,36,17) | 36.79 units on a scale | Standard Deviation 9.76 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=40,20,44,13,55,64,60,53,12,36,17) | 38.74 units on a scale | Standard Deviation 10.58 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=40,20,44,13,55,64,60,53,12,36,17) | 36.87 units on a scale | Standard Deviation 7.75 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=40,20,44,13,55,64,60,53,12,36,17) | 34.30 units on a scale | Standard Deviation 10.59 |
| CP-690,550 3 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=63,0,59,0,64,65,65,70,0,61,0) | 46.80 units on a scale | Standard Deviation 10.08 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=40,20,44,13,55,64,60,53,12,36,17) | 41.45 units on a scale | Standard Deviation 10.05 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=40,20,44,13,55,64,60,53,12,36,17) | 48.76 units on a scale | Standard Deviation 11.25 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 42.84 units on a scale | Standard Deviation 12.53 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=40,20,44,13,55,64,60,53,12,36,17) | 39.88 units on a scale | Standard Deviation 11.85 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=70,0,68,0,71,73,75,80,0,69,0) | 40.07 units on a scale | Standard Deviation 11.65 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=70,0,68,0,71,73,75,80,0,69,0) | 38.88 units on a scale | Standard Deviation 11.35 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=70,0,68,0,71,73,75,80,0,69,0) | 34.45 units on a scale | Standard Deviation 10.52 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=63,0,59,0,64,65,65,70,0,61,0) | 39.04 units on a scale | Standard Deviation 8.74 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=63,0,59,0,64,65,65,70,0,61,0) | 42.76 units on a scale | Standard Deviation 11.3 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=40,20,44,13,55,64,60,53,12,36,17) | 40.59 units on a scale | Standard Deviation 13.86 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 38.38 units on a scale | Standard Deviation 11.35 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=70,0,68,0,71,73,75,80,0,69,0) | 42.36 units on a scale | Standard Deviation 10.07 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=63,0,59,0,64,65,65,70,0,61,0) | 38.70 units on a scale | Standard Deviation 9.73 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=70,0,68,0,71,73,75,80,0,69,0) | 34.60 units on a scale | Standard Deviation 8.35 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=70,0,68,0,71,73,75,80,0,69,0) | 33.73 units on a scale | Standard Deviation 8.33 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=63,0,59,0,64,65,65,70,0,61,0) | 43.54 units on a scale | Standard Deviation 11.2 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=63,0,59,0,64,65,65,70,0,61,0) | 44.57 units on a scale | Standard Deviation 10.95 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=40,20,44,13,55,64,60,53,12,36,17) | 44.15 units on a scale | Standard Deviation 10.31 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=40,20,44,13,55,64,60,53,12,36,17) | 40.31 units on a scale | Standard Deviation 9.95 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=63,0,59,0,64,65,65,70,0,61,0) | 45.47 units on a scale | Standard Deviation 11.1 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=70,0,68,0,71,73,75,80,0,69,0) | 33.20 units on a scale | Standard Deviation 11.04 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=40,20,44,13,55,64,60,53,12,36,17) | 45.66 units on a scale | Standard Deviation 12.59 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=63,0,59,0,64,65,65,70,0,61,0) | 36.49 units on a scale | Standard Deviation 11.63 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=70,0,68,0,71,73,75,80,0,69,0) | 35.17 units on a scale | Standard Deviation 8.02 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C(n=40,20,44,13,55,64,60,53,12,36,17) | 46.21 units on a scale | Standard Deviation 13.26 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=63,0,59,0,64,65,65,70,0,61,0) | 39.14 units on a scale | Standard Deviation 12.47 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=63,0,59,0,64,65,65,70,0,61,0) | 39.25 units on a scale | Standard Deviation 10.85 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=70,0,68,0,71,73,75,80,0,69,0) | 35.18 units on a scale | Standard Deviation 14.16 |
| CP-690,550 5 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=70,0,68,0,71,73,75,80,0,69,0) | 41.47 units on a scale | Standard Deviation 12.68 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 43.84 units on a scale | Standard Deviation 9.05 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=40,20,44,13,55,64,60,53,12,36,17) | 38.96 units on a scale | Standard Deviation 10.26 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=40,20,44,13,55,64,60,53,12,36,17) | 44.59 units on a scale | Standard Deviation 7.04 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 39.39 units on a scale | Standard Deviation 11.83 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=40,20,44,13,55,64,60,53,12,36,17) | 37.35 units on a scale | Standard Deviation 5.95 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=40,20,44,13,55,64,60,53,12,36,17) | 43.07 units on a scale | Standard Deviation 9.91 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C(n=40,20,44,13,55,64,60,53,12,36,17) | 44.52 units on a scale | Standard Deviation 7.18 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=40,20,44,13,55,64,60,53,12,36,17) | 37.94 units on a scale | Standard Deviation 12.35 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=40,20,44,13,55,64,60,53,12,36,17) | 47.29 units on a scale | Standard Deviation 6.58 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=40,20,44,13,55,64,60,53,12,36,17) | 39.74 units on a scale | Standard Deviation 9.76 |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=40,20,44,13,55,64,60,53,12,36,17) | 47.29 units on a scale | Standard Deviation 13.62 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=63,0,59,0,64,65,65,70,0,61,0) | 36.45 units on a scale | Standard Deviation 9.78 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=70,0,68,0,71,73,75,80,0,69,0) | 41.88 units on a scale | Standard Deviation 12.02 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=70,0,68,0,71,73,75,80,0,69,0) | 37.21 units on a scale | Standard Deviation 12.51 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=63,0,59,0,64,65,65,70,0,61,0) | 42.28 units on a scale | Standard Deviation 10.82 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=70,0,68,0,71,73,75,80,0,69,0) | 31.93 units on a scale | Standard Deviation 9.66 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=70,0,68,0,71,73,75,80,0,69,0) | 35.36 units on a scale | Standard Deviation 8.23 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=63,0,59,0,64,65,65,70,0,61,0) | 45.84 units on a scale | Standard Deviation 13.41 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=70,0,68,0,71,73,75,80,0,69,0) | 32.99 units on a scale | Standard Deviation 8.03 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=70,0,68,0,71,73,75,80,0,69,0) | 41.54 units on a scale | Standard Deviation 9.39 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 45.25 units on a scale | Standard Deviation 11.64 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=70,0,68,0,71,73,75,80,0,69,0) | 37.72 units on a scale | Standard Deviation 10.38 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=40,20,44,13,55,64,60,53,12,36,17) | 41.12 units on a scale | Standard Deviation 9.22 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=63,0,59,0,64,65,65,70,0,61,0) | 42.73 units on a scale | Standard Deviation 9.57 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=70,0,68,0,71,73,75,80,0,69,0) | 35.12 units on a scale | Standard Deviation 8.9 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=63,0,59,0,64,65,65,70,0,61,0) | 38.27 units on a scale | Standard Deviation 9.31 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 40.04 units on a scale | Standard Deviation 10.81 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=70,0,68,0,71,73,75,80,0,69,0) | 42.81 units on a scale | Standard Deviation 11.8 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=63,0,59,0,64,65,65,70,0,61,0) | 40.11 units on a scale | Standard Deviation 9.54 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=40,20,44,13,55,64,60,53,12,36,17) | 44.96 units on a scale | Standard Deviation 9.23 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=40,20,44,13,55,64,60,53,12,36,17) | 41.09 units on a scale | Standard Deviation 9.12 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=40,20,44,13,55,64,60,53,12,36,17) | 41.35 units on a scale | Standard Deviation 10.23 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=63,0,59,0,64,65,65,70,0,61,0) | 39.90 units on a scale | Standard Deviation 12.87 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=63,0,59,0,64,65,65,70,0,61,0) | 38.26 units on a scale | Standard Deviation 10.21 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=40,20,44,13,55,64,60,53,12,36,17) | 41.46 units on a scale | Standard Deviation 12.4 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=40,20,44,13,55,64,60,53,12,36,17) | 48.40 units on a scale | Standard Deviation 10.41 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=63,0,59,0,64,65,65,70,0,61,0) | 45.34 units on a scale | Standard Deviation 13.08 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=63,0,59,0,64,65,65,70,0,61,0) | 46.33 units on a scale | Standard Deviation 10.59 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=70,0,68,0,71,73,75,80,0,69,0) | 35.54 units on a scale | Standard Deviation 8.69 |
| CP-690,550 15 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C(n=40,20,44,13,55,64,60,53,12,36,17) | 47.34 units on a scale | Standard Deviation 13.41 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=40,20,44,13,55,64,60,53,12,36,17) | 44.52 units on a scale | Standard Deviation 10.98 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=70,0,68,0,71,73,75,80,0,69,0) | 31.92 units on a scale | Standard Deviation 9.15 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=70,0,68,0,71,73,75,80,0,69,0) | 34.64 units on a scale | Standard Deviation 10.72 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=70,0,68,0,71,73,75,80,0,69,0) | 35.11 units on a scale | Standard Deviation 7.85 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=70,0,68,0,71,73,75,80,0,69,0) | 36.52 units on a scale | Standard Deviation 9.28 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=70,0,68,0,71,73,75,80,0,69,0) | 38.99 units on a scale | Standard Deviation 10.8 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=70,0,68,0,71,73,75,80,0,69,0) | 36.23 units on a scale | Standard Deviation 12.64 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=70,0,68,0,71,73,75,80,0,69,0) | 42.79 units on a scale | Standard Deviation 10.99 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=70,0,68,0,71,73,75,80,0,69,0) | 32.96 units on a scale | Standard Deviation 8.15 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=70,0,68,0,71,73,75,80,0,69,0) | 43.53 units on a scale | Standard Deviation 11 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=63,0,59,0,64,65,65,70,0,61,0) | 39.71 units on a scale | Standard Deviation 9.69 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=63,0,59,0,64,65,65,70,0,61,0) | 39.15 units on a scale | Standard Deviation 8.76 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=63,0,59,0,64,65,65,70,0,61,0) | 45.99 units on a scale | Standard Deviation 10.68 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=63,0,59,0,64,65,65,70,0,61,0) | 39.01 units on a scale | Standard Deviation 12.07 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=63,0,59,0,64,65,65,70,0,61,0) | 43.08 units on a scale | Standard Deviation 9.84 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=63,0,59,0,64,65,65,70,0,61,0) | 39.52 units on a scale | Standard Deviation 9.3 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=63,0,59,0,64,65,65,70,0,61,0) | 44.18 units on a scale | Standard Deviation 10.26 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 38.19 units on a scale | Standard Deviation 10.88 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=40,20,44,13,55,64,60,53,12,36,17) | 40.32 units on a scale | Standard Deviation 10.91 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=40,20,44,13,55,64,60,53,12,36,17) | 41.09 units on a scale | Standard Deviation 9.27 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=40,20,44,13,55,64,60,53,12,36,17) | 47.55 units on a scale | Standard Deviation 10.18 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 43.56 units on a scale | Standard Deviation 10.73 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=40,20,44,13,55,64,60,53,12,36,17) | 40.15 units on a scale | Standard Deviation 11.58 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=40,20,44,13,55,64,60,53,12,36,17) | 43.89 units on a scale | Standard Deviation 10.93 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=40,20,44,13,55,64,60,53,12,36,17) | 40.85 units on a scale | Standard Deviation 9.79 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C(n=40,20,44,13,55,64,60,53,12,36,17) | 45.03 units on a scale | Standard Deviation 11.2 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=70,0,68,0,71,73,75,80,0,69,0) | 42.60 units on a scale | Standard Deviation 10.83 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=63,0,59,0,64,65,65,70,0,61,0) | 36.25 units on a scale | Standard Deviation 10.75 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=63,0,59,0,64,65,65,70,0,61,0) | 44.00 units on a scale | Standard Deviation 10.81 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=63,0,59,0,64,65,65,70,0,61,0) | 42.84 units on a scale | Standard Deviation 10.06 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=63,0,59,0,64,65,65,70,0,61,0) | 39.07 units on a scale | Standard Deviation 11.96 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=70,0,68,0,71,73,75,80,0,69,0) | 38.01 units on a scale | Standard Deviation 11.06 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=40,20,44,13,55,64,60,53,12,36,17) | 40.99 units on a scale | Standard Deviation 9.14 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=40,20,44,13,55,64,60,53,12,36,17) | 41.40 units on a scale | Standard Deviation 9.24 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=63,0,59,0,64,65,65,70,0,61,0) | 44.39 units on a scale | Standard Deviation 9.4 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=70,0,68,0,71,73,75,80,0,69,0) | 40.81 units on a scale | Standard Deviation 11.75 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=63,0,59,0,64,65,65,70,0,61,0) | 40.05 units on a scale | Standard Deviation 9.44 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C(n=40,20,44,13,55,64,60,53,12,36,17) | 47.21 units on a scale | Standard Deviation 11.71 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=40,20,44,13,55,64,60,53,12,36,17) | 45.76 units on a scale | Standard Deviation 9.67 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=63,0,59,0,64,65,65,70,0,61,0) | 47.82 units on a scale | Standard Deviation 10.24 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=63,0,59,0,64,65,65,70,0,61,0) | 45.61 units on a scale | Standard Deviation 10.59 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=70,0,68,0,71,73,75,80,0,69,0) | 33.70 units on a scale | Standard Deviation 9.85 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=70,0,68,0,71,73,75,80,0,69,0) | 34.98 units on a scale | Standard Deviation 8.19 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=70,0,68,0,71,73,75,80,0,69,0) | 35.94 units on a scale | Standard Deviation 8.44 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 38.62 units on a scale | Standard Deviation 11.08 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=40,20,44,13,55,64,60,53,12,36,17) | 40.39 units on a scale | Standard Deviation 11.88 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=70,0,68,0,71,73,75,80,0,69,0) | 34.73 units on a scale | Standard Deviation 14.42 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=70,0,68,0,71,73,75,80,0,69,0) | 39.68 units on a scale | Standard Deviation 12.65 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=63,0,59,0,64,65,65,70,0,61,0) | 39.97 units on a scale | Standard Deviation 8.98 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=70,0,68,0,71,73,75,80,0,69,0) | 33.19 units on a scale | Standard Deviation 7.31 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=63,0,59,0,64,65,65,70,0,61,0) | 43.93 units on a scale | Standard Deviation 9.81 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=70,0,68,0,71,73,75,80,0,69,0) | 40.92 units on a scale | Standard Deviation 13 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=63,0,59,0,64,65,65,70,0,61,0) | 45.24 units on a scale | Standard Deviation 10.7 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 44.67 units on a scale | Standard Deviation 10.31 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=40,20,44,13,55,64,60,53,12,36,17) | 46.86 units on a scale | Standard Deviation 11.73 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=40,20,44,13,55,64,60,53,12,36,17) | 50.11 units on a scale | Standard Deviation 11.68 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=63,0,59,0,64,65,65,70,0,61,0) | 39.41 units on a scale | Standard Deviation 10.03 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=63,0,59,0,64,65,65,70,0,61,0) | 37.80 units on a scale | Standard Deviation 10.76 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=70,0,68,0,71,73,75,80,0,69,0) | 31.50 units on a scale | Standard Deviation 9.29 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=40,20,44,13,55,64,60,53,12,36,17) | 40.69 units on a scale | Standard Deviation 9.67 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=40,20,44,13,55,64,60,53,12,36,17) | 50.50 units on a scale | Standard Deviation 10.98 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=63,0,59,0,64,65,65,70,0,61,0) | 46.65 units on a scale | Standard Deviation 11.64 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=70,0,68,0,71,73,75,80,0,69,0) | 30.23 units on a scale | Standard Deviation 9.7 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 46.35 units on a scale | Standard Deviation 10.53 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=63,0,59,0,64,65,65,70,0,61,0) | 39.64 units on a scale | Standard Deviation 10.2 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=40,20,44,13,55,64,60,53,12,36,17) | 42.31 units on a scale | Standard Deviation 13.71 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=40,20,44,13,55,64,60,53,12,36,17) | 47.24 units on a scale | Standard Deviation 11.36 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=63,0,59,0,64,65,65,70,0,61,0) | 41.33 units on a scale | Standard Deviation 13.3 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=40,20,44,13,55,64,60,53,12,36,17) | 42.81 units on a scale | Standard Deviation 10.22 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=63,0,59,0,64,65,65,70,0,61,0) | 46.03 units on a scale | Standard Deviation 11.42 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C(n=40,20,44,13,55,64,60,53,12,36,17) | 48.03 units on a scale | Standard Deviation 11.81 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=63,0,59,0,64,65,65,70,0,61,0) | 41.10 units on a scale | Standard Deviation 9.78 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=70,0,68,0,71,73,75,80,0,69,0) | 36.08 units on a scale | Standard Deviation 8.48 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=63,0,59,0,64,65,65,70,0,61,0) | 44.21 units on a scale | Standard Deviation 9.78 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=70,0,68,0,71,73,75,80,0,69,0) | 40.97 units on a scale | Standard Deviation 9.98 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=63,0,59,0,64,65,65,70,0,61,0) | 37.49 units on a scale | Standard Deviation 11.48 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=63,0,59,0,64,65,65,70,0,61,0) | 40.17 units on a scale | Standard Deviation 10.41 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=70,0,68,0,71,73,75,80,0,69,0) | 41.68 units on a scale | Standard Deviation 12.17 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=63,0,59,0,64,65,65,70,0,61,0) | 44.23 units on a scale | Standard Deviation 10.53 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=70,0,68,0,71,73,75,80,0,69,0) | 32.11 units on a scale | Standard Deviation 8.57 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=70,0,68,0,71,73,75,80,0,69,0) | 39.91 units on a scale | Standard Deviation 12.53 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=70,0,68,0,71,73,75,80,0,69,0) | 35.13 units on a scale | Standard Deviation 13.45 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=63,0,59,0,64,65,65,70,0,61,0) | 46.11 units on a scale | Standard Deviation 11.49 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=70,0,68,0,71,73,75,80,0,69,0) | 38.03 units on a scale | Standard Deviation 10.7 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=70,0,68,0,71,73,75,80,0,69,0) | 34.20 units on a scale | Standard Deviation 8.18 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=40,20,44,13,55,64,60,53,12,36,17) | 41.97 units on a scale | Standard Deviation 10.8 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=70,0,68,0,71,73,75,80,0,69,0) | 33.13 units on a scale | Standard Deviation 9.32 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=40,20,44,13,55,64,60,53,12,36,17) | 44.03 units on a scale | Standard Deviation 9.52 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=40,20,44,13,55,64,60,53,12,36,17) | 46.89 units on a scale | Standard Deviation 10.25 |
| CP-690,550 20 mg | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 40.51 units on a scale | Standard Deviation 12.11 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 38.67 units on a scale | Standard Deviation 12.38 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=40,20,44,13,55,64,60,53,12,36,17) | 35.02 units on a scale | Standard Deviation 10.72 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C(n=40,20,44,13,55,64,60,53,12,36,17) | 43.35 units on a scale | Standard Deviation 13.89 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=40,20,44,13,55,64,60,53,12,36,17) | 41.94 units on a scale | Standard Deviation 13.65 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=40,20,44,13,55,64,60,53,12,36,17) | 35.81 units on a scale | Standard Deviation 11.52 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=40,20,44,13,55,64,60,53,12,36,17) | 37.09 units on a scale | Standard Deviation 16.56 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=40,20,44,13,55,64,60,53,12,36,17) | 34.40 units on a scale | Standard Deviation 10.57 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=40,20,44,13,55,64,60,53,12,36,17) | 40.32 units on a scale | Standard Deviation 11 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=40,20,44,13,55,64,60,53,12,36,17) | 43.44 units on a scale | Standard Deviation 12.84 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 32.31 units on a scale | Standard Deviation 11.36 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=63,0,59,0,64,65,65,70,0,61,0) | 40.39 units on a scale | Standard Deviation 12.49 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=63,0,59,0,64,65,65,70,0,61,0) | 39.79 units on a scale | Standard Deviation 10.14 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=70,0,68,0,71,73,75,80,0,69,0) | 44.72 units on a scale | Standard Deviation 13.24 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=40,20,44,13,55,64,60,53,12,36,17) | 42.27 units on a scale | Standard Deviation 13.09 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=63,0,59,0,64,65,65,70,0,61,0) | 43.36 units on a scale | Standard Deviation 12.67 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=40,20,44,13,55,64,60,53,12,36,17) | 44.27 units on a scale | Standard Deviation 9.8 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=63,0,59,0,64,65,65,70,0,61,0) | 37.89 units on a scale | Standard Deviation 9.94 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=70,0,68,0,71,73,75,80,0,69,0) | 34.01 units on a scale | Standard Deviation 11.06 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=40,20,44,13,55,64,60,53,12,36,17) | 43.11 units on a scale | Standard Deviation 9.54 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=63,0,59,0,64,65,65,70,0,61,0) | 39.54 units on a scale | Standard Deviation 10.42 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=40,20,44,13,55,64,60,53,12,36,17) | 45.63 units on a scale | Standard Deviation 14.22 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=70,0,68,0,71,73,75,80,0,69,0) | 40.09 units on a scale | Standard Deviation 11.08 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=63,0,59,0,64,65,65,70,0,61,0) | 41.38 units on a scale | Standard Deviation 10.87 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=70,0,68,0,71,73,75,80,0,69,0) | 39.37 units on a scale | Standard Deviation 13.94 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C(n=40,20,44,13,55,64,60,53,12,36,17) | 47.08 units on a scale | Standard Deviation 15.31 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=70,0,68,0,71,73,75,80,0,69,0) | 34.41 units on a scale | Standard Deviation 8.59 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 45.18 units on a scale | Standard Deviation 10.6 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=63,0,59,0,64,65,65,70,0,61,0) | 36.23 units on a scale | Standard Deviation 11.37 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=63,0,59,0,64,65,65,70,0,61,0) | 46.48 units on a scale | Standard Deviation 12.24 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=70,0,68,0,71,73,75,80,0,69,0) | 37.23 units on a scale | Standard Deviation 9.51 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=63,0,59,0,64,65,65,70,0,61,0) | 39.46 units on a scale | Standard Deviation 10.15 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 39.44 units on a scale | Standard Deviation 10.64 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=70,0,68,0,71,73,75,80,0,69,0) | 42.91 units on a scale | Standard Deviation 13.08 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=70,0,68,0,71,73,75,80,0,69,0) | 35.93 units on a scale | Standard Deviation 8.71 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=70,0,68,0,71,73,75,80,0,69,0) | 44.08 units on a scale | Standard Deviation 11.63 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=40,20,44,13,55,64,60,53,12,36,17) | 42.09 units on a scale | Standard Deviation 9.2 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=70,0,68,0,71,73,75,80,0,69,0) | 36.50 units on a scale | Standard Deviation 9.38 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=40,20,44,13,55,64,60,53,12,36,17) | 49.75 units on a scale | Standard Deviation 11.83 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=63,0,59,0,64,65,65,70,0,61,0) | 45.08 units on a scale | Standard Deviation 12.48 |
| Placebo | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=40,20,44,13,55,64,60,53,12,36,17) | 43.16 units on a scale | Standard Deviation 9.7 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: So Fn (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-P (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: So Fn (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-E (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph C (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph Fn (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: GH (n=40,20,44,13,55,64,60,53,12,36,17) | 40.68 units on a scale | Standard Deviation 8.34 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Ph C (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Mn C (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: BP (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Vit (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Ph Fn (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph C (n=40,20,44,13,55,64,60,53,12,36,17) | 39.41 units on a scale | Standard Deviation 9.58 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Vit (n=40,20,44,13,55,64,60,53,12,36,17) | 48.23 units on a scale | Standard Deviation 11.92 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: MnH (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: MnH (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: R-E (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-E (n=40,20,44,13,55,64,60,53,12,36,17) | 46.28 units on a scale | Standard Deviation 9.13 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: So Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 43.05 units on a scale | Standard Deviation 10.04 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: Vit (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: Mn C (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: GH (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Ph Fn(n=40,20,44,13,55,64,60,53,12,36,17) | 38.09 units on a scale | Standard Deviation 10.04 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: BP (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: R-P (n=40,20,44,13,55,64,60,53,12,36,17) | 42.45 units on a scale | Standard Deviation 9.44 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Baseline: R-P (n=70,0,68,0,71,73,75,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: BP (n=40,20,44,13,55,64,60,53,12,36,17) | 44.24 units on a scale | Standard Deviation 8.09 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: Mn C(n=40,20,44,13,55,64,60,53,12,36,17) | 49.27 units on a scale | Standard Deviation 9.52 |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 12: GH (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | 36-Item Short-Form Health Survey (SF-36) | Week 24: MnH (n=40,20,44,13,55,64,60,53,12,36,17) | 47.52 units on a scale | Standard Deviation 11.26 |
Secondary
Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve
ACR-n: calculated for each participant by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The area under the curve (AUC) for ACR-n is the measure of the area under the curve of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC.
Time frame: Baseline up to Week 2, 4, 6, 8, 12
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using Last Observation Carried Forward (LOCF).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 8 | 464.42 units on a scale | Standard Deviation 1424.59 |
| CP-690,550 1 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 2 | -14.07 units on a scale | Standard Deviation 247.36 |
| CP-690,550 1 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 12 | 995.34 units on a scale | Standard Deviation 2349.99 |
| CP-690,550 1 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 6 | 244.11 units on a scale | Standard Deviation 948.25 |
| CP-690,550 1 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 4 | 61.66 units on a scale | Standard Deviation 622.43 |
| CP-690,550 3 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 4 | 163.40 units on a scale | Standard Deviation 659.05 |
| CP-690,550 3 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 8 | 772.65 units on a scale | Standard Deviation 1594.84 |
| CP-690,550 3 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 12 | 1511.40 units on a scale | Standard Deviation 2711.76 |
| CP-690,550 3 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 6 | 442.29 units on a scale | Standard Deviation 1087.57 |
| CP-690,550 3 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 2 | 22.16 units on a scale | Standard Deviation 243.19 |
| CP-690,550 5 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 12 | 1420.20 units on a scale | Standard Deviation 3284.51 |
| CP-690,550 5 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 2 | 4.47 units on a scale | Standard Deviation 319.92 |
| CP-690,550 5 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 4 | 92.24 units on a scale | Standard Deviation 919.49 |
| CP-690,550 5 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 8 | 693.90 units on a scale | Standard Deviation 1952.07 |
| CP-690,550 5 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 6 | 348.96 units on a scale | Standard Deviation 1446.07 |
| CP-690,550 10 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 12 | 588.45 units on a scale | Standard Deviation 8969.29 |
| CP-690,550 10 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 6 | 111.83 units on a scale | Standard Deviation 3626.48 |
| CP-690,550 10 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 8 | 239.54 units on a scale | Standard Deviation 5389.58 |
| CP-690,550 10 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 2 | -21.34 units on a scale | Standard Deviation 661.05 |
| CP-690,550 10 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 4 | 7.29 units on a scale | Standard Deviation 2038.26 |
| CP-690,550 15 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 4 | 341.52 units on a scale | Standard Deviation 820.16 |
| CP-690,550 15 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 12 | 1974.18 units on a scale | Standard Deviation 3231.7 |
| CP-690,550 15 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 6 | 716.69 units on a scale | Standard Deviation 1285.36 |
| CP-690,550 15 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 8 | 1154.14 units on a scale | Standard Deviation 1733.13 |
| CP-690,550 15 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 2 | 88.72 units on a scale | Standard Deviation 287.91 |
| CP-690,550 20 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 12 | 1504.58 units on a scale | Standard Deviation 2979.75 |
| CP-690,550 20 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 8 | 725.67 units on a scale | Standard Deviation 1954.96 |
| CP-690,550 20 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 2 | 36.55 units on a scale | Standard Deviation 267.26 |
| CP-690,550 20 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 6 | 402.21 units on a scale | Standard Deviation 1428.69 |
| CP-690,550 20 mg | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 4 | 170.23 units on a scale | Standard Deviation 825.49 |
| Placebo | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 12 | -755.22 units on a scale | Standard Deviation 5107.45 |
| Placebo | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 8 | -571.99 units on a scale | Standard Deviation 3310.17 |
| Placebo | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 2 | -113.31 units on a scale | Standard Deviation 429.17 |
| Placebo | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 4 | -296.38 units on a scale | Standard Deviation 1270.69 |
| Placebo | Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve | Week 6 | -453.18 units on a scale | Standard Deviation 2265.12 |
Secondary
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET
SF-36 is a standardized survey evaluating 8 domains (of 2 components \[C\]; physical \[Ph\] and mental \[Mn\]) of functional health and well being: physical and social (So) functioning (Fn), physical and emotional role (role-physical \[R-P\], role-emotional \[R-E\]) limitations, bodily pain (BP), general health (GH), vitality (Vit), mental health (MnH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Time frame: Baseline, Week 12, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 6.52 units on a scale | Standard Deviation 8.32 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=63,0,59,0,64,64,65,70,0,61,0) | 4.92 units on a scale | Standard Deviation 9.27 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=63,0,59,0,64,64,65,70,0,61,0) | 4.27 units on a scale | Standard Deviation 6.38 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 5.86 units on a scale | Standard Deviation 9.36 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=63,0,59,0,64,64,65,70,0,61,0) | 4.30 units on a scale | Standard Deviation 9.47 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=63,0,59,0,64,64,65,70,0,61,0) | 7.29 units on a scale | Standard Deviation 8.12 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=63,0,59,0,64,64,65,70,0,61,0) | 4.26 units on a scale | Standard Deviation 10.65 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=63,0,59,0,64,64,65,70,0,61,0) | 2.94 units on a scale | Standard Deviation 7.04 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=63,0,59,0,64,64,65,70,0,61,0) | 3.98 units on a scale | Standard Deviation 7.08 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=40,20,44,13,55,63,60,53,12,36,17) | 5.48 units on a scale | Standard Deviation 12.35 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=40,20,44,13,55,63,60,53,12,36,17) | 7.47 units on a scale | Standard Deviation 7.9 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=63,0,59,0,64,64,65,70,0,61,0) | 5.10 units on a scale | Standard Deviation 8.99 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=40,20,44,13,55,63,60,53,12,36,17) | 4.28 units on a scale | Standard Deviation 11.3 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=40,20,44,13,55,63,60,53,12,36,17) | 8.12 units on a scale | Standard Deviation 9.94 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=40,20,44,13,55,63,60,53,12,36,17) | 5.62 units on a scale | Standard Deviation 7.7 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=63,0,59,0,64,64,65,70,0,61,0) | 3.72 units on a scale | Standard Deviation 10.54 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=40,20,44,13,55,63,60,53,12,36,17) | 7.25 units on a scale | Standard Deviation 12.82 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=40,20,44,13,55,63,60,53,12,36,17) | 10.65 units on a scale | Standard Deviation 9.91 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=63,0,59,0,64,64,65,70,0,61,0) | 3.77 units on a scale | Standard Deviation 8 |
| CP-690,550 1 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=40,20,44,13,55,63,60,53,12,36,17) | 6.12 units on a scale | Standard Deviation 8.34 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=40,20,44,13,55,63,60,53,12,36,17) | 2.91 units on a scale | Standard Deviation 7.31 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=40,20,44,13,55,63,60,53,12,36,17) | 1.93 units on a scale | Standard Deviation 11.99 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=40,20,44,13,55,63,60,53,12,36,17) | 1.56 units on a scale | Standard Deviation 10.79 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=40,20,44,13,55,63,60,53,12,36,17) | 2.33 units on a scale | Standard Deviation 12.82 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=40,20,44,13,55,63,60,53,12,36,17) | 3.85 units on a scale | Standard Deviation 8.92 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 3.27 units on a scale | Standard Deviation 12.31 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=40,20,44,13,55,63,60,53,12,36,17) | 1.83 units on a scale | Standard Deviation 8.73 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=40,20,44,13,55,63,60,53,12,36,17) | 3.58 units on a scale | Standard Deviation 6.97 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=40,20,44,13,55,63,60,53,12,36,17) | 1.47 units on a scale | Standard Deviation 7.72 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 2.63 units on a scale | Standard Deviation 9.94 |
| CP-690,550 3 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=63,0,59,0,64,64,65,70,0,61,0) | 8.80 units on a scale | Standard Deviation 11.96 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=40,20,44,13,55,63,60,53,12,36,17) | 4.31 units on a scale | Standard Deviation 13.1 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=63,0,59,0,64,64,65,70,0,61,0) | 3.84 units on a scale | Standard Deviation 7.61 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=63,0,59,0,64,64,65,70,0,61,0) | 4.99 units on a scale | Standard Deviation 10.54 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 5.45 units on a scale | Standard Deviation 8.57 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=40,20,44,13,55,63,60,53,12,36,17) | 6.78 units on a scale | Standard Deviation 7.17 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=40,20,44,13,55,63,60,53,12,36,17) | 10.16 units on a scale | Standard Deviation 9.54 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=40,20,44,13,55,63,60,53,12,36,17) | 4.99 units on a scale | Standard Deviation 11.52 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=40,20,44,13,55,63,60,53,12,36,17) | 5.48 units on a scale | Standard Deviation 16.05 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=63,0,59,0,64,64,65,70,0,61,0) | 4.29 units on a scale | Standard Deviation 9.92 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=40,20,44,13,55,63,60,53,12,36,17) | 5.82 units on a scale | Standard Deviation 9.3 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=63,0,59,0,64,64,65,70,0,61,0) | 3.94 units on a scale | Standard Deviation 10.38 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=63,0,59,0,64,64,65,70,0,61,0) | 5.16 units on a scale | Standard Deviation 8.82 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=63,0,59,0,64,64,65,70,0,61,0) | 4.63 units on a scale | Standard Deviation 10.01 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=63,0,59,0,64,64,65,70,0,61,0) | 4.61 units on a scale | Standard Deviation 11.45 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=40,20,44,13,55,63,60,53,12,36,17) | 5.07 units on a scale | Standard Deviation 11 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=63,0,59,0,64,64,65,70,0,61,0) | 3.39 units on a scale | Standard Deviation 9.6 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 4.09 units on a scale | Standard Deviation 11.1 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=40,20,44,13,55,63,60,53,12,36,17) | 5.92 units on a scale | Standard Deviation 7.09 |
| CP-690,550 5 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=63,0,59,0,64,64,65,70,0,61,0) | 3.69 units on a scale | Standard Deviation 13.12 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 4.37 units on a scale | Standard Deviation 8.35 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=40,20,44,13,55,63,60,53,12,36,17) | 9.75 units on a scale | Standard Deviation 7.27 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=40,20,44,13,55,63,60,53,12,36,17) | 4.11 units on a scale | Standard Deviation 9.07 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=40,20,44,13,55,63,60,53,12,36,17) | 5.04 units on a scale | Standard Deviation 10.16 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=40,20,44,13,55,63,60,53,12,36,17) | -0.30 units on a scale | Standard Deviation 13.69 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=40,20,44,13,55,63,60,53,12,36,17) | 4.98 units on a scale | Standard Deviation 11.27 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=40,20,44,13,55,63,60,53,12,36,17) | 6.62 units on a scale | Standard Deviation 5.93 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=40,20,44,13,55,63,60,53,12,36,17) | 2.48 units on a scale | Standard Deviation 11.8 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=40,20,44,13,55,63,60,53,12,36,17) | 4.52 units on a scale | Standard Deviation 6.77 |
| CP-690,550 10 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 5.87 units on a scale | Standard Deviation 10.31 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=40,20,44,13,55,63,60,53,12,36,17) | 4.46 units on a scale | Standard Deviation 10.55 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 7.54 units on a scale | Standard Deviation 10.36 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=40,20,44,13,55,63,60,53,12,36,17) | 8.31 units on a scale | Standard Deviation 8.48 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=63,0,59,0,64,64,65,70,0,61,0) | 5.30 units on a scale | Standard Deviation 8.03 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=63,0,59,0,64,64,65,70,0,61,0) | 3.43 units on a scale | Standard Deviation 10.19 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=63,0,59,0,64,64,65,70,0,61,0) | 2.68 units on a scale | Standard Deviation 9.44 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=40,20,44,13,55,63,60,53,12,36,17) | 6.64 units on a scale | Standard Deviation 9.03 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=40,20,44,13,55,63,60,53,12,36,17) | 6.34 units on a scale | Standard Deviation 7.85 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 7.77 units on a scale | Standard Deviation 9.41 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=63,0,59,0,64,64,65,70,0,61,0) | 4.26 units on a scale | Standard Deviation 9.93 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=63,0,59,0,64,64,65,70,0,61,0) | 7.28 units on a scale | Standard Deviation 10.29 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=40,20,44,13,55,63,60,53,12,36,17) | 10.09 units on a scale | Standard Deviation 10.44 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=63,0,59,0,64,64,65,70,0,61,0) | 4.57 units on a scale | Standard Deviation 8.25 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=63,0,59,0,64,64,65,70,0,61,0) | 4.78 units on a scale | Standard Deviation 8.81 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=40,20,44,13,55,63,60,53,12,36,17) | 5.43 units on a scale | Standard Deviation 11.92 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=63,0,59,0,64,64,65,70,0,61,0) | 2.72 units on a scale | Standard Deviation 9.57 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=40,20,44,13,55,63,60,53,12,36,17) | 6.01 units on a scale | Standard Deviation 10.23 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=40,20,44,13,55,63,60,53,12,36,17) | 4.24 units on a scale | Standard Deviation 11.81 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=63,0,59,0,64,64,65,70,0,61,0) | 4.68 units on a scale | Standard Deviation 9.86 |
| CP-690,550 15 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=63,0,59,0,64,64,65,70,0,61,0) | 2.25 units on a scale | Standard Deviation 11.23 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=40,20,44,13,55,63,60,53,12,36,17) | 0.73 units on a scale | Standard Deviation 10.85 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=63,0,59,0,64,64,65,70,0,61,0) | 4.52 units on a scale | Standard Deviation 11.62 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=40,20,44,13,55,63,60,53,12,36,17) | 4.68 units on a scale | Standard Deviation 8.77 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=63,0,59,0,64,64,65,70,0,61,0) | 8.74 units on a scale | Standard Deviation 10.66 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=63,0,59,0,64,64,65,70,0,61,0) | 0.04 units on a scale | Standard Deviation 9.08 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=63,0,59,0,64,64,65,70,0,61,0) | 2.73 units on a scale | Standard Deviation 13.28 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=40,20,44,13,55,63,60,53,12,36,17) | 0.36 units on a scale | Standard Deviation 10.48 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=63,0,59,0,64,64,65,70,0,61,0) | 2.29 units on a scale | Standard Deviation 8.8 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 4.16 units on a scale | Standard Deviation 11.99 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 6.41 units on a scale | Standard Deviation 11.62 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=63,0,59,0,64,64,65,70,0,61,0) | 2.73 units on a scale | Standard Deviation 7.46 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=63,0,59,0,64,64,65,70,0,61,0) | 6.32 units on a scale | Standard Deviation 8.72 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=40,20,44,13,55,63,60,53,12,36,17) | 3.52 units on a scale | Standard Deviation 9.27 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=40,20,44,13,55,63,60,53,12,36,17) | 5.56 units on a scale | Standard Deviation 9.76 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=63,0,59,0,64,64,65,70,0,61,0) | 4.18 units on a scale | Standard Deviation 11.13 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=63,0,59,0,64,64,65,70,0,61,0) | 3.49 units on a scale | Standard Deviation 11.84 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=40,20,44,13,55,63,60,53,12,36,17) | 7.99 units on a scale | Standard Deviation 9.21 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=40,20,44,13,55,63,60,53,12,36,17) | 9.21 units on a scale | Standard Deviation 10.31 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=40,20,44,13,55,63,60,53,12,36,17) | 4.01 units on a scale | Standard Deviation 13.3 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=63,0,59,0,64,64,65,70,0,61,0) | 0.28 units on a scale | Standard Deviation 10.13 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=63,0,59,0,64,64,65,70,0,61,0) | 4.32 units on a scale | Standard Deviation 8.59 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=40,20,44,13,55,63,60,53,12,36,17) | 7.81 units on a scale | Standard Deviation 8.84 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=63,0,59,0,64,64,65,70,0,61,0) | 6.77 units on a scale | Standard Deviation 7.29 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=40,20,44,13,55,63,60,53,12,36,17) | 4.78 units on a scale | Standard Deviation 9.04 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 6.63 units on a scale | Standard Deviation 10.3 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=40,20,44,13,55,63,60,53,12,36,17) | 8.53 units on a scale | Standard Deviation 9.99 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=40,20,44,13,55,63,60,53,12,36,17) | 6.61 units on a scale | Standard Deviation 9.33 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=63,0,59,0,64,64,65,70,0,61,0) | 4.70 units on a scale | Standard Deviation 10.33 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=63,0,59,0,64,64,65,70,0,61,0) | 5.20 units on a scale | Standard Deviation 9.27 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=40,20,44,13,55,63,60,53,12,36,17) | 10.44 units on a scale | Standard Deviation 10.51 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=63,0,59,0,64,64,65,70,0,61,0) | 4.68 units on a scale | Standard Deviation 8.73 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=40,20,44,13,55,63,60,53,12,36,17) | 5.41 units on a scale | Standard Deviation 7.88 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=63,0,59,0,64,64,65,70,0,61,0) | 3.81 units on a scale | Standard Deviation 9.58 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=63,0,59,0,64,64,65,70,0,61,0) | 3.77 units on a scale | Standard Deviation 13.04 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=63,0,59,0,64,64,65,70,0,61,0) | 6.87 units on a scale | Standard Deviation 8.76 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 4.91 units on a scale | Standard Deviation 10.27 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=63,0,59,0,64,64,65,70,0,61,0) | 9.23 units on a scale | Standard Deviation 9.48 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=40,20,44,13,55,63,60,53,12,36,17) | 5.44 units on a scale | Standard Deviation 8.23 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=40,20,44,13,55,63,60,53,12,36,17) | 5.18 units on a scale | Standard Deviation 11.73 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=63,0,59,0,64,64,65,70,0,61,0) | 5.96 units on a scale | Standard Deviation 8.21 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=63,0,59,0,64,64,65,70,0,61,0) | 6.86 units on a scale | Standard Deviation 9.69 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=40,20,44,13,55,63,60,53,12,36,17) | 9.59 units on a scale | Standard Deviation 8.67 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=63,0,59,0,64,64,65,70,0,61,0) | 10.54 units on a scale | Standard Deviation 9.16 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=40,20,44,13,55,63,60,53,12,36,17) | 4.52 units on a scale | Standard Deviation 12.52 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 8.81 units on a scale | Standard Deviation 10.48 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=40,20,44,13,55,63,60,53,12,36,17) | 11.86 units on a scale | Standard Deviation 10.67 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=63,0,59,0,64,64,65,70,0,61,0) | 4.97 units on a scale | Standard Deviation 9.64 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=40,20,44,13,55,63,60,53,12,36,17) | 5.57 units on a scale | Standard Deviation 14.61 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=63,0,59,0,64,64,65,70,0,61,0) | 7.98 units on a scale | Standard Deviation 7.95 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=63,0,59,0,64,64,65,70,0,61,0) | 7.40 units on a scale | Standard Deviation 9.15 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=40,20,44,13,55,63,60,53,12,36,17) | 7.25 units on a scale | Standard Deviation 11.27 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=63,0,59,0,64,64,65,70,0,61,0) | 5.84 units on a scale | Standard Deviation 12.43 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=40,20,44,13,55,63,60,53,12,36,17) | 7.95 units on a scale | Standard Deviation 11.17 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=63,0,59,0,64,64,65,70,0,61,0) | 5.59 units on a scale | Standard Deviation 9.87 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=40,20,44,13,55,63,60,53,12,36,17) | 5.31 units on a scale | Standard Deviation 12.73 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=63,0,59,0,64,64,65,70,0,61,0) | 5.33 units on a scale | Standard Deviation 12.06 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 6.79 units on a scale | Standard Deviation 11.86 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=63,0,59,0,64,64,65,70,0,61,0) | 4.18 units on a scale | Standard Deviation 10.04 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=63,0,59,0,64,64,65,70,0,61,0) | 5.22 units on a scale | Standard Deviation 8.28 |
| CP-690,550 20 mg | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=40,20,44,13,55,63,60,53,12,36,17) | 6.43 units on a scale | Standard Deviation 8.93 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=40,20,44,13,55,63,60,53,12,36,17) | 5.51 units on a scale | Standard Deviation 10.5 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=40,20,44,13,55,63,60,53,12,36,17) | 10.67 units on a scale | Standard Deviation 12.01 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=40,20,44,13,55,63,60,53,12,36,17) | 5.92 units on a scale | Standard Deviation 9.84 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 3.64 units on a scale | Standard Deviation 11.71 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=40,20,44,13,55,63,60,53,12,36,17) | 2.27 units on a scale | Standard Deviation 16.86 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=40,20,44,13,55,63,60,53,12,36,17) | 6.57 units on a scale | Standard Deviation 12.84 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=40,20,44,13,55,63,60,53,12,36,17) | 7.83 units on a scale | Standard Deviation 7.89 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=40,20,44,13,55,63,60,53,12,36,17) | 3.44 units on a scale | Standard Deviation 14.1 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 6.49 units on a scale | Standard Deviation 8.15 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=40,20,44,13,55,63,60,53,12,36,17) | 6.76 units on a scale | Standard Deviation 11.52 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=63,0,59,0,64,64,65,70,0,61,0) | -0.96 units on a scale | Standard Deviation 12.04 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 3.74 units on a scale | Standard Deviation 9.56 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=63,0,59,0,64,64,65,70,0,61,0) | 2.24 units on a scale | Standard Deviation 8.79 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=40,20,44,13,55,63,60,53,12,36,17) | 5.92 units on a scale | Standard Deviation 10.51 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=63,0,59,0,64,64,65,70,0,61,0) | 2.47 units on a scale | Standard Deviation 10.32 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=40,20,44,13,55,63,60,53,12,36,17) | 5.85 units on a scale | Standard Deviation 11.43 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=63,0,59,0,64,64,65,70,0,61,0) | 0.80 units on a scale | Standard Deviation 9.7 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 3.33 units on a scale | Standard Deviation 12.73 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=40,20,44,13,55,63,60,53,12,36,17) | 0.70 units on a scale | Standard Deviation 9.97 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=63,0,59,0,64,64,65,70,0,61,0) | -0.88 units on a scale | Standard Deviation 9.76 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=40,20,44,13,55,63,60,53,12,36,17) | 0.97 units on a scale | Standard Deviation 13.7 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=63,0,59,0,64,64,65,70,0,61,0) | 2.01 units on a scale | Standard Deviation 9.91 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=40,20,44,13,55,63,60,53,12,36,17) | 4.20 units on a scale | Standard Deviation 12.05 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=63,0,59,0,64,64,65,70,0,61,0) | 1.45 units on a scale | Standard Deviation 11.66 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=63,0,59,0,64,64,65,70,0,61,0) | 3.23 units on a scale | Standard Deviation 8.98 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=40,20,44,13,55,63,60,53,12,36,17) | 2.08 units on a scale | Standard Deviation 13.86 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=40,20,44,13,55,63,60,53,12,36,17) | 6.26 units on a scale | Standard Deviation 9.97 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=63,0,59,0,64,64,65,70,0,61,0) | 3.71 units on a scale | Standard Deviation 7.43 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=40,20,44,13,55,63,60,53,12,36,17) | -0.07 units on a scale | Standard Deviation 12.42 |
| Placebo | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=63,0,59,0,64,64,65,70,0,61,0) | -1.40 units on a scale | Standard Deviation 9.18 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Mn C (n=40,20,44,13,55,63,60,53,12,36,17) | 1.57 units on a scale | Standard Deviation 8.22 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: MnH (n=40,20,44,13,55,63,60,53,12,36,17) | 0.99 units on a scale | Standard Deviation 10.1 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: GH (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: So Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 3.85 units on a scale | Standard Deviation 9.2 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: BP (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: So Fn (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-P (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: GH (n=40,20,44,13,55,63,60,53,12,36,17) | 4.04 units on a scale | Standard Deviation 3.82 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Vit (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: BP (n=40,20,44,13,55,63,60,53,12,36,17) | 7.73 units on a scale | Standard Deviation 7.63 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-P (n=40,20,44,13,55,63,60,53,12,36,17) | 4.75 units on a scale | Standard Deviation 8.64 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph Fn(n=40,20,44,13,55,63,60,53,12,36,17) | 4.21 units on a scale | Standard Deviation 9.84 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph C (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: MnH (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Vit (n=40,20,44,13,55,63,60,53,12,36,17) | 6.06 units on a scale | Standard Deviation 6.19 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Mn C (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: Ph Fn (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: Ph C (n=40,20,44,13,55,63,60,53,12,36,17) | 6.40 units on a scale | Standard Deviation 8.08 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 12: R-E (n=63,0,59,0,64,64,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24/ET | Week 24: R-E (n=40,20,44,13,55,63,60,53,12,36,17) | 2.29 units on a scale | Standard Deviation 11.17 |
Secondary
Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultra-sensitive assay. Normal range of CRP is 0 mg/dL to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | -5.92 mg/dL | Standard Deviation 16.61 |
| CP-690,550 1 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,43,43,53,63,56,52,12,36,17) | -7.61 mg/dL | Standard Deviation 11.78 |
| CP-690,550 1 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | -5.94 mg/dL | Standard Deviation 16.03 |
| CP-690,550 1 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -6.96 mg/dL | Standard Deviation 10.61 |
| CP-690,550 1 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | -6.07 mg/dL | Standard Deviation 14.44 |
| CP-690,550 1 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | -2.05 mg/dL | Standard Deviation 18.32 |
| CP-690,550 1 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -6.21 mg/dL | Standard Deviation 10.94 |
| CP-690,550 1 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | -7.56 mg/dL | Standard Deviation 17.07 |
| CP-690,550 3 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | NA mg/dL | — |
| CP-690,550 3 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | NA mg/dL | — |
| CP-690,550 3 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | NA mg/dL | — |
| CP-690,550 3 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,43,43,53,63,56,52,12,36,17) | -8.07 mg/dL | Standard Deviation 10.28 |
| CP-690,550 3 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA mg/dL | — |
| CP-690,550 3 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -11.26 mg/dL | Standard Deviation 21.64 |
| CP-690,550 3 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | NA mg/dL | — |
| CP-690,550 3 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -9.73 mg/dL | Standard Deviation 22.12 |
| CP-690,550 5 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | -6.28 mg/dL | Standard Deviation 14.07 |
| CP-690,550 5 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | -5.12 mg/dL | Standard Deviation 17.24 |
| CP-690,550 5 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | -6.93 mg/dL | Standard Deviation 14.85 |
| CP-690,550 5 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,43,43,53,63,56,52,12,36,17) | -7.57 mg/dL | Standard Deviation 22.26 |
| CP-690,550 5 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | -6.97 mg/dL | Standard Deviation 17.77 |
| CP-690,550 5 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | -7.42 mg/dL | Standard Deviation 14.21 |
| CP-690,550 5 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -11.31 mg/dL | Standard Deviation 16.46 |
| CP-690,550 5 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -7.04 mg/dL | Standard Deviation 21.18 |
| CP-690,550 10 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,43,43,53,63,56,52,12,36,17) | 0.40 mg/dL | Standard Deviation 16.5 |
| CP-690,550 10 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -0.90 mg/dL | Standard Deviation 20.08 |
| CP-690,550 10 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | NA mg/dL | — |
| CP-690,550 10 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA mg/dL | — |
| CP-690,550 10 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | NA mg/dL | — |
| CP-690,550 10 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | NA mg/dL | — |
| CP-690,550 10 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | NA mg/dL | — |
| CP-690,550 10 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -6.33 mg/dL | Standard Deviation 10.48 |
| CP-690,550 15 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,43,43,53,63,56,52,12,36,17) | -8.18 mg/dL | Standard Deviation 19.26 |
| CP-690,550 15 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | -9.81 mg/dL | Standard Deviation 23.67 |
| CP-690,550 15 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | -11.38 mg/dL | Standard Deviation 19.27 |
| CP-690,550 15 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | -8.54 mg/dL | Standard Deviation 16.65 |
| CP-690,550 15 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -7.80 mg/dL | Standard Deviation 23.28 |
| CP-690,550 15 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -11.53 mg/dL | Standard Deviation 22 |
| CP-690,550 15 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | -11.35 mg/dL | Standard Deviation 21.25 |
| CP-690,550 15 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | -12.52 mg/dL | Standard Deviation 23.93 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -9.60 mg/dL | Standard Deviation 19.16 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | -9.45 mg/dL | Standard Deviation 16.27 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | -5.96 mg/dL | Standard Deviation 23.26 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -8.18 mg/dL | Standard Deviation 18.99 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | -9.19 mg/dL | Standard Deviation 19.9 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,43,43,53,63,56,52,12,36,17) | -8.72 mg/dL | Standard Deviation 22.73 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | -9.38 mg/dL | Standard Deviation 16.02 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | -4.97 mg/dL | Standard Deviation 24.54 |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -7.01 mg/dL | Standard Deviation 27.54 |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | -10.73 mg/dL | Standard Deviation 17.63 |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,43,43,53,63,56,52,12,36,17) | -10.65 mg/dL | Standard Deviation 18.76 |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -14.21 mg/dL | Standard Deviation 16.73 |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | -10.18 mg/dL | Standard Deviation 16.26 |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | -8.67 mg/dL | Standard Deviation 18.05 |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | -11.87 mg/dL | Standard Deviation 15.22 |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | -11.70 mg/dL | Standard Deviation 17.89 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,43,43,53,63,56,52,12,36,17) | -8.75 mg/dL | Standard Deviation 15.4 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | -6.69 mg/dL | Standard Deviation 13.99 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | -6.56 mg/dL | Standard Deviation 12.7 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -8.16 mg/dL | Standard Deviation 17.01 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | -5.03 mg/dL | Standard Deviation 17.94 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | -5.71 mg/dL | Standard Deviation 20.18 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -9.65 mg/dL | Standard Deviation 15.32 |
| CP-690,550 20 mg | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | -6.11 mg/dL | Standard Deviation 19.97 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -10.22 mg/dL | Standard Deviation 13.83 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -7.59 mg/dL | Standard Deviation 12.45 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | NA mg/dL | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,43,43,53,63,56,52,12,36,17) | -10.92 mg/dL | Standard Deviation 15.78 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA mg/dL | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | NA mg/dL | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | NA mg/dL | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | NA mg/dL | — |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | -1.26 mg/dL | Standard Deviation 12.51 |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | 3.70 mg/dL | Standard Deviation 25.55 |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 0.11 mg/dL | Standard Deviation 15.15 |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | 2.07 mg/dL | Standard Deviation 15.9 |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -2.59 mg/dL | Standard Deviation 13.79 |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | 0.64 mg/dL | Standard Deviation 14.26 |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,43,43,53,63,56,52,12,36,17) | -2.16 mg/dL | Standard Deviation 16.06 |
| Placebo | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | -0.51 mg/dL | Standard Deviation 12.72 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | NA mg/dL | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -7.52 mg/dL | Standard Deviation 20.34 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | NA mg/dL | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -13.44 mg/dL | Standard Deviation 12.75 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | NA mg/dL | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA mg/dL | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | NA mg/dL | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in C-Reactive Protein (CRP) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,43,43,53,63,56,52,12,36,17) | -3.41 mg/dL | Standard Deviation 26.61 |
Secondary
Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,69,0,61,0) | -0.99 units on a scale | Standard Deviation 0.91 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | -1.45 units on a scale | Standard Deviation 1.13 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -1.94 units on a scale | Standard Deviation 1.26 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | -1.22 units on a scale | Standard Deviation 1.14 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | -2.06 units on a scale | Standard Deviation 1.22 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -1.87 units on a scale | Standard Deviation 1.13 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=64,0,63,0,63,69,68,73,0,61,0) | -0.55 units on a scale | Standard Deviation 0.76 |
| CP-690,550 1 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | -1.13 units on a scale | Standard Deviation 1.03 |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,69,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=64,0,63,0,63,69,68,73,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -1.14 units on a scale | Standard Deviation 0.99 |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -1.64 units on a scale | Standard Deviation 1.25 |
| CP-690,550 3 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | -1.55 units on a scale | Standard Deviation 1.07 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | -1.85 units on a scale | Standard Deviation 1.27 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | -1.52 units on a scale | Standard Deviation 1.27 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=64,0,63,0,63,69,68,73,0,61,0) | -0.78 units on a scale | Standard Deviation 0.92 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | -1.61 units on a scale | Standard Deviation 1.18 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -2.27 units on a scale | Standard Deviation 1.14 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -2.41 units on a scale | Standard Deviation 1.26 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | -2.29 units on a scale | Standard Deviation 1.19 |
| CP-690,550 5 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,69,0,61,0) | -1.23 units on a scale | Standard Deviation 1.19 |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,69,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | -0.92 units on a scale | Standard Deviation 1.17 |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -0.76 units on a scale | Standard Deviation 1.22 |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=64,0,63,0,63,69,68,73,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -0.81 units on a scale | Standard Deviation 1.2 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | -1.56 units on a scale | Standard Deviation 0.97 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | -1.59 units on a scale | Standard Deviation 1.18 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | -1.44 units on a scale | Standard Deviation 0.99 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | -2.06 units on a scale | Standard Deviation 1.04 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -1.93 units on a scale | Standard Deviation 1.12 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,69,0,61,0) | -1.09 units on a scale | Standard Deviation 0.94 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -2.05 units on a scale | Standard Deviation 1.15 |
| CP-690,550 15 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=64,0,63,0,63,69,68,73,0,61,0) | -0.86 units on a scale | Standard Deviation 0.82 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=64,0,63,0,63,69,68,73,0,61,0) | -1.07 units on a scale | Standard Deviation 0.84 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | -2.13 units on a scale | Standard Deviation 1.12 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | -1.63 units on a scale | Standard Deviation 1.25 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -2.09 units on a scale | Standard Deviation 1.28 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | -1.82 units on a scale | Standard Deviation 1.17 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | -1.66 units on a scale | Standard Deviation 1.18 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -1.89 units on a scale | Standard Deviation 1.13 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,69,0,61,0) | -1.58 units on a scale | Standard Deviation 1.09 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,69,0,61,0) | -1.71 units on a scale | Standard Deviation 1.2 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=64,0,63,0,63,69,68,73,0,61,0) | -1.22 units on a scale | Standard Deviation 1.08 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | -1.81 units on a scale | Standard Deviation 1.17 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | -2.02 units on a scale | Standard Deviation 1.14 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -2.31 units on a scale | Standard Deviation 1.39 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -2.49 units on a scale | Standard Deviation 1.26 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | -2.13 units on a scale | Standard Deviation 1.32 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | -2.49 units on a scale | Standard Deviation 1.27 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -2.17 units on a scale | Standard Deviation 0.96 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | -1.72 units on a scale | Standard Deviation 1.13 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -2.13 units on a scale | Standard Deviation 1.04 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | -2.19 units on a scale | Standard Deviation 1.04 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,69,0,61,0) | -1.30 units on a scale | Standard Deviation 1.06 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=64,0,63,0,63,69,68,73,0,61,0) | -1.01 units on a scale | Standard Deviation 0.97 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | -1.63 units on a scale | Standard Deviation 1.17 |
| CP-690,550 20 mg | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | -1.38 units on a scale | Standard Deviation 1.07 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -0.95 units on a scale | Standard Deviation 0.81 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | -1.26 units on a scale | Standard Deviation 1.23 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,69,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -0.88 units on a scale | Standard Deviation 0.95 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=64,0,63,0,63,69,68,73,0,61,0) | NA units on a scale | — |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -1.27 units on a scale | Standard Deviation 1.37 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -1.14 units on a scale | Standard Deviation 1.03 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | -0.82 units on a scale | Standard Deviation 1.11 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,69,0,61,0) | -0.57 units on a scale | Standard Deviation 0.88 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | -0.83 units on a scale | Standard Deviation 1.11 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | -0.80 units on a scale | Standard Deviation 0.93 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=64,0,63,0,63,69,68,73,0,61,0) | -0.26 units on a scale | Standard Deviation 0.78 |
| Placebo | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | -1.55 units on a scale | Standard Deviation 1.25 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | -1.47 units on a scale | Standard Deviation 1.04 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=64,0,63,0,63,69,68,73,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | -1.25 units on a scale | Standard Deviation 0.96 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | -1.43 units on a scale | Standard Deviation 0.7 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=65,0,61,0,62,64,65,69,0,61,0) | NA units on a scale | — |
Secondary
Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Time frame: Baseline, Week 12, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.20 units on a scale | Standard Deviation 0.3 |
| CP-690,550 1 mg | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | 0.15 units on a scale | Standard Deviation 0.26 |
| CP-690,550 3 mg | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.00 units on a scale | Standard Deviation 0.3 |
| CP-690,550 3 mg | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 5 mg | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | 0.16 units on a scale | Standard Deviation 0.37 |
| CP-690,550 5 mg | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.23 units on a scale | Standard Deviation 0.33 |
| CP-690,550 10 mg | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.23 units on a scale | Standard Deviation 0.37 |
| CP-690,550 15 mg | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.19 units on a scale | Standard Deviation 0.3 |
| CP-690,550 15 mg | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | 0.11 units on a scale | Standard Deviation 0.32 |
| CP-690,550 20 mg | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | 0.17 units on a scale | Standard Deviation 0.27 |
| CP-690,550 20 mg | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.20 units on a scale | Standard Deviation 0.31 |
| Placebo | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.18 units on a scale | Standard Deviation 0.29 |
| Placebo | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | 0.18 units on a scale | Standard Deviation 0.29 |
| CP-690,550 20 mg | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | 0.16 units on a scale | Standard Deviation 0.29 |
| CP-690,550 20 mg | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.17 units on a scale | Standard Deviation 0.32 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.20 units on a scale | Standard Deviation 0.45 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | NA units on a scale | — |
| Placebo | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | 0.05 units on a scale | Standard Deviation 0.35 |
| Placebo | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.13 units on a scale | Standard Deviation 0.3 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility at Week 12 and 24/ET | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.03 units on a scale | Standard Deviation 0.29 |
Secondary
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET
FACIT-FS is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.
Time frame: Baseline, Week 2, 12, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=68,0,68,0,68,72,73,78,0,66,0) | 1.96 units on a scale | Standard Deviation 7.99 |
| CP-690,550 1 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | 4.82 units on a scale | Standard Deviation 8.53 |
| CP-690,550 1 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=39,20,44,13,55,64,59,50,12,35,17) | 6.23 units on a scale | Standard Deviation 9.66 |
| CP-690,550 3 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=39,20,44,13,55,64,59,50,12,35,17) | 3.73 units on a scale | Standard Deviation 10.35 |
| CP-690,550 3 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=68,0,68,0,68,72,73,78,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | NA units on a scale | — |
| CP-690,550 5 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | 5.79 units on a scale | Standard Deviation 10.95 |
| CP-690,550 5 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=39,20,44,13,55,64,59,50,12,35,17) | 5.33 units on a scale | Standard Deviation 9.42 |
| CP-690,550 5 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=68,0,68,0,68,72,73,78,0,66,0) | 2.74 units on a scale | Standard Deviation 7.8 |
| CP-690,550 10 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=68,0,68,0,68,72,73,78,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=39,20,44,13,55,64,59,50,12,35,17) | 5.62 units on a scale | Standard Deviation 11.57 |
| CP-690,550 10 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | NA units on a scale | — |
| CP-690,550 15 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=39,20,44,13,55,64,59,50,12,35,17) | 7.18 units on a scale | Standard Deviation 9.08 |
| CP-690,550 15 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | 4.90 units on a scale | Standard Deviation 8.98 |
| CP-690,550 15 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=68,0,68,0,68,72,73,78,0,66,0) | 3.54 units on a scale | Standard Deviation 7.71 |
| CP-690,550 20 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=68,0,68,0,68,72,73,78,0,66,0) | 2.80 units on a scale | Standard Deviation 7.4 |
| CP-690,550 20 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=39,20,44,13,55,64,59,50,12,35,17) | 4.49 units on a scale | Standard Deviation 9.43 |
| CP-690,550 20 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | 2.18 units on a scale | Standard Deviation 9.25 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=39,20,44,13,55,64,59,50,12,35,17) | 6.54 units on a scale | Standard Deviation 8.9 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=68,0,68,0,68,72,73,78,0,66,0) | 3.68 units on a scale | Standard Deviation 7.24 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | 5.41 units on a scale | Standard Deviation 9.02 |
| CP-690,550 20 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=68,0,68,0,68,72,73,78,0,66,0) | 3.37 units on a scale | Standard Deviation 6.56 |
| CP-690,550 20 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | 4.51 units on a scale | Standard Deviation 9.27 |
| CP-690,550 20 mg | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=39,20,44,13,55,64,59,50,12,35,17) | 6.88 units on a scale | Standard Deviation 9.28 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=68,0,68,0,68,72,73,78,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=39,20,44,13,55,64,59,50,12,35,17) | 4.75 units on a scale | Standard Deviation 10.84 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=68,0,68,0,68,72,73,78,0,66,0) | 1.61 units on a scale | Standard Deviation 6.21 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | 2.71 units on a scale | Standard Deviation 9.94 |
| Placebo | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=39,20,44,13,55,64,59,50,12,35,17) | 3.23 units on a scale | Standard Deviation 12.13 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 24 (n=39,20,44,13,55,64,59,50,12,35,17) | 4.18 units on a scale | Standard Deviation 6.09 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 2 (n=68,0,68,0,68,72,73,78,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale at Week 2, 12 and 24/ET | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | NA units on a scale | — |
Secondary
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Change = scores at observation minus score at Baseline, and total possible score ranged from -3 to 3. A negative value in change from baseline indicates an improvement.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,58,0,64,65,66,68,0,61,0) | -0.37 units on a scale | Standard Deviation 0.48 |
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,62,0,69,71,72,74,0,61,0) | -0.31 units on a scale | Standard Deviation 0.45 |
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -0.52 units on a scale | Standard Deviation 0.48 |
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | -0.62 units on a scale | Standard Deviation 0.47 |
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -0.15 units on a scale | Standard Deviation 0.38 |
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,75,0,66,0) | -0.24 units on a scale | Standard Deviation 0.46 |
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,54,63,59,53,12,36,17) | -0.60 units on a scale | Standard Deviation 0.52 |
| CP-690,550 1 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,61,0,66,67,70,71,0,61,0) | -0.34 units on a scale | Standard Deviation 0.48 |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -0.16 units on a scale | Standard Deviation 0.5 |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,61,0,66,67,70,71,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,58,0,64,65,66,68,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,62,0,69,71,72,74,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,54,63,59,53,12,36,17) | -0.21 units on a scale | Standard Deviation 0.58 |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,75,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | -0.24 units on a scale | Standard Deviation 0.42 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -0.23 units on a scale | Standard Deviation 0.49 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | -0.62 units on a scale | Standard Deviation 0.68 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,61,0,66,67,70,71,0,61,0) | -0.41 units on a scale | Standard Deviation 0.63 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -0.59 units on a scale | Standard Deviation 0.64 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,58,0,64,65,66,68,0,61,0) | -0.48 units on a scale | Standard Deviation 0.61 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,75,0,66,0) | -0.36 units on a scale | Standard Deviation 0.52 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,62,0,69,71,72,74,0,61,0) | -0.39 units on a scale | Standard Deviation 0.53 |
| CP-690,550 5 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,54,63,59,53,12,36,17) | -0.53 units on a scale | Standard Deviation 0.65 |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,58,0,64,65,66,68,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -0.08 units on a scale | Standard Deviation 0.31 |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,54,63,59,53,12,36,17) | -0.21 units on a scale | Standard Deviation 0.32 |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | -0.13 units on a scale | Standard Deviation 0.41 |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,75,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,62,0,69,71,72,74,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,61,0,66,67,70,71,0,61,0) | NA units on a scale | — |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -0.52 units on a scale | Standard Deviation 0.59 |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,62,0,69,71,72,74,0,61,0) | -0.42 units on a scale | Standard Deviation 0.54 |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,61,0,66,67,70,71,0,61,0) | -0.40 units on a scale | Standard Deviation 0.58 |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -0.23 units on a scale | Standard Deviation 0.41 |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | -0.64 units on a scale | Standard Deviation 0.62 |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,75,0,66,0) | -0.32 units on a scale | Standard Deviation 0.51 |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,54,63,59,53,12,36,17) | -0.61 units on a scale | Standard Deviation 0.65 |
| CP-690,550 15 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,58,0,64,65,66,68,0,61,0) | -0.51 units on a scale | Standard Deviation 0.61 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,62,0,69,71,72,74,0,61,0) | -0.32 units on a scale | Standard Deviation 0.57 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,54,63,59,53,12,36,17) | -0.47 units on a scale | Standard Deviation 0.62 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,61,0,66,67,70,71,0,61,0) | -0.43 units on a scale | Standard Deviation 0.66 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,75,0,66,0) | -0.25 units on a scale | Standard Deviation 0.45 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -0.18 units on a scale | Standard Deviation 0.42 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,58,0,64,65,66,68,0,61,0) | -0.37 units on a scale | Standard Deviation 0.63 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -0.41 units on a scale | Standard Deviation 0.63 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | -0.49 units on a scale | Standard Deviation 0.58 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -0.24 units on a scale | Standard Deviation 0.4 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,58,0,64,65,66,68,0,61,0) | -0.45 units on a scale | Standard Deviation 0.5 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | -0.51 units on a scale | Standard Deviation 0.59 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -0.45 units on a scale | Standard Deviation 0.6 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,54,63,59,53,12,36,17) | -0.53 units on a scale | Standard Deviation 0.6 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,61,0,66,67,70,71,0,61,0) | -0.39 units on a scale | Standard Deviation 0.49 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,62,0,69,71,72,74,0,61,0) | -0.34 units on a scale | Standard Deviation 0.47 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,75,0,66,0) | -0.31 units on a scale | Standard Deviation 0.44 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,58,0,64,65,66,68,0,61,0) | -0.58 units on a scale | Standard Deviation 0.61 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | -0.67 units on a scale | Standard Deviation 0.65 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,61,0,66,67,70,71,0,61,0) | -0.50 units on a scale | Standard Deviation 0.61 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,62,0,69,71,72,74,0,61,0) | -0.42 units on a scale | Standard Deviation 0.52 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,75,0,66,0) | -0.34 units on a scale | Standard Deviation 0.5 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -0.62 units on a scale | Standard Deviation 0.62 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -0.23 units on a scale | Standard Deviation 0.45 |
| CP-690,550 20 mg | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,54,63,59,53,12,36,17) | -0.66 units on a scale | Standard Deviation 0.72 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,61,0,66,67,70,71,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,75,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,62,0,69,71,72,74,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,58,0,64,65,66,68,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -0.46 units on a scale | Standard Deviation 0.58 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | -0.41 units on a scale | Standard Deviation 0.55 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,54,63,59,53,12,36,17) | -0.48 units on a scale | Standard Deviation 0.74 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -0.30 units on a scale | Standard Deviation 0.52 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,61,0,66,67,70,71,0,61,0) | -0.12 units on a scale | Standard Deviation 0.55 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,62,0,69,71,72,74,0,61,0) | -0.13 units on a scale | Standard Deviation 0.59 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -0.05 units on a scale | Standard Deviation 0.36 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,75,0,66,0) | -0.05 units on a scale | Standard Deviation 0.46 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,54,63,59,53,12,36,17) | -0.37 units on a scale | Standard Deviation 0.54 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,58,0,64,65,66,68,0,61,0) | -0.10 units on a scale | Standard Deviation 0.57 |
| Placebo | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | -0.38 units on a scale | Standard Deviation 0.54 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | -0.11 units on a scale | Standard Deviation 0.3 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -0.01 units on a scale | Standard Deviation 0.29 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,54,63,59,53,12,36,17) | -0.08 units on a scale | Standard Deviation 0.29 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,58,0,64,65,66,68,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,62,0,69,71,72,74,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,61,0,66,67,70,71,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,75,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
Secondary
Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET
Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range: 0-100); sleep quantity (Qua) (range: 0-24), and optimal (Opt) sleep (yes: 1, no: 0) and 9 item index measures of sleep disturbance were constructed to provide 2 composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range\*100); total score range: 0 to 100; higher score = greater intensity of attribute.
Time frame: Baseline, Week 2, 12, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.00 units on a scale | Standard Deviation 0.51 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=62,0,59,0,63,65,63,69,0,61,0) | -7.27 units on a scale | Standard Deviation 11.71 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=68,0,68,0,68,73,73,79,0,65,0) | -5.64 units on a scale | Standard Deviation 13.23 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | -13.66 units on a scale | Standard Deviation 18.64 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | -9.74 units on a scale | Standard Deviation 16.98 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=40,20,44,13,55,64,58,52,12,34,17) | 7.75 units on a scale | Standard Deviation 26.36 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=62,0,59,0,63,65,63,70,0,61,0) | -5.54 units on a scale | Standard Deviation 12.21 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=40,20,44,13,55,64,58,52,12,34,17) | -8.25 units on a scale | Standard Deviation 15.47 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=68,0,68,0,68,73,72,79,0,66,0) | -3.68 units on a scale | Standard Deviation 22.72 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=67,0,68,0,68,73,72,78,0,65,0) | -2.94 units on a scale | Standard Deviation 10.26 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | -3.87 units on a scale | Standard Deviation 24.52 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,66,0) | -0.29 units on a scale | Standard Deviation 19.7 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17) | -3.50 units on a scale | Standard Deviation 20.2 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=62,0,57,0,63,65,64,68,0,61,0) | 0.16 units on a scale | Standard Deviation 1.43 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=62,0,59,0,63,65,63,70,0,61,0) | 1.45 units on a scale | Standard Deviation 22.39 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=40,20,43,13,55,64,59,51,11,35,17) | -0.10 units on a scale | Standard Deviation 1.26 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=40,19,44,13,54,64,59,52,12,34,17) | 3.50 units on a scale | Standard Deviation 25.17 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=67,0,68,0,68,73,72,79,0,66,0) | -0.95 units on a scale | Standard Deviation 11.35 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | 0.00 units on a scale | Standard Deviation 0.54 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | -0.10 units on a scale | Standard Deviation 0.52 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=40,20,44,13,55,64,58,51,12,34,17) | -10.18 units on a scale | Standard Deviation 14.38 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | 0.66 units on a scale | Standard Deviation 22.2 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=40,20,44,13,55,64,59,51,11,34,17) | -5.33 units on a scale | Standard Deviation 21.94 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=68,0,67,0,68,73,73,77,0,66,0) | -0.13 units on a scale | Standard Deviation 1.21 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=62,0,59,0,63,65,64,68,0,61,0) | -6.56 units on a scale | Standard Deviation 18.6 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=67,0,68,0,68,73,73,77,0,66,0) | -3.18 units on a scale | Standard Deviation 18.47 |
| CP-690,550 1 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=67,0,68,0,67,73,73,79,0,66,0) | 3.28 units on a scale | Standard Deviation 22.99 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=62,0,59,0,63,65,63,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=67,0,68,0,68,73,72,79,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=40,20,44,13,55,64,58,51,12,34,17) | -2.81 units on a scale | Standard Deviation 14.39 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=40,20,44,13,55,64,58,52,12,34,17) | -6.00 units on a scale | Standard Deviation 25.42 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17) | -7.00 units on a scale | Standard Deviation 29.22 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=68,0,68,0,68,73,73,79,0,65,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=67,0,68,0,68,73,73,77,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=62,0,59,0,63,65,64,68,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.00 units on a scale | Standard Deviation 0.65 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=62,0,59,0,63,65,63,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=68,0,68,0,68,73,72,79,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | -6.31 units on a scale | Standard Deviation 17.76 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=67,0,68,0,68,73,72,78,0,65,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=67,0,68,0,67,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=40,20,44,13,55,64,58,52,12,34,17) | -0.50 units on a scale | Standard Deviation 15.83 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=40,19,44,13,54,64,59,52,12,34,17) | -1.05 units on a scale | Standard Deviation 23.55 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=68,0,67,0,68,73,73,77,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=62,0,57,0,63,65,64,68,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=40,20,44,13,55,64,59,51,11,34,17) | 0.67 units on a scale | Standard Deviation 18.34 |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=62,0,59,0,63,65,63,69,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=40,20,43,13,55,64,59,51,11,35,17) | 0.00 units on a scale | Standard Deviation 1.65 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=62,0,59,0,63,65,63,70,0,61,0) | 11.19 units on a scale | Standard Deviation 27.55 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=40,20,43,13,55,64,59,51,11,35,17) | 0.35 units on a scale | Standard Deviation 1.56 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=40,20,44,13,55,64,58,52,12,34,17) | 11.59 units on a scale | Standard Deviation 24.3 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=62,0,59,0,63,65,64,68,0,61,0) | -6.33 units on a scale | Standard Deviation 19.08 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=40,20,44,13,55,64,58,51,12,34,17) | -12.16 units on a scale | Standard Deviation 17.87 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=40,20,44,13,55,64,58,52,12,34,17) | -11.97 units on a scale | Standard Deviation 19.23 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,66,0) | -5.29 units on a scale | Standard Deviation 20.62 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17) | -11.36 units on a scale | Standard Deviation 27.42 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=68,0,68,0,68,73,73,79,0,65,0) | -9.89 units on a scale | Standard Deviation 17.97 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | 0.07 units on a scale | Standard Deviation 0.61 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=40,20,44,13,55,64,59,51,11,34,17) | -2.58 units on a scale | Standard Deviation 20.29 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=68,0,67,0,68,73,73,77,0,66,0) | 0.03 units on a scale | Standard Deviation 1.07 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=67,0,68,0,67,73,73,79,0,66,0) | 0.29 units on a scale | Standard Deviation 22.26 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | -0.01 units on a scale | Standard Deviation 0.47 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=67,0,68,0,68,73,73,77,0,66,0) | -5.00 units on a scale | Standard Deviation 18.33 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=68,0,68,0,68,73,72,79,0,66,0) | 5.74 units on a scale | Standard Deviation 21.04 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=40,19,44,13,54,64,59,52,12,34,17) | 2.73 units on a scale | Standard Deviation 28.48 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=62,0,59,0,63,65,63,70,0,61,0) | -10.51 units on a scale | Standard Deviation 20.72 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | -15.88 units on a scale | Standard Deviation 24.63 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=67,0,68,0,68,73,72,79,0,66,0) | -6.57 units on a scale | Standard Deviation 15.2 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=62,0,59,0,63,65,63,69,0,61,0) | -11.21 units on a scale | Standard Deviation 18.59 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=67,0,68,0,68,73,72,78,0,65,0) | -7.76 units on a scale | Standard Deviation 14.28 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | -7.46 units on a scale | Standard Deviation 24.89 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | -13.43 units on a scale | Standard Deviation 22.93 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=62,0,57,0,63,65,64,68,0,61,0) | 0.40 units on a scale | Standard Deviation 1.32 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | -0.34 units on a scale | Standard Deviation 27.67 |
| CP-690,550 5 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.07 units on a scale | Standard Deviation 0.62 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=62,0,59,0,63,65,63,69,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=62,0,59,0,63,65,63,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=67,0,68,0,67,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=40,20,44,13,55,64,58,52,12,34,17) | 9.23 units on a scale | Standard Deviation 23.97 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=40,20,44,13,55,64,58,51,12,34,17) | -8.50 units on a scale | Standard Deviation 16 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17) | -1.54 units on a scale | Standard Deviation 26.41 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | -13.75 units on a scale | Standard Deviation 21.22 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | -0.08 units on a scale | Standard Deviation 0.64 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=68,0,67,0,68,73,73,77,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=40,20,44,13,55,64,59,51,11,34,17) | -4.10 units on a scale | Standard Deviation 15.04 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=68,0,68,0,68,73,73,79,0,65,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=40,20,43,13,55,64,59,51,11,35,17) | 0.38 units on a scale | Standard Deviation 1.66 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=40,19,44,13,54,64,59,52,12,34,17) | 6.15 units on a scale | Standard Deviation 18.95 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=68,0,68,0,68,73,72,79,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=67,0,68,0,68,73,72,79,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=62,0,59,0,63,65,63,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=67,0,68,0,68,73,73,77,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=67,0,68,0,68,73,72,78,0,65,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=62,0,57,0,63,65,64,68,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=40,20,44,13,55,64,58,52,12,34,17) | -6.92 units on a scale | Standard Deviation 18.13 |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=62,0,59,0,63,65,64,68,0,61,0) | NA units on a scale | — |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | 0.03 units on a scale | Standard Deviation 0.64 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=62,0,57,0,63,65,64,68,0,61,0) | -0.73 units on a scale | Standard Deviation 8.24 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=40,20,44,13,55,64,58,52,12,34,17) | -4.12 units on a scale | Standard Deviation 20.03 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=68,0,68,0,68,73,73,79,0,65,0) | -6.82 units on a scale | Standard Deviation 18.04 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=67,0,68,0,68,73,72,79,0,66,0) | -3.43 units on a scale | Standard Deviation 16.51 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=40,20,44,13,55,64,59,51,11,34,17) | -2.18 units on a scale | Standard Deviation 21.08 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | 0.04 units on a scale | Standard Deviation 0.44 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=68,0,67,0,68,73,73,77,0,66,0) | -0.69 units on a scale | Standard Deviation 7.75 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=67,0,68,0,67,73,73,79,0,66,0) | -7.46 units on a scale | Standard Deviation 21.97 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=67,0,68,0,68,73,73,77,0,66,0) | -1.37 units on a scale | Standard Deviation 18.05 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=62,0,59,0,63,65,63,70,0,61,0) | -3.97 units on a scale | Standard Deviation 18.57 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=40,20,43,13,55,64,59,51,11,35,17) | 0.33 units on a scale | Standard Deviation 2.13 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | -2.54 units on a scale | Standard Deviation 28.85 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=40,20,44,13,55,64,58,51,12,34,17) | -6.04 units on a scale | Standard Deviation 19.83 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.02 units on a scale | Standard Deviation 0.62 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=40,19,44,13,54,64,59,52,12,34,17) | -7.04 units on a scale | Standard Deviation 24.92 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | -6.59 units on a scale | Standard Deviation 25.51 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,66,0) | 0.29 units on a scale | Standard Deviation 25.27 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=67,0,68,0,68,73,72,78,0,65,0) | -4.93 units on a scale | Standard Deviation 14.92 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17) | -3.27 units on a scale | Standard Deviation 24.27 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=62,0,59,0,63,65,63,69,0,61,0) | -5.59 units on a scale | Standard Deviation 18.71 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=62,0,59,0,63,65,64,68,0,61,0) | -1.06 units on a scale | Standard Deviation 19.2 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=62,0,59,0,63,65,63,70,0,61,0) | 5.87 units on a scale | Standard Deviation 27.51 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=40,20,44,13,55,64,58,52,12,34,17) | 8.00 units on a scale | Standard Deviation 28.11 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | 3.81 units on a scale | Standard Deviation 28.7 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | -9.25 units on a scale | Standard Deviation 23.07 |
| CP-690,550 15 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=68,0,68,0,68,73,72,79,0,66,0) | 6.76 units on a scale | Standard Deviation 25.06 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=40,20,44,13,55,64,58,52,12,34,17) | 6.72 units on a scale | Standard Deviation 29.33 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=62,0,59,0,63,65,63,69,0,61,0) | -3.64 units on a scale | Standard Deviation 18.32 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | -2.15 units on a scale | Standard Deviation 26.25 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=67,0,68,0,68,73,72,78,0,65,0) | -3.75 units on a scale | Standard Deviation 12.36 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=68,0,68,0,68,73,73,79,0,65,0) | -6.73 units on a scale | Standard Deviation 15.61 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | 0.08 units on a scale | Standard Deviation 0.62 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=67,0,68,0,67,73,73,79,0,66,0) | -4.66 units on a scale | Standard Deviation 23.46 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | 0.07 units on a scale | Standard Deviation 0.56 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=68,0,67,0,68,73,73,77,0,66,0) | -0.21 units on a scale | Standard Deviation 3.75 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | -6.64 units on a scale | Standard Deviation 22.53 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=67,0,68,0,68,73,72,79,0,66,0) | -2.05 units on a scale | Standard Deviation 14.11 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=40,20,44,13,55,64,58,51,12,34,17) | -4.83 units on a scale | Standard Deviation 16.17 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=40,20,44,13,55,64,59,51,11,34,17) | -1.04 units on a scale | Standard Deviation 20.03 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | 2.46 units on a scale | Standard Deviation 26.1 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=62,0,57,0,63,65,64,68,0,61,0) | -0.42 units on a scale | Standard Deviation 3.8 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=40,20,43,13,55,64,59,51,11,35,17) | -0.42 units on a scale | Standard Deviation 3.97 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=62,0,59,0,63,65,63,70,0,61,0) | 4.77 units on a scale | Standard Deviation 29.32 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=62,0,59,0,63,65,63,70,0,61,0) | -2.00 units on a scale | Standard Deviation 19.98 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=40,20,44,13,55,64,58,52,12,34,17) | -3.33 units on a scale | Standard Deviation 16.38 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,66,0) | 5.48 units on a scale | Standard Deviation 21.15 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=62,0,59,0,63,65,64,68,0,61,0) | 1.54 units on a scale | Standard Deviation 23.06 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=67,0,68,0,68,73,73,77,0,66,0) | -0.73 units on a scale | Standard Deviation 16.2 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=40,19,44,13,54,64,59,52,12,34,17) | 0.31 units on a scale | Standard Deviation 28.84 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.08 units on a scale | Standard Deviation 0.65 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=68,0,68,0,68,73,72,79,0,66,0) | 3.70 units on a scale | Standard Deviation 26.11 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | -6.73 units on a scale | Standard Deviation 22.54 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17) | 0.63 units on a scale | Standard Deviation 24.94 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=40,20,44,13,55,64,58,51,12,34,17) | -9.82 units on a scale | Standard Deviation 16.06 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=62,0,57,0,63,65,64,68,0,61,0) | 0.28 units on a scale | Standard Deviation 1.52 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | -0.05 units on a scale | Standard Deviation 0.57 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | -8.22 units on a scale | Standard Deviation 20.59 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=40,20,43,13,55,64,59,51,11,35,17) | 0.31 units on a scale | Standard Deviation 1.44 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | -2.81 units on a scale | Standard Deviation 23.87 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=62,0,59,0,63,65,63,70,0,61,0) | -5.19 units on a scale | Standard Deviation 19.19 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=67,0,68,0,68,73,72,79,0,66,0) | -7.45 units on a scale | Standard Deviation 11.74 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=67,0,68,0,68,73,73,77,0,66,0) | -2.74 units on a scale | Standard Deviation 15.79 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17) | -10.17 units on a scale | Standard Deviation 25.56 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=67,0,68,0,67,73,73,79,0,66,0) | -4.11 units on a scale | Standard Deviation 21.33 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=68,0,67,0,68,73,73,77,0,66,0) | 0.41 units on a scale | Standard Deviation 1.21 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=67,0,68,0,68,73,72,78,0,65,0) | -7.06 units on a scale | Standard Deviation 10.93 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=40,19,44,13,54,64,59,52,12,34,17) | 2.37 units on a scale | Standard Deviation 22.92 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | 0.04 units on a scale | Standard Deviation 0.54 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=62,0,59,0,63,65,63,69,0,61,0) | -5.63 units on a scale | Standard Deviation 17.18 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=68,0,68,0,68,73,73,79,0,65,0) | -8.77 units on a scale | Standard Deviation 15.11 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=40,20,44,13,55,64,58,52,12,34,17) | 5.52 units on a scale | Standard Deviation 26.7 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | 1.56 units on a scale | Standard Deviation 24.25 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,66,0) | -6.03 units on a scale | Standard Deviation 21.78 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=40,20,44,13,55,64,58,52,12,34,17) | -8.62 units on a scale | Standard Deviation 18.34 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=62,0,59,0,63,65,63,70,0,61,0) | 6.51 units on a scale | Standard Deviation 25.15 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=68,0,68,0,68,73,72,79,0,66,0) | 7.64 units on a scale | Standard Deviation 16.74 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=62,0,59,0,63,65,64,68,0,61,0) | -2.81 units on a scale | Standard Deviation 20.33 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | -0.05 units on a scale | Standard Deviation 0.53 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=40,20,44,13,55,64,59,51,11,34,17) | -6.55 units on a scale | Standard Deviation 20.02 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | -13.98 units on a scale | Standard Deviation 18.7 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,66,0) | 0.00 units on a scale | Standard Deviation 20.51 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=40,20,43,13,55,64,59,51,11,35,17) | 0.08 units on a scale | Standard Deviation 1.04 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=67,0,68,0,68,73,73,77,0,66,0) | -3.03 units on a scale | Standard Deviation 17.76 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=62,0,59,0,63,65,64,68,0,61,0) | -4.90 units on a scale | Standard Deviation 20.72 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=67,0,68,0,68,73,72,78,0,65,0) | -4.07 units on a scale | Standard Deviation 15.98 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17) | -5.38 units on a scale | Standard Deviation 19.45 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=62,0,59,0,63,65,63,70,0,61,0) | 6.57 units on a scale | Standard Deviation 32.16 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=40,20,44,13,55,64,58,52,12,34,17) | -7.82 units on a scale | Standard Deviation 18.23 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=68,0,68,0,68,73,72,79,0,66,0) | -0.51 units on a scale | Standard Deviation 28.68 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | -1.14 units on a scale | Standard Deviation 22.04 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=67,0,68,0,68,73,72,79,0,66,0) | -2.36 units on a scale | Standard Deviation 17.85 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=62,0,59,0,63,65,63,70,0,61,0) | -4.62 units on a scale | Standard Deviation 17.24 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | 1.43 units on a scale | Standard Deviation 24.15 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | -8.94 units on a scale | Standard Deviation 22.39 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=40,19,44,13,54,64,59,52,12,34,17) | 1.54 units on a scale | Standard Deviation 28.79 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=68,0,67,0,68,73,73,77,0,66,0) | -0.09 units on a scale | Standard Deviation 1.16 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=40,20,44,13,55,64,58,51,12,34,17) | -9.24 units on a scale | Standard Deviation 18 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=40,20,44,13,55,64,58,52,12,34,17) | 11.92 units on a scale | Standard Deviation 32.36 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | -0.05 units on a scale | Standard Deviation 0.53 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=68,0,68,0,68,73,73,79,0,65,0) | -7.85 units on a scale | Standard Deviation 20.8 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=67,0,68,0,67,73,73,79,0,66,0) | -4.05 units on a scale | Standard Deviation 23.62 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=40,20,44,13,55,64,59,51,11,34,17) | -6.80 units on a scale | Standard Deviation 21.19 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=62,0,59,0,63,65,63,69,0,61,0) | -6.42 units on a scale | Standard Deviation 15.31 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=62,0,57,0,63,65,64,68,0,61,0) | 0.74 units on a scale | Standard Deviation 5.57 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.02 units on a scale | Standard Deviation 0.54 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | -8.45 units on a scale | Standard Deviation 18.59 |
| CP-690,550 20 mg | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | 0.01 units on a scale | Standard Deviation 0.58 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=62,0,59,0,63,65,63,69,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=67,0,68,0,68,73,72,79,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=68,0,68,0,68,73,72,79,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=68,0,68,0,68,73,73,79,0,65,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=67,0,68,0,68,73,73,77,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=62,0,59,0,63,65,63,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.00 units on a scale | Standard Deviation 0.74 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=40,19,44,13,54,64,59,52,12,34,17) | 5.00 units on a scale | Standard Deviation 30.9 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=40,20,44,13,55,64,59,51,11,34,17) | -4.24 units on a scale | Standard Deviation 18.68 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=67,0,68,0,68,73,72,78,0,65,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=62,0,57,0,63,65,64,68,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=68,0,67,0,68,73,73,77,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=67,0,68,0,67,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=62,0,59,0,63,65,63,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=62,0,59,0,63,65,64,68,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=40,20,44,13,55,64,58,52,12,34,17) | -3.33 units on a scale | Standard Deviation 20.84 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=40,20,44,13,55,64,58,51,12,34,17) | -3.38 units on a scale | Standard Deviation 18.83 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=40,20,44,13,55,64,58,52,12,34,17) | -1.67 units on a scale | Standard Deviation 39.73 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17) | -6.67 units on a scale | Standard Deviation 21.46 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | -7.19 units on a scale | Standard Deviation 18.41 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=40,20,43,13,55,64,59,51,11,35,17) | 3.36 units on a scale | Standard Deviation 13.89 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,66,0) | -5.76 units on a scale | Standard Deviation 25.24 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17) | -11.18 units on a scale | Standard Deviation 21.57 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=62,0,59,0,63,65,63,69,0,61,0) | -3.03 units on a scale | Standard Deviation 17.7 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=40,20,44,13,55,64,58,52,12,34,17) | -1.18 units on a scale | Standard Deviation 29.72 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=67,0,68,0,68,73,72,79,0,66,0) | -4.29 units on a scale | Standard Deviation 13.12 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=68,0,68,0,68,73,72,79,0,66,0) | 3.18 units on a scale | Standard Deviation 19.7 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=40,20,44,13,55,64,58,52,12,34,17) | -6.27 units on a scale | Standard Deviation 19.96 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=40,20,44,13,55,64,58,51,12,34,17) | -6.01 units on a scale | Standard Deviation 18.67 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=62,0,59,0,63,65,64,68,0,61,0) | -4.37 units on a scale | Standard Deviation 21.56 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=67,0,68,0,68,73,72,78,0,65,0) | -3.30 units on a scale | Standard Deviation 12.13 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | -0.08 units on a scale | Standard Deviation 0.53 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | -1.97 units on a scale | Standard Deviation 25.22 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=62,0,59,0,63,65,63,70,0,61,0) | 0.82 units on a scale | Standard Deviation 23.47 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=62,0,59,0,63,65,63,70,0,61,0) | -2.95 units on a scale | Standard Deviation 18.2 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=40,19,44,13,54,64,59,52,12,34,17) | -6.47 units on a scale | Standard Deviation 26.84 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=67,0,68,0,68,73,73,77,0,66,0) | -2.22 units on a scale | Standard Deviation 18.47 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=67,0,68,0,67,73,73,79,0,66,0) | 0.91 units on a scale | Standard Deviation 23.91 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=40,20,44,13,55,64,59,51,11,34,17) | -7.06 units on a scale | Standard Deviation 17.36 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=68,0,67,0,68,73,73,77,0,66,0) | 0.36 units on a scale | Standard Deviation 0.99 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=40,20,43,13,55,64,59,51,11,35,17) | 0.29 units on a scale | Standard Deviation 1.45 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | 0.08 units on a scale | Standard Deviation 0.36 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | -7.06 units on a scale | Standard Deviation 23.78 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | -3.28 units on a scale | Standard Deviation 19.38 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | -0.08 units on a scale | Standard Deviation 0.6 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=62,0,57,0,63,65,64,68,0,61,0) | 1.33 units on a scale | Standard Deviation 9.25 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=68,0,68,0,68,73,73,79,0,65,0) | -2.81 units on a scale | Standard Deviation 17.05 |
| Placebo | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | -2.97 units on a scale | Standard Deviation 21.46 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: OSP (n=40,20,44,13,55,64,58,51,12,34,17) | -1.96 units on a scale | Standard Deviation 18.7 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Ade (n=62,0,59,0,63,65,63,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: OSP (n=62,0,59,0,63,65,63,69,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: SPS (n=62,0,59,0,63,65,63,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Ade (n=68,0,68,0,68,73,72,79,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: OSP (n=67,0,68,0,68,73,72,78,0,65,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SPS (n=67,0,68,0,68,73,72,79,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Sno (n=40,19,44,13,54,64,59,52,12,34,17) | -1.18 units on a scale | Standard Deviation 11.11 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Qua (n=40,20,43,13,55,64,59,51,11,35,17) | 0.24 units on a scale | Standard Deviation 1.25 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | -1.18 units on a scale | Standard Deviation 27.63 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17) | 3.53 units on a scale | Standard Deviation 26.68 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Ade (n=40,20,44,13,55,64,58,52,12,34,17) | 8.82 units on a scale | Standard Deviation 19 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | -0.06 units on a scale | Standard Deviation 0.56 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: SPS (n=40,20,44,13,55,64,58,52,12,34,17) | -2.16 units on a scale | Standard Deviation 16.71 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Som (n=62,0,59,0,63,65,64,68,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 24: Som (n=40,20,44,13,55,64,59,51,11,34,17) | -2.35 units on a scale | Standard Deviation 15.45 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Som (n=67,0,68,0,68,73,73,77,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Sno (n=67,0,68,0,67,73,73,79,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Qua (n=68,0,67,0,68,73,73,77,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 12: Qua (n=62,0,57,0,63,65,64,68,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Medical Outcome Study- Sleep Scale (MOS-SS) at Week 2, 12 and 24/ET | Week 2: SD (n=68,0,68,0,68,73,73,79,0,65,0) | NA units on a scale | — |
Secondary
Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,68,0,68,73,73,79,0,66,0) | -9.49 mm | Standard Deviation 24.31 |
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | -34.02 mm | Standard Deviation 31.75 |
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,57,0,64,65,66,70,0,61,0) | -23.16 mm | Standard Deviation 28.49 |
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,76,0,66,0) | -13.44 mm | Standard Deviation 26.39 |
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,41,13,57,65,59,55,12,37,17) | -31.54 mm | Standard Deviation 36.96 |
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,63,0,69,71,72,74,0,61,0) | -19.56 mm | Standard Deviation 31.29 |
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,60,0,66,67,70,73,0,61,0) | -19.91 mm | Standard Deviation 26.68 |
| CP-690,550 1 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,55,63,60,53,12,36,17) | -36.08 mm | Standard Deviation 32.62 |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,60,0,66,67,70,73,0,61,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,41,13,57,65,59,55,12,37,17) | -18.14 mm | Standard Deviation 25.06 |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | -13.48 mm | Standard Deviation 25.66 |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,57,0,64,65,66,70,0,61,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,55,63,60,53,12,36,17) | -15.40 mm | Standard Deviation 24.78 |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,63,0,69,71,72,74,0,61,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,76,0,66,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,68,0,68,73,73,79,0,66,0) | -11.00 mm | Standard Deviation 20.82 |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,55,63,60,53,12,36,17) | -33.19 mm | Standard Deviation 25.68 |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,63,0,69,71,72,74,0,61,0) | -22.71 mm | Standard Deviation 28.84 |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,76,0,66,0) | -17.11 mm | Standard Deviation 23.98 |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,41,13,57,65,59,55,12,37,17) | -32.37 mm | Standard Deviation 26.83 |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | -27.19 mm | Standard Deviation 24.93 |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,60,0,66,67,70,73,0,61,0) | -26.23 mm | Standard Deviation 29.28 |
| CP-690,550 5 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,57,0,64,65,66,70,0,61,0) | -24.39 mm | Standard Deviation 30.89 |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,63,0,69,71,72,74,0,61,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,55,63,60,53,12,36,17) | -18.85 mm | Standard Deviation 24.73 |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | -15.15 mm | Standard Deviation 21.97 |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,76,0,66,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,57,0,64,65,66,70,0,61,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,60,0,66,67,70,73,0,61,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,41,13,57,65,59,55,12,37,17) | -12.15 mm | Standard Deviation 25.36 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,60,0,66,67,70,73,0,61,0) | -18.11 mm | Standard Deviation 29.71 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,63,0,69,71,72,74,0,61,0) | -21.07 mm | Standard Deviation 29.07 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,41,13,57,65,59,55,12,37,17) | -29.54 mm | Standard Deviation 30.99 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,55,63,60,53,12,36,17) | -29.89 mm | Standard Deviation 30.87 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,68,0,68,73,73,79,0,66,0) | -10.76 mm | Standard Deviation 26.22 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,76,0,66,0) | -14.76 mm | Standard Deviation 24.06 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,57,0,64,65,66,70,0,61,0) | -25.75 mm | Standard Deviation 29.47 |
| CP-690,550 15 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | -26.50 mm | Standard Deviation 28.81 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,55,63,60,53,12,36,17) | -28.51 mm | Standard Deviation 28.01 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,76,0,66,0) | -17.80 mm | Standard Deviation 30.25 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,60,0,66,67,70,73,0,61,0) | -21.84 mm | Standard Deviation 30.42 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,68,0,68,73,73,79,0,66,0) | -15.30 mm | Standard Deviation 25.46 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,41,13,57,65,59,55,12,37,17) | -22.78 mm | Standard Deviation 30.27 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,63,0,69,71,72,74,0,61,0) | -22.94 mm | Standard Deviation 29.71 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | -26.64 mm | Standard Deviation 25.04 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,57,0,64,65,66,70,0,61,0) | -24.02 mm | Standard Deviation 27.96 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,68,0,68,73,73,79,0,66,0) | -17.67 mm | Standard Deviation 24.58 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | -27.97 mm | Standard Deviation 29.32 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,76,0,66,0) | -20.39 mm | Standard Deviation 28.95 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,57,0,64,65,66,70,0,61,0) | -23.95 mm | Standard Deviation 29.9 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,63,0,69,71,72,74,0,61,0) | -22.61 mm | Standard Deviation 28.87 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,55,63,60,53,12,36,17) | -31.00 mm | Standard Deviation 31.88 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,60,0,66,67,70,73,0,61,0) | -24.66 mm | Standard Deviation 30.16 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,41,13,57,65,59,55,12,37,17) | -30.97 mm | Standard Deviation 31.28 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,57,0,64,65,66,70,0,61,0) | -29.67 mm | Standard Deviation 28.25 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,60,0,66,67,70,73,0,61,0) | -29.08 mm | Standard Deviation 27.13 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,63,0,69,71,72,74,0,61,0) | -26.97 mm | Standard Deviation 26.15 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,55,63,60,53,12,36,17) | -36.98 mm | Standard Deviation 27.86 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,68,0,68,73,73,79,0,66,0) | -18.84 mm | Standard Deviation 25.59 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,76,0,66,0) | -24.74 mm | Standard Deviation 26.39 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,41,13,57,65,59,55,12,37,17) | -32.95 mm | Standard Deviation 27.48 |
| CP-690,550 20 mg | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | -32.09 mm | Standard Deviation 24.84 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,60,0,66,67,70,73,0,61,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,41,13,57,65,59,55,12,37,17) | -26.33 mm | Standard Deviation 33.15 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | -19.00 mm | Standard Deviation 29.73 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,63,0,69,71,72,74,0,61,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,55,63,60,53,12,36,17) | -34.92 mm | Standard Deviation 31.74 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,57,0,64,65,66,70,0,61,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,76,0,66,0) | NA mm | — |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,63,0,69,71,72,74,0,61,0) | -8.61 mm | Standard Deviation 29.03 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,76,0,66,0) | -9.26 mm | Standard Deviation 28.24 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,57,0,64,65,66,70,0,61,0) | -10.30 mm | Standard Deviation 30.14 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,60,0,66,67,70,73,0,61,0) | -9.97 mm | Standard Deviation 28.48 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,55,63,60,53,12,36,17) | -21.08 mm | Standard Deviation 32.99 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,68,0,68,73,73,79,0,66,0) | -4.55 mm | Standard Deviation 25.28 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | -17.22 mm | Standard Deviation 35.13 |
| Placebo | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,41,13,57,65,59,55,12,37,17) | -22.22 mm | Standard Deviation 30.68 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,41,13,57,65,59,55,12,37,17) | -21.82 mm | Standard Deviation 21.49 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | -18.19 mm | Standard Deviation 21.36 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,60,0,66,67,70,73,0,61,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,57,0,64,65,66,70,0,61,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,63,0,67,70,72,76,0,66,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=65,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,42,13,55,63,60,53,12,36,17) | -21.18 mm | Standard Deviation 26.3 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Assessment of Arthritis Pain at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,63,0,69,71,72,74,0,61,0) | NA mm | — |
Secondary
Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Participants answered: Considering all the ways your arthritis affects you, how are you feeling today? Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,54,12,36,17) | -34.56 mm | Standard Deviation 31.99 |
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,65,66,69,0,60,0) | -22.78 mm | Standard Deviation 28.81 |
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,72,0,61,0) | -20.35 mm | Standard Deviation 27.84 |
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,53,12,37,16) | -33.60 mm | Standard Deviation 31.45 |
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -36.68 mm | Standard Deviation 29.89 |
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | -13.90 mm | Standard Deviation 25.53 |
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | -8.57 mm | Standard Deviation 26.12 |
| CP-690,550 1 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,73,0,61,0) | -18.71 mm | Standard Deviation 29.02 |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,65,66,69,0,60,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -15.30 mm | Standard Deviation 32.99 |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,54,12,36,17) | -16.19 mm | Standard Deviation 24.18 |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,53,12,37,16) | -15.86 mm | Standard Deviation 22.28 |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,72,0,61,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,73,0,61,0) | NA mm | — |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,65,66,69,0,60,0) | -23.95 mm | Standard Deviation 29.82 |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | -16.96 mm | Standard Deviation 20.11 |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -32.11 mm | Standard Deviation 25.76 |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,73,0,61,0) | -22.02 mm | Standard Deviation 25.83 |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | -19.40 mm | Standard Deviation 25.4 |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,72,0,61,0) | -27.48 mm | Standard Deviation 26.13 |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,54,12,36,17) | -30.93 mm | Standard Deviation 25.67 |
| CP-690,550 5 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,53,12,37,16) | -28.00 mm | Standard Deviation 28.15 |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,54,12,36,17) | -19.23 mm | Standard Deviation 28.78 |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,65,66,69,0,60,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,73,0,61,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,72,0,61,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,53,12,37,16) | -22.00 mm | Standard Deviation 26.01 |
| CP-690,550 10 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -23.08 mm | Standard Deviation 31.06 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,73,0,61,0) | -20.81 mm | Standard Deviation 24.06 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,72,0,61,0) | -17.44 mm | Standard Deviation 28.12 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | -15.70 mm | Standard Deviation 22.92 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,54,12,36,17) | -28.33 mm | Standard Deviation 26.93 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | -12.37 mm | Standard Deviation 21.83 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,65,66,69,0,60,0) | -24.30 mm | Standard Deviation 24.57 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -29.84 mm | Standard Deviation 27.59 |
| CP-690,550 15 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,53,12,37,16) | -24.05 mm | Standard Deviation 28 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,65,66,69,0,60,0) | -24.77 mm | Standard Deviation 26.21 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,73,0,61,0) | -24.03 mm | Standard Deviation 23.89 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,54,12,36,17) | -23.95 mm | Standard Deviation 27.82 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,72,0,61,0) | -22.58 mm | Standard Deviation 25.37 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -28.61 mm | Standard Deviation 25.31 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | -20.76 mm | Standard Deviation 26.76 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | -16.74 mm | Standard Deviation 24.15 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,53,12,37,16) | -27.97 mm | Standard Deviation 24.02 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,53,12,37,16) | -28.90 mm | Standard Deviation 29.36 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,72,0,61,0) | -24.81 mm | Standard Deviation 31.07 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -30.83 mm | Standard Deviation 32.96 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | -21.82 mm | Standard Deviation 28.55 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,65,66,69,0,60,0) | -23.08 mm | Standard Deviation 30.87 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,54,12,36,17) | -31.12 mm | Standard Deviation 32.09 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,73,0,61,0) | -25.26 mm | Standard Deviation 30.85 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | -20.25 mm | Standard Deviation 26.92 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,53,12,37,16) | -29.68 mm | Standard Deviation 31.2 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | -19.04 mm | Standard Deviation 29.28 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,54,12,36,17) | -30.67 mm | Standard Deviation 31.38 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -33.04 mm | Standard Deviation 32.02 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,72,0,61,0) | -25.92 mm | Standard Deviation 30.55 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,65,66,69,0,60,0) | -28.09 mm | Standard Deviation 30.23 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | -15.38 mm | Standard Deviation 30.86 |
| CP-690,550 20 mg | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,73,0,61,0) | -22.99 mm | Standard Deviation 29.63 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,73,0,61,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,72,0,61,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,65,66,69,0,60,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,54,12,36,17) | -19.92 mm | Standard Deviation 34.52 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,53,12,37,16) | -13.67 mm | Standard Deviation 35.93 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -29.50 mm | Standard Deviation 32.33 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,65,66,69,0,60,0) | -12.75 mm | Standard Deviation 28.2 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,53,12,37,16) | -20.97 mm | Standard Deviation 31.57 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,73,0,61,0) | -9.46 mm | Standard Deviation 23.9 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | -10.65 mm | Standard Deviation 27.81 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,54,12,36,17) | -23.22 mm | Standard Deviation 27.31 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | -5.82 mm | Standard Deviation 24.96 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -21.92 mm | Standard Deviation 27.51 |
| Placebo | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,72,0,61,0) | -11.48 mm | Standard Deviation 25.89 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -15.88 mm | Standard Deviation 25.95 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,65,66,69,0,60,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,53,12,37,16) | -14.81 mm | Standard Deviation 17.72 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,72,0,61,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,73,0,61,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,43,13,57,66,59,54,12,36,17) | -13.53 mm | Standard Deviation 22.22 |
Secondary
Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | -12.88 mm | Standard Deviation 17.84 |
| CP-690,550 1 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -25.02 mm | Standard Deviation 20.89 |
| CP-690,550 1 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=63,0,59,0,64,66,66,70,0,61,0) | -28.76 mm | Standard Deviation 23.5 |
| CP-690,550 1 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -39.33 mm | Standard Deviation 19.85 |
| CP-690,550 1 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -42.21 mm | Standard Deviation 23.73 |
| CP-690,550 1 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -26.50 mm | Standard Deviation 22.83 |
| CP-690,550 1 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | -44.15 mm | Standard Deviation 22.39 |
| CP-690,550 1 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | -20.66 mm | Standard Deviation 19.47 |
| CP-690,550 3 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -26.86 mm | Standard Deviation 23.81 |
| CP-690,550 3 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -16.95 mm | Standard Deviation 26.42 |
| CP-690,550 3 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=63,0,59,0,64,66,66,70,0,61,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA mm | — |
| CP-690,550 3 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | -24.11 mm | Standard Deviation 24.91 |
| CP-690,550 5 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | -39.98 mm | Standard Deviation 21.13 |
| CP-690,550 5 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -30.92 mm | Standard Deviation 22.85 |
| CP-690,550 5 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -26.34 mm | Standard Deviation 24.05 |
| CP-690,550 5 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | -16.43 mm | Standard Deviation 19.2 |
| CP-690,550 5 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -38.70 mm | Standard Deviation 20.41 |
| CP-690,550 5 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=63,0,59,0,64,66,66,70,0,61,0) | -31.69 mm | Standard Deviation 24.3 |
| CP-690,550 5 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -39.23 mm | Standard Deviation 23.11 |
| CP-690,550 5 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | -20.80 mm | Standard Deviation 22.47 |
| CP-690,550 10 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | -24.62 mm | Standard Deviation 19.99 |
| CP-690,550 10 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -23.85 mm | Standard Deviation 19.42 |
| CP-690,550 10 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -24.23 mm | Standard Deviation 22.29 |
| CP-690,550 10 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=63,0,59,0,64,66,66,70,0,61,0) | NA mm | — |
| CP-690,550 10 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
| CP-690,550 15 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | -39.51 mm | Standard Deviation 22.83 |
| CP-690,550 15 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -29.67 mm | Standard Deviation 24.3 |
| CP-690,550 15 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -33.47 mm | Standard Deviation 26.06 |
| CP-690,550 15 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -36.81 mm | Standard Deviation 24.26 |
| CP-690,550 15 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | -14.60 mm | Standard Deviation 24.01 |
| CP-690,550 15 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | -22.00 mm | Standard Deviation 20.79 |
| CP-690,550 15 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -28.80 mm | Standard Deviation 20.44 |
| CP-690,550 15 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=63,0,59,0,64,66,66,70,0,61,0) | -31.58 mm | Standard Deviation 23.09 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -30.39 mm | Standard Deviation 20.61 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -33.63 mm | Standard Deviation 21.96 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | -40.61 mm | Standard Deviation 20.1 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=63,0,59,0,64,66,66,70,0,61,0) | -34.98 mm | Standard Deviation 20.53 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | -27.67 mm | Standard Deviation 20.61 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | -17.88 mm | Standard Deviation 17.66 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -37.41 mm | Standard Deviation 18.99 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -38.45 mm | Standard Deviation 20.53 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | -27.43 mm | Standard Deviation 21.04 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | -24.30 mm | Standard Deviation 18.32 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -33.26 mm | Standard Deviation 19.4 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | -44.65 mm | Standard Deviation 16.76 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -43.42 mm | Standard Deviation 16.85 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -37.26 mm | Standard Deviation 19.37 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -39.70 mm | Standard Deviation 20.34 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=63,0,59,0,64,66,66,70,0,61,0) | -36.80 mm | Standard Deviation 20.78 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | -41.91 mm | Standard Deviation 17.09 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -38.65 mm | Standard Deviation 17.68 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=63,0,59,0,64,66,66,70,0,61,0) | -30.27 mm | Standard Deviation 22.44 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -25.93 mm | Standard Deviation 23.04 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -38.16 mm | Standard Deviation 19.33 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -30.66 mm | Standard Deviation 21.1 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | -16.61 mm | Standard Deviation 19.17 |
| CP-690,550 20 mg | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | -25.31 mm | Standard Deviation 22.01 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | -28.64 mm | Standard Deviation 31.29 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=63,0,59,0,64,66,66,70,0,61,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -19.08 mm | Standard Deviation 29.2 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -22.83 mm | Standard Deviation 26.51 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -29.89 mm | Standard Deviation 22.16 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=63,0,59,0,64,66,66,70,0,61,0) | -21.77 mm | Standard Deviation 24.51 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -34.16 mm | Standard Deviation 23.25 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -20.15 mm | Standard Deviation 22.19 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | -17.79 mm | Standard Deviation 18.95 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | -8.82 mm | Standard Deviation 13.2 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -22.82 mm | Standard Deviation 22.89 |
| Placebo | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | -35.06 mm | Standard Deviation 21.26 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=63,0,59,0,64,66,66,70,0,61,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | -28.06 mm | Standard Deviation 20.84 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | -32.56 mm | Standard Deviation 15.65 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Physician Global Assessment of Arthritis at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -26.29 mm | Standard Deviation 24.43 |
Secondary
Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -7.41 swollen joints | Standard Deviation 6.58 |
| CP-690,550 1 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -10.95 swollen joints | Standard Deviation 8.32 |
| CP-690,550 1 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -3.43 swollen joints | Standard Deviation 5.98 |
| CP-690,550 1 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -12.15 swollen joints | Standard Deviation 7.83 |
| CP-690,550 1 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -7.80 swollen joints | Standard Deviation 8.13 |
| CP-690,550 1 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | -6.19 swollen joints | Standard Deviation 6.5 |
| CP-690,550 1 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -10.67 swollen joints | Standard Deviation 8.78 |
| CP-690,550 1 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | -7.61 swollen joints | Standard Deviation 9.15 |
| CP-690,550 3 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA swollen joints | — |
| CP-690,550 3 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -5.95 swollen joints | Standard Deviation 6.99 |
| CP-690,550 3 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA swollen joints | — |
| CP-690,550 3 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -6.60 swollen joints | Standard Deviation 7.5 |
| CP-690,550 3 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA swollen joints | — |
| CP-690,550 3 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -7.52 swollen joints | Standard Deviation 8.2 |
| CP-690,550 3 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA swollen joints | — |
| CP-690,550 3 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA swollen joints | — |
| CP-690,550 5 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -13.00 swollen joints | Standard Deviation 8.52 |
| CP-690,550 5 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -4.71 swollen joints | Standard Deviation 7.4 |
| CP-690,550 5 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -8.42 swollen joints | Standard Deviation 9.28 |
| CP-690,550 5 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | -10.47 swollen joints | Standard Deviation 9.71 |
| CP-690,550 5 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -13.36 swollen joints | Standard Deviation 8.25 |
| CP-690,550 5 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -13.00 swollen joints | Standard Deviation 8.9 |
| CP-690,550 5 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | -7.25 swollen joints | Standard Deviation 8.8 |
| CP-690,550 5 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -9.03 swollen joints | Standard Deviation 9.79 |
| CP-690,550 10 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -5.46 swollen joints | Standard Deviation 6.77 |
| CP-690,550 10 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA swollen joints | — |
| CP-690,550 10 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA swollen joints | — |
| CP-690,550 10 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -2.46 swollen joints | Standard Deviation 5.77 |
| CP-690,550 10 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA swollen joints | — |
| CP-690,550 10 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -3.92 swollen joints | Standard Deviation 5.72 |
| CP-690,550 10 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA swollen joints | — |
| CP-690,550 10 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA swollen joints | — |
| CP-690,550 15 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -7.68 swollen joints | Standard Deviation 6.3 |
| CP-690,550 15 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -10.25 swollen joints | Standard Deviation 6.7 |
| CP-690,550 15 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | -8.13 swollen joints | Standard Deviation 8 |
| CP-690,550 15 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -4.24 swollen joints | Standard Deviation 6.33 |
| CP-690,550 15 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | -5.97 swollen joints | Standard Deviation 5.44 |
| CP-690,550 15 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -8.74 swollen joints | Standard Deviation 6.94 |
| CP-690,550 15 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -10.60 swollen joints | Standard Deviation 7.43 |
| CP-690,550 15 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -10.39 swollen joints | Standard Deviation 6.98 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -8.06 swollen joints | Standard Deviation 7.4 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -4.75 swollen joints | Standard Deviation 5.57 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -7.68 swollen joints | Standard Deviation 7.35 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | -9.20 swollen joints | Standard Deviation 7.16 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -10.48 swollen joints | Standard Deviation 6.33 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | -7.34 swollen joints | Standard Deviation 6.27 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -10.48 swollen joints | Standard Deviation 7.21 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -9.95 swollen joints | Standard Deviation 6.97 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -10.66 swollen joints | Standard Deviation 6.75 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | -10.68 swollen joints | Standard Deviation 7.37 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -8.68 swollen joints | Standard Deviation 6.73 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -9.31 swollen joints | Standard Deviation 7.51 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -5.45 swollen joints | Standard Deviation 7.74 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -11.61 swollen joints | Standard Deviation 6.35 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | -7.64 swollen joints | Standard Deviation 6.77 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -11.70 swollen joints | Standard Deviation 6.38 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -5.04 swollen joints | Standard Deviation 7.45 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -10.65 swollen joints | Standard Deviation 7.09 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -11.57 swollen joints | Standard Deviation 7.5 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | -8.84 swollen joints | Standard Deviation 8.48 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -11.00 swollen joints | Standard Deviation 6.99 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | -6.74 swollen joints | Standard Deviation 8.13 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -7.97 swollen joints | Standard Deviation 7.54 |
| CP-690,550 20 mg | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -8.26 swollen joints | Standard Deviation 8.3 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -8.08 swollen joints | Standard Deviation 9.89 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA swollen joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -5.83 swollen joints | Standard Deviation 13.62 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA swollen joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA swollen joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA swollen joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA swollen joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -9.08 swollen joints | Standard Deviation 11.99 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | -4.56 swollen joints | Standard Deviation 5.61 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -10.28 swollen joints | Standard Deviation 7.46 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -9.62 swollen joints | Standard Deviation 7.31 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -5.48 swollen joints | Standard Deviation 6.91 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -8.65 swollen joints | Standard Deviation 6.58 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | -6.52 swollen joints | Standard Deviation 8.28 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -7.15 swollen joints | Standard Deviation 6.82 |
| Placebo | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -2.12 swollen joints | Standard Deviation 5 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -6.88 swollen joints | Standard Deviation 6.51 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | -7.35 swollen joints | Standard Deviation 6.47 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -7.88 swollen joints | Standard Deviation 9.21 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Swollen Joints Count (SJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA swollen joints | — |
Secondary
Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET
Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | -8.28 tender joints | Standard Deviation 8.68 |
| CP-690,550 1 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -13.64 tender joints | Standard Deviation 10.63 |
| CP-690,550 1 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -14.05 tender joints | Standard Deviation 9.97 |
| CP-690,550 1 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -4.68 tender joints | Standard Deviation 7.26 |
| CP-690,550 1 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | -10.67 tender joints | Standard Deviation 10.73 |
| CP-690,550 1 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,21,44,13,55,64,60,53,12,36,17) | -14.53 tender joints | Standard Deviation 10.83 |
| CP-690,550 1 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -9.08 tender joints | Standard Deviation 10.79 |
| CP-690,550 1 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -8.86 tender joints | Standard Deviation 10.26 |
| CP-690,550 3 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA tender joints | — |
| CP-690,550 3 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA tender joints | — |
| CP-690,550 3 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA tender joints | — |
| CP-690,550 3 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -12.38 tender joints | Standard Deviation 10.61 |
| CP-690,550 3 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -6.81 tender joints | Standard Deviation 7.9 |
| CP-690,550 3 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA tender joints | — |
| CP-690,550 3 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA tender joints | — |
| CP-690,550 3 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,21,44,13,55,64,60,53,12,36,17) | -10.40 tender joints | Standard Deviation 11.27 |
| CP-690,550 5 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -17.44 tender joints | Standard Deviation 10.54 |
| CP-690,550 5 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -18.36 tender joints | Standard Deviation 9.52 |
| CP-690,550 5 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | -10.26 tender joints | Standard Deviation 9.63 |
| CP-690,550 5 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -11.78 tender joints | Standard Deviation 10.82 |
| CP-690,550 5 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,21,44,13,55,64,60,53,12,36,17) | -18.16 tender joints | Standard Deviation 9.82 |
| CP-690,550 5 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -12.69 tender joints | Standard Deviation 11.57 |
| CP-690,550 5 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -5.09 tender joints | Standard Deviation 9.91 |
| CP-690,550 5 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | -14.00 tender joints | Standard Deviation 12.56 |
| CP-690,550 10 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -1.00 tender joints | Standard Deviation 14.29 |
| CP-690,550 10 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA tender joints | — |
| CP-690,550 10 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA tender joints | — |
| CP-690,550 10 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA tender joints | — |
| CP-690,550 10 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,21,44,13,55,64,60,53,12,36,17) | -6.23 tender joints | Standard Deviation 10.54 |
| CP-690,550 10 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA tender joints | — |
| CP-690,550 10 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA tender joints | — |
| CP-690,550 10 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -5.15 tender joints | Standard Deviation 11.07 |
| CP-690,550 15 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -11.01 tender joints | Standard Deviation 9.64 |
| CP-690,550 15 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -14.58 tender joints | Standard Deviation 11.94 |
| CP-690,550 15 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,21,44,13,55,64,60,53,12,36,17) | -14.93 tender joints | Standard Deviation 11.72 |
| CP-690,550 15 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -11.50 tender joints | Standard Deviation 9.06 |
| CP-690,550 15 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -12.93 tender joints | Standard Deviation 12.63 |
| CP-690,550 15 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -6.06 tender joints | Standard Deviation 9.36 |
| CP-690,550 15 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | -8.42 tender joints | Standard Deviation 9.73 |
| CP-690,550 15 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | -10.88 tender joints | Standard Deviation 11.01 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -16.08 tender joints | Standard Deviation 10.43 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -11.93 tender joints | Standard Deviation 10.92 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -11.07 tender joints | Standard Deviation 9.94 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | -13.47 tender joints | Standard Deviation 9.96 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | -10.77 tender joints | Standard Deviation 10.25 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -14.58 tender joints | Standard Deviation 11.19 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,21,44,13,55,64,60,53,12,36,17) | -16.36 tender joints | Standard Deviation 9.39 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -7.62 tender joints | Standard Deviation 8.48 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -15.05 tender joints | Standard Deviation 11.31 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | -10.90 tender joints | Standard Deviation 11.13 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -12.14 tender joints | Standard Deviation 10.07 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,21,44,13,55,64,60,53,12,36,17) | -17.03 tender joints | Standard Deviation 10.39 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -16.64 tender joints | Standard Deviation 10.73 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -13.76 tender joints | Standard Deviation 11.73 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -7.68 tender joints | Standard Deviation 10.2 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | -14.24 tender joints | Standard Deviation 11.8 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | -9.59 tender joints | Standard Deviation 10.42 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,21,44,13,55,64,60,53,12,36,17) | -16.36 tender joints | Standard Deviation 10.6 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -10.58 tender joints | Standard Deviation 9.6 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -7.78 tender joints | Standard Deviation 9.67 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -12.26 tender joints | Standard Deviation 9.96 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -15.65 tender joints | Standard Deviation 9.29 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | -12.77 tender joints | Standard Deviation 10.92 |
| CP-690,550 20 mg | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -15.67 tender joints | Standard Deviation 9.33 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA tender joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA tender joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA tender joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA tender joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA tender joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -2.33 tender joints | Standard Deviation 15.69 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -5.58 tender joints | Standard Deviation 11.32 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,21,44,13,55,64,60,53,12,36,17) | -6.92 tender joints | Standard Deviation 12.62 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -10.16 tender joints | Standard Deviation 9.92 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | -6.84 tender joints | Standard Deviation 12.84 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,21,44,13,55,64,60,53,12,36,17) | -13.17 tender joints | Standard Deviation 9.9 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -11.05 tender joints | Standard Deviation 11.86 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | -7.03 tender joints | Standard Deviation 13.26 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | -6.69 tender joints | Standard Deviation 11.68 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | -5.03 tender joints | Standard Deviation 10.05 |
| Placebo | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | -2.27 tender joints | Standard Deviation 7.5 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 24 (n=40,21,44,13,55,64,60,53,12,36,17) | -7.59 tender joints | Standard Deviation 12.39 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | -8.06 tender joints | Standard Deviation 10.88 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | -8.24 tender joints | Standard Deviation 11.19 |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Change From Baseline in Tender Joints Count (TJC) at Week 2, 4, 6, 8, 12, 16, 20 and 24/ET | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA tender joints | — |
Secondary
C-Reactive Protein (CRP)
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per deciliter (mg/dL) to 10 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | 14.54 mg/dL | Standard Deviation 19.53 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 24 (n=39,20,43,13,53,63,56,52,12,36,17) | 7.63 mg/dL | Standard Deviation 10.26 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 8.96 mg/dL | Standard Deviation 11.64 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | 10.28 mg/dL | Standard Deviation 11.83 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | 10.55 mg/dL | Standard Deviation 9.79 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 16.30 mg/dL | Standard Deviation 18.08 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 7.80 mg/dL | Standard Deviation 10.3 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | 8.53 mg/dL | Standard Deviation 9.59 |
| CP-690,550 1 mg | C-Reactive Protein (CRP) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | 9.62 mg/dL | Standard Deviation 11.78 |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | NA mg/dL | — |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 24 (n=39,20,43,13,53,63,56,52,12,36,17) | 6.02 mg/dL | Standard Deviation 7.31 |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | NA mg/dL | — |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA mg/dL | — |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA mg/dL | — |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 8.55 mg/dL | Standard Deviation 12.87 |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | NA mg/dL | — |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | NA mg/dL | — |
| CP-690,550 3 mg | C-Reactive Protein (CRP) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 7.02 mg/dL | Standard Deviation 8.51 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | 9.54 mg/dL | Standard Deviation 13.52 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | 8.34 mg/dL | Standard Deviation 13.7 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | 8.20 mg/dL | Standard Deviation 11.77 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | 7.64 mg/dL | Standard Deviation 11.54 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | 10.11 mg/dL | Standard Deviation 15.29 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 10.72 mg/dL | Standard Deviation 18.93 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 7.71 mg/dL | Standard Deviation 10.88 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 15.85 mg/dL | Standard Deviation 19.34 |
| CP-690,550 5 mg | C-Reactive Protein (CRP) | Week 24 (n=39,20,43,13,53,63,56,52,12,36,17) | 10.31 mg/dL | Standard Deviation 17.43 |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | NA mg/dL | — |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA mg/dL | — |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 5.85 mg/dL | Standard Deviation 5.47 |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 24 (n=39,20,43,13,53,63,56,52,12,36,17) | 12.58 mg/dL | Standard Deviation 12.19 |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | NA mg/dL | — |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | NA mg/dL | — |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA mg/dL | — |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | NA mg/dL | — |
| CP-690,550 10 mg | C-Reactive Protein (CRP) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 11.28 mg/dL | Standard Deviation 17.83 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | 8.63 mg/dL | Standard Deviation 12.54 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 5.40 mg/dL | Standard Deviation 8.06 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | 8.26 mg/dL | Standard Deviation 14.3 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 7.93 mg/dL | Standard Deviation 19.22 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 18.03 mg/dL | Standard Deviation 24.96 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | 6.98 mg/dL | Standard Deviation 10.05 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | 6.54 mg/dL | Standard Deviation 9.68 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 24 (n=39,20,43,13,53,63,56,52,12,36,17) | 5.92 mg/dL | Standard Deviation 14.78 |
| CP-690,550 15 mg | C-Reactive Protein (CRP) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | 7.17 mg/dL | Standard Deviation 11.47 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | 5.46 mg/dL | Standard Deviation 9.76 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 5.58 mg/dL | Standard Deviation 8.69 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | 5.24 mg/dL | Standard Deviation 9.59 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | 5.42 mg/dL | Standard Deviation 10.04 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 24 (n=39,20,43,13,53,63,56,52,12,36,17) | 6.66 mg/dL | Standard Deviation 17.03 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 6.77 mg/dL | Standard Deviation 10.27 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | 10.18 mg/dL | Standard Deviation 24.04 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | 9.11 mg/dL | Standard Deviation 20.08 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 14.42 mg/dL | Standard Deviation 17.81 |
| Placebo | C-Reactive Protein (CRP) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 17.21 mg/dL | Standard Deviation 16.94 |
| Placebo | C-Reactive Protein (CRP) | Week 24 (n=39,20,43,13,53,63,56,52,12,36,17) | 6.51 mg/dL | Standard Deviation 11.04 |
| Placebo | C-Reactive Protein (CRP) | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | 4.08 mg/dL | Standard Deviation 4.79 |
| Placebo | C-Reactive Protein (CRP) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 9.79 mg/dL | Standard Deviation 22.24 |
| Placebo | C-Reactive Protein (CRP) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | 4.63 mg/dL | Standard Deviation 8.68 |
| Placebo | C-Reactive Protein (CRP) | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | 5.41 mg/dL | Standard Deviation 8.63 |
| Placebo | C-Reactive Protein (CRP) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | 8.39 mg/dL | Standard Deviation 11.39 |
| Placebo | C-Reactive Protein (CRP) | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | 5.81 mg/dL | Standard Deviation 7.25 |
| Placebo | C-Reactive Protein (CRP) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 3.46 mg/dL | Standard Deviation 3.17 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | 9.75 mg/dL | Standard Deviation 18.92 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 4.75 mg/dL | Standard Deviation 5.28 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 6.52 mg/dL | Standard Deviation 11.33 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | 8.35 mg/dL | Standard Deviation 13.48 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 14.68 mg/dL | Standard Deviation 17.19 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | 10.68 mg/dL | Standard Deviation 17.49 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 24 (n=39,20,43,13,53,63,56,52,12,36,17) | 4.54 mg/dL | Standard Deviation 4.69 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | 8.67 mg/dL | Standard Deviation 13.62 |
| CP-690,550 20 mg | C-Reactive Protein (CRP) | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | 9.53 mg/dL | Standard Deviation 15.08 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | NA mg/dL | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 24 (n=39,20,43,13,53,63,56,52,12,36,17) | 7.19 mg/dL | Standard Deviation 8.18 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | NA mg/dL | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA mg/dL | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA mg/dL | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | NA mg/dL | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 6.89 mg/dL | Standard Deviation 7.06 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | NA mg/dL | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 7.89 mg/dL | Standard Deviation 9.08 |
| Placebo | C-Reactive Protein (CRP) | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | 15.18 mg/dL | Standard Deviation 19.32 |
| Placebo | C-Reactive Protein (CRP) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | 20.38 mg/dL | Standard Deviation 30.37 |
| Placebo | C-Reactive Protein (CRP) | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | 18.10 mg/dL | Standard Deviation 20.41 |
| Placebo | C-Reactive Protein (CRP) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 13.08 mg/dL | Standard Deviation 11.49 |
| Placebo | C-Reactive Protein (CRP) | Week 24 (n=39,20,43,13,53,63,56,52,12,36,17) | 13.39 mg/dL | Standard Deviation 15.05 |
| Placebo | C-Reactive Protein (CRP) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 16.14 mg/dL | Standard Deviation 16.63 |
| Placebo | C-Reactive Protein (CRP) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 18.88 mg/dL | Standard Deviation 19.55 |
| Placebo | C-Reactive Protein (CRP) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | 15.30 mg/dL | Standard Deviation 16.85 |
| Placebo | C-Reactive Protein (CRP) | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | 19.69 mg/dL | Standard Deviation 20.07 |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA mg/dL | — |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | NA mg/dL | — |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 6.52 mg/dL | Standard Deviation 7.3 |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 2 (n=65,0,63,0,63,69,68,74,0,61,0) | NA mg/dL | — |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 6 (n=64,0,61,0,66,67,66,69,0,58,0) | NA mg/dL | — |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 24 (n=39,20,43,13,53,63,56,52,12,36,17) | 16.21 mg/dL | Standard Deviation 26.51 |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 12 (n=61,0,57,0,60,63,62,65,0,60,0) | NA mg/dL | — |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA mg/dL | — |
| Placebo to CP-690,550 5 mg (R) | C-Reactive Protein (CRP) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 12.10 mg/dL | Standard Deviation 18.21 |
Secondary
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) less than or equal to (\<=) 3.2 implied low disease activity and more than (\>) 3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) less than (\<) 2.6 = remission.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | 4.32 units on a scale | Standard Deviation 1.12 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=64,0,63,0,63,69,68,74,0,61,0) | 4.88 units on a scale | Standard Deviation 1.04 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | 4.45 units on a scale | Standard Deviation 1.08 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 3.59 units on a scale | Standard Deviation 1.15 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 3.48 units on a scale | Standard Deviation 1.28 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | 4.21 units on a scale | Standard Deviation 1.22 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | 3.98 units on a scale | Standard Deviation 1.15 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | 5.48 units on a scale | Standard Deviation 0.8 |
| CP-690,550 1 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 3.39 units on a scale | Standard Deviation 1.15 |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 3.83 units on a scale | Standard Deviation 1.62 |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=64,0,63,0,63,69,68,74,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 3.88 units on a scale | Standard Deviation 1.49 |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 4.33 units on a scale | Standard Deviation 1.16 |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | NA units on a scale | — |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | 4.03 units on a scale | Standard Deviation 1.17 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 3.14 units on a scale | Standard Deviation 1.26 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=64,0,63,0,63,69,68,74,0,61,0) | 4.46 units on a scale | Standard Deviation 1.03 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | 5.31 units on a scale | Standard Deviation 0.95 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 3.11 units on a scale | Standard Deviation 1.23 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | 3.74 units on a scale | Standard Deviation 1.3 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | 3.46 units on a scale | Standard Deviation 1.38 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | 3.63 units on a scale | Standard Deviation 1.27 |
| CP-690,550 5 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 3.06 units on a scale | Standard Deviation 1.25 |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=64,0,63,0,63,69,68,74,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 4.08 units on a scale | Standard Deviation 1.35 |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 4.19 units on a scale | Standard Deviation 1.48 |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 4.24 units on a scale | Standard Deviation 1.56 |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | NA units on a scale | — |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 3.19 units on a scale | Standard Deviation 1.1 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | 5.14 units on a scale | Standard Deviation 0.84 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=64,0,63,0,63,69,68,74,0,61,0) | 4.26 units on a scale | Standard Deviation 0.9 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | 3.54 units on a scale | Standard Deviation 1.01 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 3.09 units on a scale | Standard Deviation 1.17 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | 4.03 units on a scale | Standard Deviation 0.96 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | 3.68 units on a scale | Standard Deviation 1 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | 3.57 units on a scale | Standard Deviation 1.09 |
| CP-690,550 15 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 3.03 units on a scale | Standard Deviation 1.05 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | 3.59 units on a scale | Standard Deviation 1.27 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 3.15 units on a scale | Standard Deviation 1.19 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | 3.61 units on a scale | Standard Deviation 1.23 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | 5.28 units on a scale | Standard Deviation 0.85 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | 3.40 units on a scale | Standard Deviation 1.27 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 3.34 units on a scale | Standard Deviation 1.22 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | 3.66 units on a scale | Standard Deviation 1.12 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=64,0,63,0,63,69,68,74,0,61,0) | 4.18 units on a scale | Standard Deviation 1.04 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 3.14 units on a scale | Standard Deviation 1.29 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=64,0,63,0,63,69,68,74,0,61,0) | 4.18 units on a scale | Standard Deviation 1.16 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | 3.60 units on a scale | Standard Deviation 1.13 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 2.94 units on a scale | Standard Deviation 1.04 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 3.12 units on a scale | Standard Deviation 1.25 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | 3.28 units on a scale | Standard Deviation 1.25 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 2.91 units on a scale | Standard Deviation 1.12 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | 3.38 units on a scale | Standard Deviation 1.1 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | 3.75 units on a scale | Standard Deviation 1.13 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | 5.39 units on a scale | Standard Deviation 0.89 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 3.07 units on a scale | Standard Deviation 0.98 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 3.08 units on a scale | Standard Deviation 1.11 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | 3.94 units on a scale | Standard Deviation 1.16 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=64,0,63,0,63,69,68,74,0,61,0) | 4.28 units on a scale | Standard Deviation 1.07 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | 3.99 units on a scale | Standard Deviation 1.11 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | 3.61 units on a scale | Standard Deviation 1.25 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 3.14 units on a scale | Standard Deviation 1.06 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | 5.34 units on a scale | Standard Deviation 0.87 |
| CP-690,550 20 mg | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | 3.72 units on a scale | Standard Deviation 1.35 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 4.51 units on a scale | Standard Deviation 1.61 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 4.65 units on a scale | Standard Deviation 1.08 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 4.82 units on a scale | Standard Deviation 1.24 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=64,0,63,0,63,69,68,74,0,61,0) | NA units on a scale | — |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | 4.60 units on a scale | Standard Deviation 1.01 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | 4.35 units on a scale | Standard Deviation 1.04 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | 4.37 units on a scale | Standard Deviation 1.29 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | 5.26 units on a scale | Standard Deviation 0.96 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 3.81 units on a scale | Standard Deviation 1.23 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=64,0,63,0,63,69,68,74,0,61,0) | 4.91 units on a scale | Standard Deviation 1.07 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 3.93 units on a scale | Standard Deviation 1.06 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | 4.30 units on a scale | Standard Deviation 1.08 |
| Placebo | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 3.48 units on a scale | Standard Deviation 1.06 |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 4 (n=65,0,61,0,62,64,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 8 (n=63,0,59,0,62,62,67,67,0,58,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 12 (n=61,0,55,0,60,63,62,65,0,60,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 6 (n=63,0,61,0,66,67,66,69,0,58,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 2 (n=64,0,63,0,63,69,68,74,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 20 (n=39,21,44,13,57,63,57,55,12,36,17) | 3.86 units on a scale | Standard Deviation 1.24 |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 4.08 units on a scale | Standard Deviation 1.37 |
| Placebo to CP-690,550 5 mg (R) | Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) | Week 16 (n=42,21,43,13,54,64,58,55,9,37,16) | 3.91 units on a scale | Standard Deviation 1.19 |
Secondary
Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Time frame: Baseline, Week 12, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | 0.63 units on a scale | Standard Deviation 0.2 |
| CP-690,550 1 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 0.45 units on a scale | Standard Deviation 0.29 |
| CP-690,550 1 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.66 units on a scale | Standard Deviation 0.23 |
| CP-690,550 3 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.46 units on a scale | Standard Deviation 0.42 |
| CP-690,550 3 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 5 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.67 units on a scale | Standard Deviation 0.26 |
| CP-690,550 5 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | 0.59 units on a scale | Standard Deviation 0.3 |
| CP-690,550 5 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 0.46 units on a scale | Standard Deviation 0.33 |
| CP-690,550 10 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.64 units on a scale | Standard Deviation 0.25 |
| CP-690,550 15 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.70 units on a scale | Standard Deviation 0.23 |
| CP-690,550 15 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 0.50 units on a scale | Standard Deviation 0.3 |
| CP-690,550 15 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | 0.62 units on a scale | Standard Deviation 0.26 |
| CP-690,550 20 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | 0.65 units on a scale | Standard Deviation 0.23 |
| CP-690,550 20 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 0.48 units on a scale | Standard Deviation 0.28 |
| CP-690,550 20 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.68 units on a scale | Standard Deviation 0.23 |
| Placebo | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 0.46 units on a scale | Standard Deviation 0.31 |
| Placebo | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | 0.63 units on a scale | Standard Deviation 0.27 |
| Placebo | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.65 units on a scale | Standard Deviation 0.25 |
| CP-690,550 20 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 0.49 units on a scale | Standard Deviation 0.28 |
| CP-690,550 20 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | 0.64 units on a scale | Standard Deviation 0.25 |
| CP-690,550 20 mg | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.71 units on a scale | Standard Deviation 0.27 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.56 units on a scale | Standard Deviation 0.32 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | NA units on a scale | — |
| Placebo | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 0.49 units on a scale | Standard Deviation 0.33 |
| Placebo | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.65 units on a scale | Standard Deviation 0.22 |
| Placebo | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | 0.55 units on a scale | Standard Deviation 0.31 |
| Placebo to CP-690,550 5 mg (R) | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 24 (n=40,20,44,13,55,63,60,52,12,36,17) | 0.58 units on a scale | Standard Deviation 0.32 |
| Placebo to CP-690,550 5 mg (R) | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Euro Quality of Life-5 Dimentions (EQ-5D) - Health State Profile Utility Score | Week 12 (n=63,0,59,0,64,65,64,70,0,61,0) | NA units on a scale | — |
Secondary
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale
FACIT-Fatigue scale (FS) is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.
Time frame: Baseline, Week 2, 12, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | 33.25 units on a scale | Standard Deviation 10.8 |
| CP-690,550 1 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=70,0,68,0,71,73,75,79,0,69,0) | 28.17 units on a scale | Standard Deviation 10.5 |
| CP-690,550 1 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | 30.41 units on a scale | Standard Deviation 12.01 |
| CP-690,550 1 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=39,20,44,13,55,64,59,51,12,35,17) | 36.69 units on a scale | Standard Deviation 10.42 |
| CP-690,550 3 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=70,0,68,0,71,73,75,79,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=39,20,44,13,55,64,59,51,12,35,17) | 28.08 units on a scale | Standard Deviation 11.07 |
| CP-690,550 3 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | NA units on a scale | — |
| CP-690,550 5 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | 32.65 units on a scale | Standard Deviation 10.64 |
| CP-690,550 5 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | 35.44 units on a scale | Standard Deviation 11.16 |
| CP-690,550 5 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=39,20,44,13,55,64,59,51,12,35,17) | 35.48 units on a scale | Standard Deviation 11.66 |
| CP-690,550 5 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=70,0,68,0,71,73,75,79,0,69,0) | 29.92 units on a scale | Standard Deviation 11.98 |
| CP-690,550 10 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=70,0,68,0,71,73,75,79,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=39,20,44,13,55,64,59,51,12,35,17) | 34.92 units on a scale | Standard Deviation 9.4 |
| CP-690,550 10 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | NA units on a scale | — |
| CP-690,550 15 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=39,20,44,13,55,64,59,51,12,35,17) | 36.78 units on a scale | Standard Deviation 10.75 |
| CP-690,550 15 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | 32.46 units on a scale | Standard Deviation 11.78 |
| CP-690,550 15 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | 34.30 units on a scale | Standard Deviation 10.87 |
| CP-690,550 15 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=70,0,68,0,71,73,75,79,0,69,0) | 28.76 units on a scale | Standard Deviation 10.42 |
| CP-690,550 20 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=70,0,68,0,71,73,75,79,0,69,0) | 30.06 units on a scale | Standard Deviation 10.85 |
| CP-690,550 20 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | 33.17 units on a scale | Standard Deviation 9.43 |
| CP-690,550 20 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=39,20,44,13,55,64,59,51,12,35,17) | 35.36 units on a scale | Standard Deviation 10.01 |
| CP-690,550 20 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | 32.51 units on a scale | Standard Deviation 10.58 |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | 35.05 units on a scale | Standard Deviation 10.17 |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=70,0,68,0,71,73,75,79,0,69,0) | 29.48 units on a scale | Standard Deviation 10.19 |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | 33.41 units on a scale | Standard Deviation 10.1 |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=39,20,44,13,55,64,59,51,12,35,17) | 36.80 units on a scale | Standard Deviation 9.85 |
| CP-690,550 20 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | 33.36 units on a scale | Standard Deviation 10.93 |
| CP-690,550 20 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | 33.99 units on a scale | Standard Deviation 11.61 |
| CP-690,550 20 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=70,0,68,0,71,73,75,79,0,69,0) | 29.76 units on a scale | Standard Deviation 11.02 |
| CP-690,550 20 mg | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=39,20,44,13,55,64,59,51,12,35,17) | 38.24 units on a scale | Standard Deviation 9.46 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=70,0,68,0,71,73,75,79,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=39,20,44,13,55,64,59,51,12,35,17) | 29.50 units on a scale | Standard Deviation 12.27 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | NA units on a scale | — |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | 33.88 units on a scale | Standard Deviation 8.9 |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=39,20,44,13,55,64,59,51,12,35,17) | 37.17 units on a scale | Standard Deviation 10.12 |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | 35.42 units on a scale | Standard Deviation 10.04 |
| Placebo | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=70,0,68,0,71,73,75,79,0,69,0) | 32.23 units on a scale | Standard Deviation 11.13 |
| Placebo to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Baseline (n=70,0,68,0,71,73,75,79,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 2 (n=68,0,68,0,68,73,73,78,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 12 (n=61,0,59,0,63,65,64,69,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale | Week 24 (n=39,20,44,13,55,64,59,51,12,35,17) | 37.47 units on a scale | Standard Deviation 9.87 |
Secondary
Health Assessment Questionnaire-Disability Index (HAQ-DI)
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=66,0,62,0,66,67,70,71,0,61,0) | 1.22 units on a scale | Standard Deviation 0.59 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=66,0,64,0,69,71,72,74,0,61,0) | 1.23 units on a scale | Standard Deviation 0.57 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 1.41 units on a scale | Standard Deviation 0.61 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | 1.32 units on a scale | Standard Deviation 0.61 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 1.05 units on a scale | Standard Deviation 0.59 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 0.95 units on a scale | Standard Deviation 0.58 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=40,20,44,13,54,63,59,53,12,36,17) | 0.99 units on a scale | Standard Deviation 0.57 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=64,0,59,0,64,65,66,68,0,61,0) | 1.19 units on a scale | Standard Deviation 0.63 |
| CP-690,550 1 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | 1.58 units on a scale | Standard Deviation 0.57 |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 1.42 units on a scale | Standard Deviation 0.64 |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=64,0,59,0,64,65,66,68,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=66,0,62,0,66,67,70,71,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=66,0,64,0,69,71,72,74,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=40,20,44,13,54,63,59,53,12,36,17) | 1.38 units on a scale | Standard Deviation 0.74 |
| CP-690,550 3 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 1.33 units on a scale | Standard Deviation 0.72 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | 1.03 units on a scale | Standard Deviation 0.69 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=40,20,44,13,54,63,59,53,12,36,17) | 0.85 units on a scale | Standard Deviation 0.68 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 1.14 units on a scale | Standard Deviation 0.75 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 0.82 units on a scale | Standard Deviation 0.72 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=66,0,62,0,66,67,70,71,0,61,0) | 0.93 units on a scale | Standard Deviation 0.68 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=64,0,59,0,64,65,66,68,0,61,0) | 0.92 units on a scale | Standard Deviation 0.75 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=66,0,64,0,69,71,72,74,0,61,0) | 0.96 units on a scale | Standard Deviation 0.69 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | 1.36 units on a scale | Standard Deviation 0.75 |
| CP-690,550 5 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 0.77 units on a scale | Standard Deviation 0.68 |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=66,0,64,0,69,71,72,74,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=66,0,62,0,66,67,70,71,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=64,0,59,0,64,65,66,68,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 1.18 units on a scale | Standard Deviation 0.77 |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 1.13 units on a scale | Standard Deviation 0.78 |
| CP-690,550 10 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=40,20,44,13,54,63,59,53,12,36,17) | 1.05 units on a scale | Standard Deviation 0.84 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 0.78 units on a scale | Standard Deviation 0.57 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=64,0,59,0,64,65,66,68,0,61,0) | 0.94 units on a scale | Standard Deviation 0.65 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=66,0,62,0,66,67,70,71,0,61,0) | 1.06 units on a scale | Standard Deviation 0.66 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | 1.13 units on a scale | Standard Deviation 0.65 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=66,0,64,0,69,71,72,74,0,61,0) | 1.03 units on a scale | Standard Deviation 0.61 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | 1.44 units on a scale | Standard Deviation 0.64 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 0.92 units on a scale | Standard Deviation 0.6 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 1.20 units on a scale | Standard Deviation 0.58 |
| CP-690,550 15 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=40,20,44,13,54,63,59,53,12,36,17) | 0.78 units on a scale | Standard Deviation 0.62 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=66,0,64,0,69,71,72,74,0,61,0) | 1.02 units on a scale | Standard Deviation 0.65 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | 1.08 units on a scale | Standard Deviation 0.64 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 0.91 units on a scale | Standard Deviation 0.68 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 0.84 units on a scale | Standard Deviation 0.65 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=66,0,62,0,66,67,70,71,0,61,0) | 0.89 units on a scale | Standard Deviation 0.67 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=40,20,44,13,54,63,59,53,12,36,17) | 0.85 units on a scale | Standard Deviation 0.66 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=64,0,59,0,64,65,66,68,0,61,0) | 0.95 units on a scale | Standard Deviation 0.68 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | 1.33 units on a scale | Standard Deviation 0.6 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 1.16 units on a scale | Standard Deviation 0.61 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | 1.12 units on a scale | Standard Deviation 0.69 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 1.15 units on a scale | Standard Deviation 0.67 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | 1.41 units on a scale | Standard Deviation 0.64 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 0.97 units on a scale | Standard Deviation 0.75 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=64,0,59,0,64,65,66,68,0,61,0) | 0.96 units on a scale | Standard Deviation 0.69 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=40,20,44,13,54,63,59,53,12,36,17) | 0.88 units on a scale | Standard Deviation 0.69 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 0.92 units on a scale | Standard Deviation 0.72 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=66,0,64,0,69,71,72,74,0,61,0) | 1.05 units on a scale | Standard Deviation 0.69 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=66,0,62,0,66,67,70,71,0,61,0) | 0.98 units on a scale | Standard Deviation 0.68 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=64,0,59,0,64,65,66,68,0,61,0) | 0.90 units on a scale | Standard Deviation 0.67 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 0.81 units on a scale | Standard Deviation 0.67 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | 1.14 units on a scale | Standard Deviation 0.65 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 1.23 units on a scale | Standard Deviation 0.63 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=66,0,64,0,69,71,72,74,0,61,0) | 1.05 units on a scale | Standard Deviation 0.65 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=40,20,44,13,54,63,59,53,12,36,17) | 0.72 units on a scale | Standard Deviation 0.61 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 0.75 units on a scale | Standard Deviation 0.63 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=66,0,62,0,66,67,70,71,0,61,0) | 0.98 units on a scale | Standard Deviation 0.72 |
| CP-690,550 20 mg | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | 1.46 units on a scale | Standard Deviation 0.58 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=64,0,59,0,64,65,66,68,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=40,20,44,13,54,63,59,53,12,36,17) | 1.34 units on a scale | Standard Deviation 0.78 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 1.36 units on a scale | Standard Deviation 0.67 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=66,0,62,0,66,67,70,71,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=66,0,64,0,69,71,72,74,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 1.42 units on a scale | Standard Deviation 0.62 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 0.73 units on a scale | Standard Deviation 0.65 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=40,20,44,13,54,63,59,53,12,36,17) | 0.74 units on a scale | Standard Deviation 0.66 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=64,0,59,0,64,65,66,68,0,61,0) | 1.08 units on a scale | Standard Deviation 0.74 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 1.15 units on a scale | Standard Deviation 0.64 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 0.80 units on a scale | Standard Deviation 0.64 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=66,0,62,0,66,67,70,71,0,61,0) | 1.05 units on a scale | Standard Deviation 0.71 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=66,0,64,0,69,71,72,74,0,61,0) | 1.07 units on a scale | Standard Deviation 0.7 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | 1.14 units on a scale | Standard Deviation 0.66 |
| Placebo | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | 1.20 units on a scale | Standard Deviation 0.73 |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 8 (n=66,0,62,0,66,67,70,71,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 12 (n=64,0,59,0,64,65,66,68,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 24 (n=40,20,44,13,54,63,59,53,12,36,17) | 0.95 units on a scale | Standard Deviation 0.68 |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 0.92 units on a scale | Standard Deviation 0.75 |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 1.05 units on a scale | Standard Deviation 0.8 |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Health Assessment Questionnaire-Disability Index (HAQ-DI) | Week 6 (n=66,0,64,0,69,71,72,74,0,61,0) | NA units on a scale | — |
Secondary
Medical Outcome Study- Sleep Scale (MOS-SS)
Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 subscales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0)and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range\* 100); total score range: 0 to 100; higher score = greater intensity of attribute.
Time frame: Baseline, Week 2, 12, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=62,0,59,0,63,65,64,70,0,61,0) | 35.05 units on a scale | Standard Deviation 16.56 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=67,0,68,0,68,73,73,79,0,66,0) | 32.34 units on a scale | Standard Deviation 21.03 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | 0.41 units on a scale | Standard Deviation 0.5 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=68,0,67,0,68,73,73,79,0,66,0) | 32.94 units on a scale | Standard Deviation 29.88 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=68,0,68,0,68,73,73,79,0,66,0) | 6.75 units on a scale | Standard Deviation 1.73 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,65,0) | 20.29 units on a scale | Standard Deviation 25.04 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17 | 14.00 units on a scale | Standard Deviation 17.66 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=40,20,44,13,55,64,59,52,12,34,17) | 57.00 units on a scale | Standard Deviation 25.74 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=62,0,59,0,63,65,64,70,0,61,0) | 28.82 units on a scale | Standard Deviation 18.61 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | 0.52 units on a scale | Standard Deviation 0.5 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=70,0,67,0,71,74,75,78,0,69,0) | 6.87 units on a scale | Standard Deviation 1.73 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: ASOB (n=70,0,68,0,71,74,75,80,0,69,0) | 20.00 units on a scale | Standard Deviation 24.55 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | 34.94 units on a scale | Standard Deviation 20 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=70,0,68,0,71,74,74,80,0,69,0) | 40.62 units on a scale | Standard Deviation 18.87 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=69,0,68,0,71,74,74,80,0,69,0) | 31.59 units on a scale | Standard Deviation 30.76 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=70,0,68,0,71,74,75,78,0,69,0) | 35.14 units on a scale | Standard Deviation 20.3 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=70,0,68,0,71,74,74,79,0,69,0) | 41.94 units on a scale | Standard Deviation 18.04 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=40,20,44,13,55,64,59,52,12,34,17) | 29.50 units on a scale | Standard Deviation 19.33 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=70,0,68,0,71,74,74,80,0,69,0) | 48.14 units on a scale | Standard Deviation 25.5 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=40,20,44,13,54,64,59,52,12,34,17) | 26.50 units on a scale | Standard Deviation 23.7 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.53 units on a scale | Standard Deviation 0.51 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=40,20,44,13,55,64,59,52,12,34,17) | 6.88 units on a scale | Standard Deviation 1.44 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | 32.31 units on a scale | Standard Deviation 19.05 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=70,0,68,0,71,74,75,80,0,69,0) | 44.43 units on a scale | Standard Deviation 23.13 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=67,0,68,0,68,73,73,79,0,65,0) | 39.65 units on a scale | Standard Deviation 21 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=40,20,44,13,55,64,59,52,12,34,17) | 31.64 units on a scale | Standard Deviation 16.38 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=40,20,44,13,55,64,59,52,12,34,17) | 32.17 units on a scale | Standard Deviation 17.35 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=68,0,68,0,68,73,73,79,0,66,0) | 39.04 units on a scale | Standard Deviation 19.7 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=70,0,68,0,71,74,75,80,0,69,0) | 0.51 units on a scale | Standard Deviation 0.5 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | 29.18 units on a scale | Standard Deviation 26.97 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=62,0,58,0,63,65,64,70,0,61,0) | 7.08 units on a scale | Standard Deviation 1.41 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=68,0,68,0,68,73,73,79,0,66,0) | 45.15 units on a scale | Standard Deviation 27.62 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | 15.16 units on a scale | Standard Deviation 22.52 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=62,0,59,0,63,65,64,70,0,61,0) | 49.35 units on a scale | Standard Deviation 24.69 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=62,0,59,0,63,65,64,70,0,61,0) | 34.78 units on a scale | Standard Deviation 16.37 |
| CP-690,550 1 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=68,0,68,0,68,73,73,79,0,66,0) | 39.15 units on a scale | Standard Deviation 22.53 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17 | 20.00 units on a scale | Standard Deviation 26.75 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=67,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=70,0,68,0,71,74,74,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=40,20,44,13,55,64,59,52,12,34,17) | 39.50 units on a scale | Standard Deviation 27.81 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.50 units on a scale | Standard Deviation 0.51 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=68,0,67,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=40,20,44,13,55,64,59,52,12,34,17) | 42.86 units on a scale | Standard Deviation 19.06 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=40,20,44,13,55,64,59,52,12,34,17) | 40.67 units on a scale | Standard Deviation 20.85 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=62,0,58,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=67,0,68,0,68,73,73,79,0,65,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: ASOB (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=70,0,68,0,71,74,74,79,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=70,0,68,0,71,74,74,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,65,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | 40.19 units on a scale | Standard Deviation 21.76 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=40,20,44,13,55,64,59,52,12,34,17) | 43.67 units on a scale | Standard Deviation 20.23 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=70,0,68,0,71,74,75,78,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=69,0,68,0,71,74,74,80,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=70,0,67,0,71,74,75,78,0,69,0) | NA units on a scale | — |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=40,20,44,13,55,64,59,52,12,34,17) | 6.80 units on a scale | Standard Deviation 1.4 |
| CP-690,550 3 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=40,20,44,13,54,64,59,52,12,34,17) | 38.00 units on a scale | Standard Deviation 32.38 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=70,0,68,0,71,74,74,79,0,69,0) | 45.65 units on a scale | Standard Deviation 20.86 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=40,20,44,13,55,64,59,52,12,34,17) | 34.39 units on a scale | Standard Deviation 25.39 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=40,20,44,13,54,64,59,52,12,34,17) | 35.00 units on a scale | Standard Deviation 31.73 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=70,0,68,0,71,74,74,80,0,69,0) | 43.82 units on a scale | Standard Deviation 26.99 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | 13.90 units on a scale | Standard Deviation 19.39 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=40,20,44,13,55,64,59,52,12,34,17) | 7.25 units on a scale | Standard Deviation 1.31 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.55 units on a scale | Standard Deviation 0.5 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | 30.80 units on a scale | Standard Deviation 24.04 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: ASOB (n=70,0,68,0,71,74,75,80,0,69,0) | 22.94 units on a scale | Standard Deviation 24.5 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,65,0) | 17.65 units on a scale | Standard Deviation 22.27 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17 | 12.73 units on a scale | Standard Deviation 18.85 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=40,20,44,13,55,64,59,52,12,34,17) | 58.41 units on a scale | Standard Deviation 28.69 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=40,20,44,13,55,64,59,52,12,34,17) | 31.46 units on a scale | Standard Deviation 19.54 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=70,0,68,0,71,74,75,80,0,69,0) | 0.44 units on a scale | Standard Deviation 0.5 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=70,0,68,0,71,74,75,80,0,69,0) | 49.10 units on a scale | Standard Deviation 27.47 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=68,0,68,0,68,73,73,79,0,66,0) | 39.21 units on a scale | Standard Deviation 27.05 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=67,0,68,0,68,73,73,79,0,65,0) | 37.89 units on a scale | Standard Deviation 22.17 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | 0.43 units on a scale | Standard Deviation 0.5 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | 35.66 units on a scale | Standard Deviation 26.03 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=62,0,59,0,63,65,64,70,0,61,0) | 32.20 units on a scale | Standard Deviation 21.52 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=67,0,68,0,68,73,73,79,0,66,0) | 33.63 units on a scale | Standard Deviation 24.25 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | 34.92 units on a scale | Standard Deviation 32.71 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=68,0,67,0,68,73,73,79,0,66,0) | 35.59 units on a scale | Standard Deviation 32.94 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=62,0,59,0,63,65,64,70,0,61,0) | 34.23 units on a scale | Standard Deviation 20.63 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=68,0,68,0,68,73,73,79,0,66,0) | 6.76 units on a scale | Standard Deviation 1.4 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=68,0,68,0,68,73,73,79,0,66,0) | 37.88 units on a scale | Standard Deviation 21.48 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=40,20,44,13,55,64,59,52,12,34,17) | 30.68 units on a scale | Standard Deviation 21.02 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=62,0,59,0,63,65,64,70,0,61,0) | 33.62 units on a scale | Standard Deviation 22.04 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=62,0,58,0,63,65,64,70,0,61,0) | 7.05 units on a scale | Standard Deviation 1.53 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=70,0,67,0,71,74,75,78,0,69,0) | 6.72 units on a scale | Standard Deviation 1.6 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=70,0,68,0,71,74,74,80,0,69,0) | 44.46 units on a scale | Standard Deviation 21.58 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=62,0,59,0,63,65,64,70,0,61,0) | 54.92 units on a scale | Standard Deviation 32.24 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=68,0,68,0,68,73,73,79,0,66,0) | 49.56 units on a scale | Standard Deviation 28.31 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=70,0,68,0,71,74,75,78,0,69,0) | 38.63 units on a scale | Standard Deviation 23.51 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=69,0,68,0,71,74,74,80,0,69,0) | 35.29 units on a scale | Standard Deviation 32.07 |
| CP-690,550 5 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | 0.53 units on a scale | Standard Deviation 0.5 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=40,20,44,13,55,64,59,52,12,34,17) | 31.79 units on a scale | Standard Deviation 18.49 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=70,0,68,0,71,74,75,78,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=70,0,68,0,71,74,74,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=70,0,68,0,71,74,74,79,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=70,0,68,0,71,74,74,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: ASOB (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=67,0,68,0,68,73,73,79,0,65,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,65,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=67,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=62,0,58,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=40,20,44,13,55,64,59,52,12,34,17) | 38.80 units on a scale | Standard Deviation 18.07 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=40,20,44,13,55,64,59,52,12,34,17) | 46.15 units on a scale | Standard Deviation 18.05 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17 | 18.46 units on a scale | Standard Deviation 17.25 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=40,20,44,13,55,64,59,52,12,34,17) | 6.69 units on a scale | Standard Deviation 1.65 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=70,0,67,0,71,74,75,78,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=69,0,68,0,71,74,74,80,0,69,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=40,20,44,13,55,64,59,52,12,34,17) | 38.21 units on a scale | Standard Deviation 17.46 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=68,0,67,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | 38.08 units on a scale | Standard Deviation 28.62 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.38 units on a scale | Standard Deviation 0.51 |
| CP-690,550 10 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=40,20,44,13,54,64,59,52,12,34,17) | 44.62 units on a scale | Standard Deviation 32.82 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=62,0,59,0,63,65,64,70,0,61,0) | 31.01 units on a scale | Standard Deviation 23.1 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=68,0,68,0,68,73,73,79,0,66,0) | 35.00 units on a scale | Standard Deviation 23.8 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=70,0,68,0,71,74,75,80,0,69,0) | 0.46 units on a scale | Standard Deviation 0.5 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | 41.59 units on a scale | Standard Deviation 32.19 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=70,0,68,0,71,74,74,79,0,69,0) | 40.22 units on a scale | Standard Deviation 19 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | 32.52 units on a scale | Standard Deviation 23.96 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=40,20,44,13,55,64,59,52,12,34,17) | 29.94 units on a scale | Standard Deviation 20.68 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=70,0,68,0,71,74,74,80,0,69,0) | 38.12 units on a scale | Standard Deviation 18.93 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=62,0,59,0,63,65,64,70,0,61,0) | 33.39 units on a scale | Standard Deviation 20.64 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=70,0,68,0,71,74,75,78,0,69,0) | 32.86 units on a scale | Standard Deviation 19.17 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=68,0,68,0,68,73,73,79,0,66,0) | 34.74 units on a scale | Standard Deviation 20.11 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=40,20,44,13,55,64,59,52,12,34,17) | 32.18 units on a scale | Standard Deviation 21.24 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.45 units on a scale | Standard Deviation 0.5 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=68,0,68,0,68,73,73,79,0,66,0) | 53.24 units on a scale | Standard Deviation 31.64 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | 0.48 units on a scale | Standard Deviation 0.5 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=67,0,68,0,68,73,73,79,0,65,0) | 34.22 units on a scale | Standard Deviation 21.1 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=62,0,58,0,63,65,64,70,0,61,0) | 6.71 units on a scale | Standard Deviation 1.49 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=67,0,68,0,68,73,73,79,0,66,0) | 31.08 units on a scale | Standard Deviation 21.66 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=40,20,44,13,54,64,59,52,12,34,17) | 37.41 units on a scale | Standard Deviation 32.05 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=70,0,68,0,71,74,75,80,0,69,0) | 42.61 units on a scale | Standard Deviation 25.4 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=68,0,68,0,68,73,73,79,0,66,0) | 6.72 units on a scale | Standard Deviation 1.26 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=70,0,67,0,71,74,75,78,0,69,0) | 7.32 units on a scale | Standard Deviation 7.65 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=40,20,44,13,55,64,59,52,12,34,17) | 7.93 units on a scale | Standard Deviation 7.26 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=62,0,59,0,63,65,64,70,0,61,0) | 33.61 units on a scale | Standard Deviation 19.83 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=70,0,68,0,71,74,74,80,0,69,0) | 46.20 units on a scale | Standard Deviation 27.95 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=62,0,59,0,63,65,64,70,0,61,0) | 53.17 units on a scale | Standard Deviation 29.99 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17 | 14.18 units on a scale | Standard Deviation 20.61 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=40,20,44,13,55,64,59,52,12,34,17) | 32.55 units on a scale | Standard Deviation 22.35 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: ASOB (n=70,0,68,0,71,74,75,80,0,69,0) | 17.75 units on a scale | Standard Deviation 22.82 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=69,0,68,0,71,74,74,80,0,69,0) | 44.51 units on a scale | Standard Deviation 33.16 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=40,20,44,13,55,64,59,52,12,34,17) | 55.64 units on a scale | Standard Deviation 31.61 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,65,0) | 17.94 units on a scale | Standard Deviation 22.7 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | 32.77 units on a scale | Standard Deviation 25.76 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | 0.53 units on a scale | Standard Deviation 0.5 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=68,0,67,0,68,73,73,79,0,66,0) | 37.01 units on a scale | Standard Deviation 31.38 |
| CP-690,550 15 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | 20.32 units on a scale | Standard Deviation 27.24 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=40,20,44,13,55,64,59,52,12,34,17) | 32.40 units on a scale | Standard Deviation 24.05 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=68,0,68,0,68,73,73,79,0,66,0) | 7.05 units on a scale | Standard Deviation 1.3 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17 | 17.19 units on a scale | Standard Deviation 23.33 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=62,0,59,0,63,65,64,70,0,61,0) | 35.26 units on a scale | Standard Deviation 19.48 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: ASOB (n=70,0,68,0,71,74,75,80,0,69,0) | 17.30 units on a scale | Standard Deviation 22.29 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=70,0,68,0,71,74,74,80,0,69,0) | 50.27 units on a scale | Standard Deviation 26.84 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | 32.73 units on a scale | Standard Deviation 26.78 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.55 units on a scale | Standard Deviation 0.5 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,65,0) | 22.74 units on a scale | Standard Deviation 24.11 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=68,0,68,0,68,73,73,79,0,66,0) | 34.93 units on a scale | Standard Deviation 24.83 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=62,0,59,0,63,65,64,70,0,61,0) | 54.00 units on a scale | Standard Deviation 26.74 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | 20.00 units on a scale | Standard Deviation 23.72 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | 0.52 units on a scale | Standard Deviation 0.5 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=40,20,44,13,54,64,59,52,12,34,17) | 38.13 units on a scale | Standard Deviation 33.37 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=70,0,68,0,71,74,75,80,0,69,0) | 0.45 units on a scale | Standard Deviation 0.5 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | 34.27 units on a scale | Standard Deviation 25 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=40,20,44,13,55,64,59,52,12,34,17) | 32.50 units on a scale | Standard Deviation 18.22 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=68,0,68,0,68,73,73,79,0,66,0) | 53.42 units on a scale | Standard Deviation 25.4 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | 0.54 units on a scale | Standard Deviation 0.5 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=62,0,59,0,63,65,64,70,0,61,0) | 34.92 units on a scale | Standard Deviation 18.85 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=70,0,67,0,71,74,75,78,0,69,0) | 7.28 units on a scale | Standard Deviation 3.54 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=70,0,68,0,71,74,74,79,0,69,0) | 39.05 units on a scale | Standard Deviation 18.56 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=62,0,58,0,63,65,64,70,0,61,0) | 6.85 units on a scale | Standard Deviation 1.33 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=70,0,68,0,71,74,75,78,0,69,0) | 34.50 units on a scale | Standard Deviation 19.03 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=68,0,68,0,68,73,73,79,0,66,0) | 35.65 units on a scale | Standard Deviation 19.37 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | 35.69 units on a scale | Standard Deviation 32.11 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=70,0,68,0,71,74,74,80,0,69,0) | 36.94 units on a scale | Standard Deviation 18.49 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=68,0,67,0,68,73,73,79,0,66,0) | 35.62 units on a scale | Standard Deviation 33.21 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=62,0,59,0,63,65,64,70,0,61,0) | 34.36 units on a scale | Standard Deviation 23.22 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=69,0,68,0,71,74,74,80,0,69,0) | 39.73 units on a scale | Standard Deviation 33.19 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=67,0,68,0,68,73,73,79,0,65,0) | 35.25 units on a scale | Standard Deviation 19.1 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=67,0,68,0,68,73,73,79,0,66,0) | 33.79 units on a scale | Standard Deviation 20.97 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=40,20,44,13,55,64,59,52,12,34,17) | 6.94 units on a scale | Standard Deviation 1.23 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=40,20,44,13,55,64,59,52,12,34,17) | 32.95 units on a scale | Standard Deviation 18.88 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=70,0,68,0,71,74,75,80,0,69,0) | 41.17 units on a scale | Standard Deviation 25.36 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=40,20,44,13,55,64,59,52,12,34,17) | 57.34 units on a scale | Standard Deviation 26.32 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=68,0,68,0,68,73,73,79,0,66,0) | 57.53 units on a scale | Standard Deviation 28.81 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=40,20,44,13,54,64,59,52,12,34,17) | 35.25 units on a scale | Standard Deviation 30.25 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=68,0,67,0,68,73,73,79,0,66,0) | 30.96 units on a scale | Standard Deviation 33.01 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=40,20,44,13,55,64,59,52,12,34,17) | 31.18 units on a scale | Standard Deviation 19.77 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=70,0,68,0,71,74,74,80,0,69,0) | 40.90 units on a scale | Standard Deviation 22.41 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | 0.52 units on a scale | Standard Deviation 0.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | 18.75 units on a scale | Standard Deviation 22.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=62,0,59,0,63,65,64,70,0,61,0) | 36.33 units on a scale | Standard Deviation 19.86 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=62,0,59,0,63,65,64,70,0,61,0) | 32.29 units on a scale | Standard Deviation 20.62 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,65,0) | 15.34 units on a scale | Standard Deviation 21.74 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=69,0,68,0,71,74,74,80,0,69,0) | 36.00 units on a scale | Standard Deviation 34.01 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=40,20,44,13,55,64,59,52,12,34,17) | 7.05 units on a scale | Standard Deviation 1.85 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=70,0,68,0,71,74,75,80,0,69,0) | 48.37 units on a scale | Standard Deviation 25.66 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=67,0,68,0,68,73,73,79,0,65,0) | 32.97 units on a scale | Standard Deviation 21.75 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17 | 11.53 units on a scale | Standard Deviation 19.72 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=62,0,59,0,63,65,64,70,0,61,0) | 56.09 units on a scale | Standard Deviation 28.21 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=40,20,44,13,55,64,59,52,12,34,17) | 29.89 units on a scale | Standard Deviation 18.91 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=70,0,67,0,71,74,75,78,0,69,0) | 6.64 units on a scale | Standard Deviation 1.61 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=68,0,68,0,68,73,73,79,0,66,0) | 38.73 units on a scale | Standard Deviation 26.23 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=68,0,68,0,68,73,73,79,0,66,0) | 7.10 units on a scale | Standard Deviation 1.7 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=70,0,68,0,71,74,75,80,0,69,0) | 0.47 units on a scale | Standard Deviation 0.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | 34.69 units on a scale | Standard Deviation 32.71 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=70,0,68,0,71,74,74,80,0,69,0) | 49.19 units on a scale | Standard Deviation 28.13 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=70,0,68,0,71,74,74,79,0,69,0) | 42.87 units on a scale | Standard Deviation 20.62 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=40,20,44,13,55,64,59,52,12,34,17) | 28.70 units on a scale | Standard Deviation 19.93 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | 0.45 units on a scale | Standard Deviation 0.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: ASOB (n=70,0,68,0,71,74,75,80,0,69,0) | 21.87 units on a scale | Standard Deviation 25.93 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=62,0,58,0,63,65,64,70,0,61,0) | 6.98 units on a scale | Standard Deviation 1.74 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=62,0,59,0,63,65,64,70,0,61,0) | 35.00 units on a scale | Standard Deviation 19.41 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=70,0,68,0,71,74,75,78,0,69,0) | 35.91 units on a scale | Standard Deviation 22.08 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | 32.61 units on a scale | Standard Deviation 26.23 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=67,0,68,0,68,73,73,79,0,66,0) | 32.69 units on a scale | Standard Deviation 21.26 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=68,0,68,0,68,73,73,79,0,66,0) | 35.27 units on a scale | Standard Deviation 20.56 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.45 units on a scale | Standard Deviation 0.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=40,20,44,13,55,64,59,52,12,34,17) | 57.46 units on a scale | Standard Deviation 26.43 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | 39.16 units on a scale | Standard Deviation 25.16 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=40,20,44,13,55,64,59,52,12,34,17) | 26.03 units on a scale | Standard Deviation 21.42 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=67,0,68,0,68,73,73,79,0,66,0) | 31.73 units on a scale | Standard Deviation 22.32 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=62,0,59,0,63,65,64,70,0,61,0) | 32.81 units on a scale | Standard Deviation 21.22 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=62,0,59,0,63,65,64,70,0,61,0) | 33.44 units on a scale | Standard Deviation 21.57 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,65,0) | 20.25 units on a scale | Standard Deviation 26.11 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=62,0,59,0,63,65,64,70,0,61,0) | 58.43 units on a scale | Standard Deviation 27.59 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | 21.43 units on a scale | Standard Deviation 26 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | 34.18 units on a scale | Standard Deviation 27.1 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | 0.51 units on a scale | Standard Deviation 0.5 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=62,0,58,0,63,65,64,70,0,61,0) | 7.60 units on a scale | Standard Deviation 5.37 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=68,0,68,0,68,73,73,79,0,66,0) | 36.22 units on a scale | Standard Deviation 19.65 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | 33.43 units on a scale | Standard Deviation 29.63 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=67,0,68,0,68,73,73,79,0,65,0) | 35.78 units on a scale | Standard Deviation 20.4 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=62,0,59,0,63,65,64,70,0,61,0) | 30.57 units on a scale | Standard Deviation 25.16 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=40,20,44,13,55,64,59,52,12,34,17) | 26.76 units on a scale | Standard Deviation 17.75 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=40,20,44,13,55,64,59,52,12,34,17) | 66.92 units on a scale | Standard Deviation 28.6 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: ASOB (n=70,0,68,0,71,74,75,80,0,69,0) | 20.50 units on a scale | Standard Deviation 27.55 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17 | 11.15 units on a scale | Standard Deviation 18.33 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | 28.49 units on a scale | Standard Deviation 23.7 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=70,0,68,0,71,74,74,80,0,69,0) | 51.00 units on a scale | Standard Deviation 30.55 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.57 units on a scale | Standard Deviation 0.5 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=40,20,44,13,55,64,59,52,12,34,17) | 7.12 units on a scale | Standard Deviation 1.2 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=40,20,44,13,54,64,59,52,12,34,17) | 38.46 units on a scale | Standard Deviation 32.62 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=70,0,68,0,71,74,75,80,0,69,0) | 0.50 units on a scale | Standard Deviation 0.5 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=70,0,67,0,71,74,75,78,0,69,0) | 6.90 units on a scale | Standard Deviation 1.52 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=69,0,68,0,71,74,74,80,0,69,0) | 35.25 units on a scale | Standard Deviation 32.49 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=70,0,68,0,71,74,74,80,0,69,0) | 38.46 units on a scale | Standard Deviation 21.21 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=70,0,68,0,71,74,75,78,0,69,0) | 35.04 units on a scale | Standard Deviation 22.93 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=70,0,68,0,71,74,74,79,0,69,0) | 40.49 units on a scale | Standard Deviation 21.33 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=70,0,68,0,71,74,75,80,0,69,0) | 44.42 units on a scale | Standard Deviation 27.37 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=40,20,44,13,55,64,59,52,12,34,17) | 25.45 units on a scale | Standard Deviation 17.75 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=68,0,68,0,68,73,73,79,0,66,0) | 50.51 units on a scale | Standard Deviation 27.68 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=68,0,68,0,68,73,73,79,0,66,0) | 6.78 units on a scale | Standard Deviation 1.65 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | 0.44 units on a scale | Standard Deviation 0.5 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=68,0,67,0,68,73,73,79,0,66,0) | 30.63 units on a scale | Standard Deviation 30.18 |
| CP-690,550 20 mg | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=68,0,68,0,68,73,73,79,0,66,0) | 35.87 units on a scale | Standard Deviation 24.33 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=67,0,68,0,68,73,73,79,0,65,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | 52.19 units on a scale | Standard Deviation 29.21 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=62,0,58,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=68,0,67,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=70,0,68,0,71,74,75,78,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,65,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17 | 25.00 units on a scale | Standard Deviation 32.05 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=40,20,44,13,55,64,59,52,12,34,17) | 33.89 units on a scale | Standard Deviation 25.34 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=70,0,68,0,71,74,74,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=70,0,67,0,71,74,75,78,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=40,20,44,13,55,64,59,52,12,34,17) | 44.17 units on a scale | Standard Deviation 34.5 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=67,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.33 units on a scale | Standard Deviation 0.49 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=40,20,44,13,55,64,59,52,12,34,17) | 44.44 units on a scale | Standard Deviation 27.09 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=40,20,44,13,55,64,59,52,12,34,17) | 9.42 units on a scale | Standard Deviation 12.87 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=70,0,68,0,71,74,74,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=70,0,68,0,71,74,74,79,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=69,0,68,0,71,74,74,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: ASOB (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=40,20,44,13,54,64,59,52,12,34,17) | 35.00 units on a scale | Standard Deviation 28.44 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=40,20,44,13,55,64,59,52,12,34,17) | 47.27 units on a scale | Standard Deviation 27.08 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=40,20,44,13,55,64,59,52,12,34,17) | 7.43 units on a scale | Standard Deviation 1.09 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=40,20,44,13,54,64,59,52,12,34,17) | 27.06 units on a scale | Standard Deviation 32.62 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=70,0,68,0,71,74,74,79,0,69,0) | 38.86 units on a scale | Standard Deviation 19.24 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: ASOB (n=70,0,68,0,71,74,75,80,0,69,0) | 22.61 units on a scale | Standard Deviation 25.88 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=40,20,44,13,55,64,59,52,12,34,17) | 27.06 units on a scale | Standard Deviation 17.67 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=40,20,44,13,55,64,59,52,12,34,17) | 29.51 units on a scale | Standard Deviation 19.04 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=70,0,68,0,71,74,74,80,0,69,0) | 38.26 units on a scale | Standard Deviation 19.58 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=62,0,59,0,63,65,64,70,0,61,0) | 28.96 units on a scale | Standard Deviation 18.77 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=69,0,68,0,71,74,74,80,0,69,0) | 35.94 units on a scale | Standard Deviation 33.88 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=62,0,59,0,63,65,64,70,0,61,0) | 34.26 units on a scale | Standard Deviation 22.07 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=70,0,67,0,71,74,75,78,0,69,0) | 6.71 units on a scale | Standard Deviation 1.47 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=67,0,68,0,68,73,73,79,0,65,0) | 34.34 units on a scale | Standard Deviation 20.21 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=62,0,58,0,63,65,64,70,0,61,0) | 8.10 units on a scale | Standard Deviation 9.47 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=70,0,68,0,71,74,75,78,0,69,0) | 33.04 units on a scale | Standard Deviation 20.69 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=68,0,67,0,68,73,73,79,0,66,0) | 35.76 units on a scale | Standard Deviation 35.17 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=68,0,68,0,68,73,73,79,0,66,0) | 35.67 units on a scale | Standard Deviation 18.79 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | 30.82 units on a scale | Standard Deviation 31.53 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=70,0,68,0,71,74,75,80,0,69,0) | 0.52 units on a scale | Standard Deviation 0.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | 0.48 units on a scale | Standard Deviation 0.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=68,0,68,0,68,73,73,79,0,66,0) | 37.33 units on a scale | Standard Deviation 25.29 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=40,20,44,13,55,64,59,52,12,34,17) | 30.41 units on a scale | Standard Deviation 18.52 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | 35.41 units on a scale | Standard Deviation 26.22 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=62,0,59,0,63,65,64,70,0,61,0) | 34.50 units on a scale | Standard Deviation 20.96 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=68,0,68,0,68,73,73,79,0,66,0) | 54.24 units on a scale | Standard Deviation 29.87 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=62,0,59,0,63,65,64,70,0,61,0) | 54.59 units on a scale | Standard Deviation 27.72 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | 0.59 units on a scale | Standard Deviation 0.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | 20.98 units on a scale | Standard Deviation 28.85 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=70,0,68,0,71,74,74,80,0,69,0) | 51.45 units on a scale | Standard Deviation 28.45 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=68,0,68,0,68,73,73,79,0,66,0) | 7.08 units on a scale | Standard Deviation 1.53 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | 30.33 units on a scale | Standard Deviation 24 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=67,0,68,0,68,73,73,79,0,66,0) | 30.51 units on a scale | Standard Deviation 20.56 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.58 units on a scale | Standard Deviation 0.5 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=70,0,68,0,71,74,75,80,0,69,0) | 40.34 units on a scale | Standard Deviation 26.04 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17 | 13.53 units on a scale | Standard Deviation 15.35 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=40,20,44,13,55,64,59,52,12,34,17) | 57.65 units on a scale | Standard Deviation 27.64 |
| Placebo | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,65,0) | 17.88 units on a scale | Standard Deviation 23.57 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: ASOB (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Som (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SPS (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Qua (n=40,20,44,13,55,64,59,52,12,34,17) | 6.41 units on a scale | Standard Deviation 1.42 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SD (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Ade (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Ade (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: SPS (n=70,0,68,0,71,74,74,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SD (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Qua (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: ASOB (n=68,0,68,0,68,73,73,79,0,65,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Som (n=40,20,44,13,55,64,59,52,12,34,17) | 23.14 units on a scale | Standard Deviation 18.12 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Opt (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Sno (n=40,20,44,13,54,64,59,52,12,34,17) | 34.12 units on a scale | Standard Deviation 33.74 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: OSP (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: OSP (n=70,0,68,0,71,74,74,79,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: SPS (n=67,0,68,0,68,73,73,79,0,65,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Opt (n=70,0,68,0,71,74,75,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Sno (n=68,0,67,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Qua (n=62,0,58,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: OSP (n=68,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SPS (n=40,20,44,13,55,64,59,52,12,34,17) | 32.55 units on a scale | Standard Deviation 22.31 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Sno (n=61,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 2: Som (n=67,0,68,0,68,73,73,79,0,66,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: Opt (n=63,0,59,0,64,65,65,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Som (n=70,0,68,0,71,74,75,78,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: ASOB (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 12: SD (n=62,0,59,0,63,65,64,70,0,61,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Opt (n=40,20,44,13,55,64,60,53,12,36,17) | 0.41 units on a scale | Standard Deviation 0.51 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Ade (n=70,0,68,0,71,74,74,80,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: OSP (n=40,20,44,13,55,64,59,52,12,34,17) | 33.04 units on a scale | Standard Deviation 21.93 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: SD (n=40,20,44,13,55,64,59,52,12,34,17) | 36.40 units on a scale | Standard Deviation 27.29 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Qua (n=70,0,67,0,71,74,75,78,0,69,0) | NA units on a scale | — |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: Ade (n=40,20,44,13,55,64,59,52,12,34,17) | 55.29 units on a scale | Standard Deviation 33.56 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Week 24: ASOB (n=40,20,44,13,55,64,59,52,12,34,17 | 14.12 units on a scale | Standard Deviation 25.26 |
| Placebo to CP-690,550 5 mg (R) | Medical Outcome Study- Sleep Scale (MOS-SS) | Baseline: Sno (n=69,0,68,0,71,74,74,80,0,69,0) | NA units on a scale | — |
Secondary
Patient Assessment of Arthritis Pain
Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 24 (n=40,20,44,13,55,63,60,53,12,36,17) | 25.53 mm | Standard Deviation 21.05 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 38.97 mm | Standard Deviation 23.33 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 27.83 mm | Standard Deviation 18.65 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 45.57 mm | Standard Deviation 24.99 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 12 (n=64,0,59,0,64,65,66,70,0,61,0) | 35.92 mm | Standard Deviation 22.49 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 20 (n=39,21,43,13,57,65,59,55,12,37,17) | 29.28 mm | Standard Deviation 22.75 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | 38.74 mm | Standard Deviation 24.31 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Week 2 (n=68,0,67,0,68,73,73,79,0,66,0) | 49.53 mm | Standard Deviation 24.99 |
| CP-690,550 1 mg | Patient Assessment of Arthritis Pain | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | 59.96 mm | Standard Deviation 25.67 |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA mm | — |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 24 (n=40,20,44,13,55,63,60,53,12,36,17) | 38.15 mm | Standard Deviation 26.27 |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | NA mm | — |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 40.38 mm | Standard Deviation 21.81 |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 2 (n=68,0,67,0,68,73,73,79,0,66,0) | NA mm | — |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 20 (n=39,21,43,13,57,65,59,55,12,37,17) | 35.71 mm | Standard Deviation 22.42 |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 12 (n=64,0,59,0,64,65,66,70,0,61,0) | NA mm | — |
| CP-690,550 3 mg | Patient Assessment of Arthritis Pain | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | NA mm | — |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 24 (n=40,20,44,13,55,63,60,53,12,36,17) | 25.98 mm | Standard Deviation 20.61 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 2 (n=68,0,67,0,68,73,73,79,0,66,0) | 43.33 mm | Standard Deviation 23.26 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | 33.75 mm | Standard Deviation 25.06 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 29.67 mm | Standard Deviation 24.13 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 28.81 mm | Standard Deviation 23.86 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 12 (n=64,0,59,0,64,65,66,70,0,61,0) | 30.90 mm | Standard Deviation 24.44 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 37.83 mm | Standard Deviation 22.77 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | 55.05 mm | Standard Deviation 24.81 |
| CP-690,550 5 mg | Patient Assessment of Arthritis Pain | Week 20 (n=39,21,43,13,57,65,59,55,12,37,17) | 26.63 mm | Standard Deviation 23.48 |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA mm | — |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 12 (n=64,0,59,0,64,65,66,70,0,61,0) | NA mm | — |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 24 (n=40,20,44,13,55,63,60,53,12,36,17) | 35.62 mm | Standard Deviation 28.27 |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 20 (n=39,21,43,13,57,65,59,55,12,37,17) | 42.31 mm | Standard Deviation 28.61 |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | NA mm | — |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 2 (n=68,0,67,0,68,73,73,79,0,66,0) | NA mm | — |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 39.31 mm | Standard Deviation 24.13 |
| CP-690,550 10 mg | Patient Assessment of Arthritis Pain | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | NA mm | — |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 28.98 mm | Standard Deviation 22.15 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | 33.33 mm | Standard Deviation 24.18 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 20 (n=39,21,43,13,57,65,59,55,12,37,17) | 25.91 mm | Standard Deviation 23.1 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 12 (n=64,0,59,0,64,65,66,70,0,61,0) | 28.88 mm | Standard Deviation 22.8 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 36.55 mm | Standard Deviation 25 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 40.03 mm | Standard Deviation 24.25 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 2 (n=68,0,67,0,68,73,73,79,0,66,0) | 44.35 mm | Standard Deviation 24.31 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | 54.87 mm | Standard Deviation 26.68 |
| CP-690,550 15 mg | Patient Assessment of Arthritis Pain | Week 24 (n=40,20,44,13,55,63,60,53,12,36,17) | 24.45 mm | Standard Deviation 20.24 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | 34.38 mm | Standard Deviation 23.15 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 30.33 mm | Standard Deviation 22.04 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 24 (n=40,20,44,13,55,63,60,53,12,36,17) | 28.65 mm | Standard Deviation 21.11 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 39.34 mm | Standard Deviation 25.09 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 20 (n=39,21,43,13,57,65,59,55,12,37,17) | 33.66 mm | Standard Deviation 24.02 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 12 (n=64,0,59,0,64,65,66,70,0,61,0) | 33.78 mm | Standard Deviation 25.5 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 34.60 mm | Standard Deviation 24.04 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 2 (n=68,0,67,0,68,73,73,79,0,66,0) | 41.26 mm | Standard Deviation 22.18 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | 56.66 mm | Standard Deviation 25.42 |
| Placebo | Patient Assessment of Arthritis Pain | Week 20 (n=39,21,43,13,57,65,59,55,12,37,17) | 24.69 mm | Standard Deviation 20.98 |
| Placebo | Patient Assessment of Arthritis Pain | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | 32.97 mm | Standard Deviation 23.5 |
| Placebo | Patient Assessment of Arthritis Pain | Week 24 (n=40,20,44,13,55,63,60,53,12,36,17) | 24.47 mm | Standard Deviation 22.23 |
| Placebo | Patient Assessment of Arthritis Pain | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | 55.83 mm | Standard Deviation 22.85 |
| Placebo | Patient Assessment of Arthritis Pain | Week 2 (n=68,0,67,0,68,73,73,79,0,66,0) | 37.82 mm | Standard Deviation 22.17 |
| Placebo | Patient Assessment of Arthritis Pain | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 35.81 mm | Standard Deviation 23.88 |
| Placebo | Patient Assessment of Arthritis Pain | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 30.26 mm | Standard Deviation 22.2 |
| Placebo | Patient Assessment of Arthritis Pain | Week 12 (n=64,0,59,0,64,65,66,70,0,61,0) | 31.48 mm | Standard Deviation 24.86 |
| Placebo | Patient Assessment of Arthritis Pain | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 27.07 mm | Standard Deviation 20.76 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | 59.61 mm | Standard Deviation 23.61 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 34.39 mm | Standard Deviation 24.29 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 20 (n=39,21,43,13,57,65,59,55,12,37,17) | 24.58 mm | Standard Deviation 26.24 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 2 (n=68,0,67,0,68,73,73,79,0,66,0) | 40.57 mm | Standard Deviation 27.24 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 24.56 mm | Standard Deviation 23.46 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 31.16 mm | Standard Deviation 24.86 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 12 (n=64,0,59,0,64,65,66,70,0,61,0) | 31.09 mm | Standard Deviation 26.57 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 24 (n=40,20,44,13,55,63,60,53,12,36,17) | 19.92 mm | Standard Deviation 18.27 |
| CP-690,550 20 mg | Patient Assessment of Arthritis Pain | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | 33.65 mm | Standard Deviation 25.47 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 24 (n=40,20,44,13,55,63,60,53,12,36,17) | 35.33 mm | Standard Deviation 27.17 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 20 (n=39,21,43,13,57,65,59,55,12,37,17) | 43.92 mm | Standard Deviation 27.07 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 12 (n=64,0,59,0,64,65,66,70,0,61,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 51.25 mm | Standard Deviation 21.95 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 2 (n=68,0,67,0,68,73,73,79,0,66,0) | NA mm | — |
| Placebo | Patient Assessment of Arthritis Pain | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 41.34 mm | Standard Deviation 26.45 |
| Placebo | Patient Assessment of Arthritis Pain | Week 24 (n=40,20,44,13,55,63,60,53,12,36,17) | 27.14 mm | Standard Deviation 21.17 |
| Placebo | Patient Assessment of Arthritis Pain | Week 12 (n=64,0,59,0,64,65,66,70,0,61,0) | 41.02 mm | Standard Deviation 26.13 |
| Placebo | Patient Assessment of Arthritis Pain | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 42.02 mm | Standard Deviation 24.4 |
| Placebo | Patient Assessment of Arthritis Pain | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 30.08 mm | Standard Deviation 22.81 |
| Placebo | Patient Assessment of Arthritis Pain | Week 2 (n=68,0,67,0,68,73,73,79,0,66,0) | 46.91 mm | Standard Deviation 25.39 |
| Placebo | Patient Assessment of Arthritis Pain | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | 51.19 mm | Standard Deviation 27.72 |
| Placebo | Patient Assessment of Arthritis Pain | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | 42.21 mm | Standard Deviation 27.12 |
| Placebo | Patient Assessment of Arthritis Pain | Week 20 (n=39,21,43,13,57,65,59,55,12,37,17) | 25.08 mm | Standard Deviation 21.19 |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 20 (n=39,21,43,13,57,65,59,55,12,37,17) | 33.00 mm | Standard Deviation 27.7 |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Baseline (n=70,0,66,0,71,74,75,80,0,69,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 38.38 mm | Standard Deviation 24.52 |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 24 (n=40,20,44,13,55,63,60,53,12,36,17) | 33.65 mm | Standard Deviation 26.15 |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 2 (n=68,0,67,0,68,73,73,79,0,66,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Assessment of Arthritis Pain | Week 12 (n=64,0,59,0,64,65,66,70,0,61,0) | NA mm | — |
Secondary
Patient Global Assessment (PtGA) of Arthritis
Participants answered: Considering all the ways your arthritis affects you, how are you feeling today? Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | 62.47 mm | Standard Deviation 24.77 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 28.23 mm | Standard Deviation 21.42 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis | Week 12 (n=64,0,59,0,64,65,66,70,0,60,0) | 38.78 mm | Standard Deviation 22.91 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | 42.30 mm | Standard Deviation 22.34 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 47.87 mm | Standard Deviation 23.21 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 30.76 mm | Standard Deviation 20.4 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 53.19 mm | Standard Deviation 22.93 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 41.06 mm | Standard Deviation 21.76 |
| CP-690,550 1 mg | Patient Global Assessment (PtGA) of Arthritis | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | 29.85 mm | Standard Deviation 22.86 |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA mm | — |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 38.55 mm | Standard Deviation 27.08 |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | NA mm | — |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 38.29 mm | Standard Deviation 19.76 |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | 37.95 mm | Standard Deviation 23.62 |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis | Week 12 (n=64,0,59,0,64,65,66,70,0,60,0) | NA mm | — |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
| CP-690,550 3 mg | Patient Global Assessment (PtGA) of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | NA mm | — |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 39.78 mm | Standard Deviation 22.47 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | 28.16 mm | Standard Deviation 22.36 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 29.84 mm | Standard Deviation 24.12 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis | Week 12 (n=64,0,59,0,64,65,66,70,0,60,0) | 34.42 mm | Standard Deviation 25.15 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 30.11 mm | Standard Deviation 22.38 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 25.93 mm | Standard Deviation 22.22 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | 58.91 mm | Standard Deviation 22.94 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | 36.08 mm | Standard Deviation 23.56 |
| CP-690,550 5 mg | Patient Global Assessment (PtGA) of Arthritis | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 41.96 mm | Standard Deviation 23.12 |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | 42.08 mm | Standard Deviation 27.48 |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 38.23 mm | Standard Deviation 27.28 |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis | Week 12 (n=64,0,59,0,64,65,66,70,0,60,0) | NA mm | — |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 39.31 mm | Standard Deviation 27.48 |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA mm | — |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | NA mm | — |
| CP-690,550 10 mg | Patient Global Assessment (PtGA) of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | NA mm | — |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | 54.62 mm | Standard Deviation 23.71 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 30.62 mm | Standard Deviation 22.56 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 42.56 mm | Standard Deviation 22.89 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 38.94 mm | Standard Deviation 22.27 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | 33.01 mm | Standard Deviation 24.06 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 36.50 mm | Standard Deviation 25.29 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis | Week 12 (n=64,0,59,0,64,65,66,70,0,60,0) | 29.66 mm | Standard Deviation 21.69 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | 26.07 mm | Standard Deviation 22.75 |
| CP-690,550 15 mg | Patient Global Assessment (PtGA) of Arthritis | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 23.64 mm | Standard Deviation 21.82 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 42.32 mm | Standard Deviation 21.98 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 36.09 mm | Standard Deviation 24.38 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | 58.35 mm | Standard Deviation 23.14 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 38.53 mm | Standard Deviation 24.49 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | 35.41 mm | Standard Deviation 22.68 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | 35.00 mm | Standard Deviation 23.51 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 30.98 mm | Standard Deviation 22.06 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 29.66 mm | Standard Deviation 21.58 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 12 (n=64,0,59,0,64,65,66,70,0,60,0) | 35.05 mm | Standard Deviation 24.65 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 26.59 mm | Standard Deviation 20.19 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | 30.56 mm | Standard Deviation 21.87 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 30.61 mm | Standard Deviation 21.6 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 12 (n=64,0,59,0,64,65,66,70,0,60,0) | 32.53 mm | Standard Deviation 24.48 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 35.73 mm | Standard Deviation 21.46 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 34.76 mm | Standard Deviation 21.33 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | 24.90 mm | Standard Deviation 20.57 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | 56.09 mm | Standard Deviation 21.42 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 25.07 mm | Standard Deviation 23.2 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 24.76 mm | Standard Deviation 22.53 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | 57.24 mm | Standard Deviation 25.64 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 12 (n=64,0,59,0,64,65,66,70,0,60,0) | 30.76 mm | Standard Deviation 25.59 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 21.85 mm | Standard Deviation 18.07 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 31.85 mm | Standard Deviation 25.35 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | 34.86 mm | Standard Deviation 25.24 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 37.47 mm | Standard Deviation 25.17 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | 25.56 mm | Standard Deviation 23.2 |
| CP-690,550 20 mg | Patient Global Assessment (PtGA) of Arthritis | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 41.80 mm | Standard Deviation 26.25 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 34.83 mm | Standard Deviation 27.04 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | 44.42 mm | Standard Deviation 27.38 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 12 (n=64,0,59,0,64,65,66,70,0,60,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 50.67 mm | Standard Deviation 23.1 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | NA mm | — |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | 43.02 mm | Standard Deviation 25.14 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 41.21 mm | Standard Deviation 24.46 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 12 (n=64,0,59,0,64,65,66,70,0,60,0) | 39.85 mm | Standard Deviation 25.75 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 28.46 mm | Standard Deviation 22.69 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 28.25 mm | Standard Deviation 21.49 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | 26.22 mm | Standard Deviation 21.09 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | 51.88 mm | Standard Deviation 26.44 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 46.33 mm | Standard Deviation 25.02 |
| Placebo | Patient Global Assessment (PtGA) of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 40.64 mm | Standard Deviation 25.32 |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 20 (n=39,21,43,13,57,66,59,55,12,37,17) | 36.94 mm | Standard Deviation 27.13 |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 16 (n=42,21,45,13,58,66,61,54,12,37,16) | 37.63 mm | Standard Deviation 23.11 |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 34.59 mm | Standard Deviation 27.87 |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 12 (n=64,0,59,0,64,65,66,70,0,60,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Baseline (n=70,0,68,0,71,74,75,79,0,69,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,61,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Patient Global Assessment (PtGA) of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
Secondary
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response
ACR20 response: \>= 20% improvement in TJC; \>= 20% improvement in SJC; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Time frame: Week 2, 4, 6, 8, 16, 20, 24/Early Termination (ET)
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using BOCF. Here n is number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 44.29 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 59.2 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 21.43 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 63.3 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 50.00 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 59.2 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 37.14 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 54.41 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 36.76 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 65.5 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 45.59 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 67.3 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 54.41 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 60.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 57.7 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 54.93 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 57.75 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 59.2 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 53.5 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 30.99 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 46.48 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 56.76 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 31.08 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 45.95 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 55.41 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 64.9 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 62.2 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 66.2 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 64.00 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 62.7 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 61.3 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 54.67 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 65.3 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 40.00 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 56.00 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 33.75 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 56.25 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 51.25 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 50.00 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 64.2 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 62.7 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 64.2 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 15.94 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 33.33 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 43.1 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 37.68 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 47.1 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 47.1 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 24.64 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
Secondary
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response
ACR50 response: \>= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Time frame: Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using BOCF. Here n is number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 10.00 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 4.29 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 1.43 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 17.14 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | 22.86 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 38.8 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 38.8 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 44.9 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | 29.41 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 32.35 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 16.18 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 45.5 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 43.6 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 29.41 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 5.88 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 34.5 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 30.99 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 38.0 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 11.27 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 5.63 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 32.39 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 39.4 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | 36.62 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 38.0 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 4.05 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | 28.38 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 27.03 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 39.2 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 40.5 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 36.5 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 28.38 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 20.27 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 41.33 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 48.0 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 32.00 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 17.33 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 40.0 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | 44.00 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 26.67 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 46.7 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 15.00 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 25.00 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 27.50 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 32.50 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 46.3 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | 36.25 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 41.8 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 47.8 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 21.6 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 31.4 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | 17.39 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 17.39 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 31.4 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 8.70 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 2.90 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 2.90 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
Secondary
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
ACR70 response: \>= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.
Time frame: Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Missing values were imputed using BOCF. Here n is number of participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 1.43 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 20.4 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 2.86 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 28.6 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 1.43 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | 4.29 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 16.3 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 8.57 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 29.1 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 13.24 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 23.6 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 14.71 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 1.47 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | 20.59 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 21.8 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 7.35 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 1.41 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 16.90 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | 18.31 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 18.3 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 0.00 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 23.9 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 11.27 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 21.1 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 24.3 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 1.35 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 14.86 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 16.22 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 9.46 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 18.9 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | 12.16 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 18.9 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 16.00 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 32.0 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | 24.00 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 16.00 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 13.33 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 28.0 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 24.0 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 6.67 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 2.50 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 28.4 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 12.50 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 17.50 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 22.4 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 28.4 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | 23.75 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 12.50 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | 1.45 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | 0.00 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | 4.35 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | 5.80 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | 5.80 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 9.8 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 13.7 percentage of participants |
| Placebo | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 9.8 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 16 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 12 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 8 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 6 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 4 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 2 (n=70,0,68,0,71,74,75,80,0,69,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 24 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response | Week 20 (n=49,21,55,13,71,74,75,67,13,51,18) | 0.0 percentage of participants |
Secondary
Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP)
Disease improvement was classified as good, moderate, and none based on improvement in DAS 28-3 (CRP) from baseline and present DAS 28-3 (CRP) score. Good: an improvement from baseline of \>1.2 and a present score of \<=3.2; none: an improvement of \<=0.6 or \>0.6 to \<=1.2 with a present score of \>5.1; remaining participants were classified as having moderate (Mod) improvement. Scores of good and moderate were considered to have therapeutic response.
Time frame: Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Good (n=42,21,43,13,54,64,58,55,9,37,16) | 40.5 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Mod (n=63,0,61,0,66,67,66,69,0,58,0) | 50.8 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Mod (n=42,21,43,13,54,64,58,55,9,37,16) | 50.0 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Mod (n=39,20,42,13,53,63,56,52,12,36,17) | 46.2 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Mod (n=65,0,61,0,62,64,65,70,0,61,0) | 41.5 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: None (n=65,0,61,0,62,64,65,70,0,61,0) | 47.7 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Mod (n=63,0,59,0,62,62,67,67,0,58,0) | 46.0 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Good (n=63,0,59,0,62,62,67,67,0,58,0) | 19.0 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Good (n=39,20,42,13,53,63,56,52,12,36,17) | 43.6 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: None (n=61,0,55,0,60,63,62,65,0,60,0) | 27.9 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Mod (n=64,0,63,0,63,69,68,74,0,61,0) | 23.4 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Good (n=65,0,61,0,62,64,65,70,0,61,0) | 10.8 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: None (n=64,0,63,0,63,69,68,74,0,61,0) | 71.9 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Mod (n=39,21,44,13,57,63,57,55,12,36,17) | 43.6 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: None (n=39,21,44,13,57,63,57,55,12,36,17) | 10.3 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Mod (n=61,0,55,0,60,63,62,65,0,60,0) | 49.2 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: None (n=63,0,61,0,66,67,66,69,0,58,0) | 38.1 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Good (n=39,21,44,13,57,63,57,55,12,36,17) | 46.2 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: None (n=42,21,43,13,54,64,58,55,9,37,16) | 9.5 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Good (n=61,0,55,0,60,63,62,65,0,60,0) | 23.0 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Good (n=64,0,63,0,63,69,68,74,0,61,0) | 4.7 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: None (n=39,20,42,13,53,63,56,52,12,36,17) | 10.3 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Good (n=63,0,61,0,66,67,66,69,0,58,0) | 11.1 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: None (n=63,0,59,0,62,62,67,67,0,58,0) | 34.9 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: None (n=63,0,59,0,62,62,67,67,0,58,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Mod (n=63,0,59,0,62,62,67,67,0,58,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Good (n=61,0,55,0,60,63,62,65,0,60,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Good (n=63,0,59,0,62,62,67,67,0,58,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: None (n=42,21,43,13,54,64,58,55,9,37,16) | 42.9 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Good (n=39,20,42,13,53,63,56,52,12,36,17) | 35.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: None (n=39,21,44,13,57,63,57,55,12,36,17) | 28.6 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Mod (n=42,21,43,13,54,64,58,55,9,37,16) | 38.1 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: None (n=65,0,61,0,62,64,65,70,0,61,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Mod (n=39,20,42,13,53,63,56,52,12,36,17) | 35.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Good (n=63,0,61,0,66,67,66,69,0,58,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Good (n=42,21,43,13,54,64,58,55,9,37,16) | 19.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Good (n=64,0,63,0,63,69,68,74,0,61,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Good (n=65,0,61,0,62,64,65,70,0,61,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Mod (n=63,0,61,0,66,67,66,69,0,58,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Mod (n=65,0,61,0,62,64,65,70,0,61,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: None (n=64,0,63,0,63,69,68,74,0,61,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: None (n=39,20,42,13,53,63,56,52,12,36,17) | 30.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: None (n=61,0,55,0,60,63,62,65,0,60,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Mod (n=39,21,44,13,57,63,57,55,12,36,17) | 28.6 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Mod (n=61,0,55,0,60,63,62,65,0,60,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: None (n=63,0,61,0,66,67,66,69,0,58,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Mod (n=64,0,63,0,63,69,68,74,0,61,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Good (n=39,21,44,13,57,63,57,55,12,36,17) | 42.9 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Mod (n=39,20,42,13,53,63,56,52,12,36,17) | 33.3 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: None (n=39,21,44,13,57,63,57,55,12,36,17) | 9.1 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: None (n=64,0,63,0,63,69,68,74,0,61,0) | 50.8 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Good (n=39,20,42,13,53,63,56,52,12,36,17) | 54.8 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Good (n=65,0,61,0,62,64,65,70,0,61,0) | 21.3 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Mod (n=65,0,61,0,62,64,65,70,0,61,0) | 45.9 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Mod (n=39,21,44,13,57,63,57,55,12,36,17) | 31.8 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Good (n=39,21,44,13,57,63,57,55,12,36,17) | 59.1 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Mod (n=64,0,63,0,63,69,68,74,0,61,0) | 44.4 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: None (n=42,21,43,13,54,64,58,55,9,37,16) | 11.6 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Good (n=63,0,59,0,62,62,67,67,0,58,0) | 30.5 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Good (n=61,0,55,0,60,63,62,65,0,60,0) | 45.5 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: None (n=63,0,59,0,62,62,67,67,0,58,0) | 22.0 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Mod (n=63,0,59,0,62,62,67,67,0,58,0) | 47.5 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: None (n=63,0,61,0,66,67,66,69,0,58,0) | 27.9 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Mod (n=61,0,55,0,60,63,62,65,0,60,0) | 32.7 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Good (n=64,0,63,0,63,69,68,74,0,61,0) | 4.8 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Mod (n=63,0,61,0,66,67,66,69,0,58,0) | 42.6 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: None (n=61,0,55,0,60,63,62,65,0,60,0) | 21.8 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Good (n=63,0,61,0,66,67,66,69,0,58,0) | 29.5 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Good (n=42,21,43,13,54,64,58,55,9,37,16) | 55.8 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: None (n=65,0,61,0,62,64,65,70,0,61,0) | 32.8 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Mod (n=42,21,43,13,54,64,58,55,9,37,16) | 32.6 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: None (n=39,20,42,13,53,63,56,52,12,36,17) | 11.9 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: None (n=63,0,61,0,66,67,66,69,0,58,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: None (n=64,0,63,0,63,69,68,74,0,61,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Good (n=39,20,42,13,53,63,56,52,12,36,17) | 23.1 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: None (n=63,0,59,0,62,62,67,67,0,58,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Mod (n=42,21,43,13,54,64,58,55,9,37,16) | 23.1 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: None (n=65,0,61,0,62,64,65,70,0,61,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Good (n=61,0,55,0,60,63,62,65,0,60,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: None (n=42,21,43,13,54,64,58,55,9,37,16) | 46.2 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Mod (n=39,20,42,13,53,63,56,52,12,36,17) | 38.5 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Good (n=63,0,59,0,62,62,67,67,0,58,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Mod (n=61,0,55,0,60,63,62,65,0,60,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Mod (n=64,0,63,0,63,69,68,74,0,61,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Mod (n=63,0,59,0,62,62,67,67,0,58,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Mod (n=63,0,61,0,66,67,66,69,0,58,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: None (n=39,21,44,13,57,63,57,55,12,36,17) | 38.5 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Good (n=63,0,61,0,66,67,66,69,0,58,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: None (n=39,20,42,13,53,63,56,52,12,36,17) | 38.5 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: None (n=61,0,55,0,60,63,62,65,0,60,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Mod (n=65,0,61,0,62,64,65,70,0,61,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Good (n=65,0,61,0,62,64,65,70,0,61,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Good (n=39,21,44,13,57,63,57,55,12,36,17) | 15.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Mod (n=39,21,44,13,57,63,57,55,12,36,17) | 46.2 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Good (n=42,21,43,13,54,64,58,55,9,37,16) | 30.8 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Good (n=64,0,63,0,63,69,68,74,0,61,0) | NA percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Mod (n=39,21,44,13,57,63,57,55,12,36,17) | 28.1 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Good (n=63,0,61,0,66,67,66,69,0,58,0) | 31.8 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Mod (n=63,0,59,0,62,62,67,67,0,58,0) | 46.8 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Good (n=39,20,42,13,53,63,56,52,12,36,17) | 52.8 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: None (n=39,21,44,13,57,63,57,55,12,36,17) | 10.5 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Mod (n=63,0,61,0,66,67,66,69,0,58,0) | 42.4 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Good (n=64,0,63,0,63,69,68,74,0,61,0) | 9.5 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Mod (n=42,21,43,13,54,64,58,55,9,37,16) | 37.0 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: None (n=65,0,61,0,62,64,65,70,0,61,0) | 35.5 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Good (n=65,0,61,0,62,64,65,70,0,61,0) | 16.1 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Good (n=61,0,55,0,60,63,62,65,0,60,0) | 33.3 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Mod (n=39,20,42,13,53,63,56,52,12,36,17) | 37.7 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Good (n=39,21,44,13,57,63,57,55,12,36,17) | 61.4 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Mod (n=65,0,61,0,62,64,65,70,0,61,0) | 48.4 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: None (n=64,0,63,0,63,69,68,74,0,61,0) | 47.6 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Good (n=42,21,43,13,54,64,58,55,9,37,16) | 51.9 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Good (n=63,0,59,0,62,62,67,67,0,58,0) | 37.1 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: None (n=39,20,42,13,53,63,56,52,12,36,17) | 9.4 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Mod (n=64,0,63,0,63,69,68,74,0,61,0) | 42.9 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: None (n=61,0,55,0,60,63,62,65,0,60,0) | 16.7 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: None (n=42,21,43,13,54,64,58,55,9,37,16) | 11.1 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: None (n=63,0,59,0,62,62,67,67,0,58,0) | 16.1 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: None (n=63,0,61,0,66,67,66,69,0,58,0) | 25.8 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Mod (n=61,0,55,0,60,63,62,65,0,60,0) | 50.0 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Good (n=63,0,61,0,66,67,66,69,0,58,0) | 29.9 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Mod (n=63,0,59,0,62,62,67,67,0,58,0) | 45.2 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: None (n=39,21,44,13,57,63,57,55,12,36,17) | 11.1 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: None (n=63,0,59,0,62,62,67,67,0,58,0) | 22.6 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Good (n=64,0,63,0,63,69,68,74,0,61,0) | 13.0 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: None (n=63,0,61,0,66,67,66,69,0,58,0) | 19.4 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: None (n=39,20,42,13,53,63,56,52,12,36,17) | 11.1 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: None (n=65,0,61,0,62,64,65,70,0,61,0) | 18.8 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Mod (n=61,0,55,0,60,63,62,65,0,60,0) | 39.7 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Good (n=39,21,44,13,57,63,57,55,12,36,17) | 52.4 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Mod (n=63,0,61,0,66,67,66,69,0,58,0) | 50.7 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Mod (n=65,0,61,0,62,64,65,70,0,61,0) | 53.1 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: None (n=61,0,55,0,60,63,62,65,0,60,0) | 19.0 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: None (n=64,0,63,0,63,69,68,74,0,61,0) | 40.6 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Good (n=42,21,43,13,54,64,58,55,9,37,16) | 50.0 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Mod (n=39,20,42,13,53,63,56,52,12,36,17) | 30.2 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Good (n=39,20,42,13,53,63,56,52,12,36,17) | 58.7 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Mod (n=39,21,44,13,57,63,57,55,12,36,17) | 36.5 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Mod (n=42,21,43,13,54,64,58,55,9,37,16) | 34.4 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Good (n=65,0,61,0,62,64,65,70,0,61,0) | 28.1 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Good (n=61,0,55,0,60,63,62,65,0,60,0) | 41.3 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Good (n=63,0,59,0,62,62,67,67,0,58,0) | 32.3 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: None (n=42,21,43,13,54,64,58,55,9,37,16) | 15.6 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Mod (n=64,0,63,0,63,69,68,74,0,61,0) | 46.4 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: None (n=42,21,43,13,54,64,58,55,9,37,16) | 8.6 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Good (n=64,0,63,0,63,69,68,74,0,61,0) | 16.2 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Mod (n=64,0,63,0,63,69,68,74,0,61,0) | 50.0 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: None (n=64,0,63,0,63,69,68,74,0,61,0) | 33.8 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Good (n=65,0,61,0,62,64,65,70,0,61,0) | 30.8 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Mod (n=65,0,61,0,62,64,65,70,0,61,0) | 49.2 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: None (n=65,0,61,0,62,64,65,70,0,61,0) | 20.0 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Good (n=63,0,61,0,66,67,66,69,0,58,0) | 31.8 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Mod (n=63,0,61,0,66,67,66,69,0,58,0) | 50.0 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Good (n=63,0,59,0,62,62,67,67,0,58,0) | 43.3 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Mod (n=63,0,59,0,62,62,67,67,0,58,0) | 47.8 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: None (n=63,0,59,0,62,62,67,67,0,58,0) | 9.0 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Good (n=61,0,55,0,60,63,62,65,0,60,0) | 51.6 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Mod (n=61,0,55,0,60,63,62,65,0,60,0) | 37.1 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: None (n=61,0,55,0,60,63,62,65,0,60,0) | 11.3 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Good (n=42,21,43,13,54,64,58,55,9,37,16) | 48.3 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Good (n=39,21,44,13,57,63,57,55,12,36,17) | 57.9 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: None (n=39,21,44,13,57,63,57,55,12,36,17) | 7.0 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Good (n=39,20,42,13,53,63,56,52,12,36,17) | 66.1 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Mod (n=39,20,42,13,53,63,56,52,12,36,17) | 23.2 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: None (n=39,20,42,13,53,63,56,52,12,36,17) | 10.7 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: None (n=63,0,61,0,66,67,66,69,0,58,0) | 18.2 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Mod (n=42,21,43,13,54,64,58,55,9,37,16) | 43.1 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Mod (n=39,21,44,13,57,63,57,55,12,36,17) | 35.1 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Good (n=39,20,42,13,53,63,56,52,12,36,17) | 59.6 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Good (n=42,21,43,13,54,64,58,55,9,37,16) | 52.7 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: None (n=63,0,59,0,62,62,67,67,0,58,0) | 22.4 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: None (n=39,20,42,13,53,63,56,52,12,36,17) | 5.8 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Good (n=63,0,59,0,62,62,67,67,0,58,0) | 37.3 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: None (n=63,0,61,0,66,67,66,69,0,58,0) | 31.9 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Mod (n=64,0,63,0,63,69,68,74,0,61,0) | 41.9 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: None (n=61,0,55,0,60,63,62,65,0,60,0) | 18.5 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Good (n=64,0,63,0,63,69,68,74,0,61,0) | 12.2 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Good (n=61,0,55,0,60,63,62,65,0,60,0) | 36.9 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: None (n=39,21,44,13,57,63,57,55,12,36,17) | 7.3 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Mod (n=61,0,55,0,60,63,62,65,0,60,0) | 44.6 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: None (n=64,0,63,0,63,69,68,74,0,61,0) | 44.6 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Good (n=39,21,44,13,57,63,57,55,12,36,17) | 52.7 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Mod (n=39,21,44,13,57,63,57,55,12,36,17) | 40.0 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Mod (n=65,0,61,0,62,64,65,70,0,61,0) | 42.9 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: None (n=42,21,43,13,54,64,58,55,9,37,16) | 3.6 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: None (n=65,0,61,0,62,64,65,70,0,61,0) | 34.3 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Good (n=65,0,61,0,62,64,65,70,0,61,0) | 21.4 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Good (n=63,0,61,0,66,67,66,69,0,58,0) | 23.2 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Mod (n=63,0,61,0,66,67,66,69,0,58,0) | 44.9 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Mod (n=42,21,43,13,54,64,58,55,9,37,16) | 43.6 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Mod (n=63,0,59,0,62,62,67,67,0,58,0) | 40.3 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Mod (n=39,20,42,13,53,63,56,52,12,36,17) | 34.6 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Good (n=39,20,42,13,53,63,56,52,12,36,17) | 25.0 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Mod (n=39,21,44,13,57,63,57,55,12,36,17) | 58.3 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Good (n=39,21,44,13,57,63,57,55,12,36,17) | 0.0 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: None (n=42,21,43,13,54,64,58,55,9,37,16) | 55.6 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: None (n=39,20,42,13,53,63,56,52,12,36,17) | 41.7 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: None (n=64,0,63,0,63,69,68,74,0,61,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Good (n=65,0,61,0,62,64,65,70,0,61,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Good (n=42,21,43,13,54,64,58,55,9,37,16) | 11.1 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: None (n=65,0,61,0,62,64,65,70,0,61,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Good (n=63,0,61,0,66,67,66,69,0,58,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: None (n=61,0,55,0,60,63,62,65,0,60,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Mod (n=61,0,55,0,60,63,62,65,0,60,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Good (n=61,0,55,0,60,63,62,65,0,60,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Mod (n=63,0,59,0,62,62,67,67,0,58,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: None (n=63,0,59,0,62,62,67,67,0,58,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Good (n=63,0,59,0,62,62,67,67,0,58,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: None (n=63,0,61,0,66,67,66,69,0,58,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Good (n=64,0,63,0,63,69,68,74,0,61,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Mod (n=42,21,43,13,54,64,58,55,9,37,16) | 33.3 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Mod (n=63,0,61,0,66,67,66,69,0,58,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Mod (n=65,0,61,0,62,64,65,70,0,61,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: None (n=39,21,44,13,57,63,57,55,12,36,17) | 41.7 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Mod (n=39,20,42,13,53,63,56,52,12,36,17) | 33.3 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Mod (n=64,0,63,0,63,69,68,74,0,61,0) | NA percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Good (n=42,21,43,13,54,64,58,55,9,37,16) | 27.0 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: None (n=42,21,43,13,54,64,58,55,9,37,16) | 32.4 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Good (n=63,0,59,0,62,62,67,67,0,58,0) | 13.8 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Mod (n=64,0,63,0,63,69,68,74,0,61,0) | 23.0 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: None (n=63,0,61,0,66,67,66,69,0,58,0) | 44.8 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: None (n=39,20,42,13,53,63,56,52,12,36,17) | 25.0 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: None (n=61,0,55,0,60,63,62,65,0,60,0) | 46.7 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Mod (n=39,20,42,13,53,63,56,52,12,36,17) | 41.7 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Mod (n=42,21,43,13,54,64,58,55,9,37,16) | 40.5 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Mod (n=63,0,61,0,66,67,66,69,0,58,0) | 43.1 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Good (n=65,0,61,0,62,64,65,70,0,61,0) | 8.2 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: None (n=65,0,61,0,62,64,65,70,0,61,0) | 57.4 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Good (n=39,21,44,13,57,63,57,55,12,36,17) | 30.6 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Mod (n=65,0,61,0,62,64,65,70,0,61,0) | 34.4 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Good (n=64,0,63,0,63,69,68,74,0,61,0) | 3.3 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: None (n=64,0,63,0,63,69,68,74,0,61,0) | 73.8 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Mod (n=39,21,44,13,57,63,57,55,12,36,17) | 36.1 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: None (n=39,21,44,13,57,63,57,55,12,36,17) | 33.3 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Good (n=61,0,55,0,60,63,62,65,0,60,0) | 16.7 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Good (n=39,20,42,13,53,63,56,52,12,36,17) | 33.3 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Mod (n=61,0,55,0,60,63,62,65,0,60,0) | 36.7 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: None (n=63,0,59,0,62,62,67,67,0,58,0) | 39.7 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Good (n=63,0,61,0,66,67,66,69,0,58,0) | 12.1 percentage of participants |
| Placebo | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Mod (n=63,0,59,0,62,62,67,67,0,58,0) | 46.6 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Good (n=61,0,55,0,60,63,62,65,0,60,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Mod (n=63,0,59,0,62,62,67,67,0,58,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: Good (n=63,0,59,0,62,62,67,67,0,58,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Good (n=39,21,44,13,57,63,57,55,12,36,17) | 29.4 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: Mod (n=61,0,55,0,60,63,62,65,0,60,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: Mod (n=39,21,44,13,57,63,57,55,12,36,17) | 47.1 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: None (n=63,0,61,0,66,67,66,69,0,58,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: None (n=64,0,63,0,63,69,68,74,0,61,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Good (n=63,0,61,0,66,67,66,69,0,58,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Good (n=39,20,42,13,53,63,56,52,12,36,17) | 23.5 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: None (n=39,20,42,13,53,63,56,52,12,36,17) | 29.4 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Good (n=42,21,43,13,54,64,58,55,9,37,16) | 18.8 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Mod (n=64,0,63,0,63,69,68,74,0,61,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 8: None (n=63,0,59,0,62,62,67,67,0,58,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 6: Mod (n=63,0,61,0,66,67,66,69,0,58,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 12: None (n=61,0,55,0,60,63,62,65,0,60,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 20: None (n=39,21,44,13,57,63,57,55,12,36,17) | 23.5 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Good (n=65,0,61,0,62,64,65,70,0,61,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: None (n=42,21,43,13,54,64,58,55,9,37,16) | 18.8 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 2: Good (n=64,0,63,0,63,69,68,74,0,61,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: None (n=65,0,61,0,62,64,65,70,0,61,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 24: Mod (n=39,20,42,13,53,63,56,52,12,36,17) | 47.1 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 16: Mod (n=42,21,43,13,54,64,58,55,9,37,16) | 62.5 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP) | Week 4: Mod (n=65,0,61,0,62,64,65,70,0,61,0) | NA percentage of participants |
Secondary
Percentage of Participants With Disease Remission Based on DAS28-3 (CRP)
DAS28-3 (CRP) defined remission was classified as a score of \<2.6.
Time frame: Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=65,0,61,0,62,63,65,70,0,61,0) | 4.62 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=63,0,61,0,66,66,66,69,0,58,0) | 3.17 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 23.1 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=64,0,63,0,63,68,68,74,0,61,0) | 1.56 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=63,0,59,0,62,61,67,67,0,58,0) | 7.94 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=42,21,43,13,54,63,58,55,9,37,16) | 14.3 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=61,0,55,0,60,62,62,65,0,60,0) | 6.56 percentage of participants |
| CP-690,550 1 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=39,21,44,13,57,62,57,55,12,36,17) | 20.5 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=61,0,55,0,60,62,62,65,0,60,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 25.0 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=64,0,63,0,63,68,68,74,0,61,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=63,0,61,0,66,66,66,69,0,58,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=39,21,44,13,57,62,57,55,12,36,17) | 28.6 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=42,21,43,13,54,63,58,55,9,37,16) | 9.5 percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=63,0,59,0,62,61,67,67,0,58,0) | NA percentage of participants |
| CP-690,550 3 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=65,0,61,0,62,63,65,70,0,61,0) | NA percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=64,0,63,0,63,68,68,74,0,61,0) | 3.17 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=39,21,44,13,57,62,57,55,12,36,17) | 43.2 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=63,0,59,0,62,61,67,67,0,58,0) | 22.03 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=65,0,61,0,62,63,65,70,0,61,0) | 14.75 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=42,21,43,13,54,63,58,55,9,37,16) | 41.9 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=61,0,55,0,60,62,62,65,0,60,0) | 30.91 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=63,0,61,0,66,66,66,69,0,58,0) | 19.67 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 35.7 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 15.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=63,0,59,0,62,61,67,67,0,58,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=63,0,61,0,66,66,66,69,0,58,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=65,0,61,0,62,63,65,70,0,61,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=64,0,63,0,63,68,68,74,0,61,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=39,21,44,13,57,62,57,55,12,36,17) | 15.4 percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=61,0,55,0,60,62,62,65,0,60,0) | NA percentage of participants |
| CP-690,550 10 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=42,21,43,13,54,63,58,55,9,37,16) | 23.1 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=63,0,59,0,62,61,67,67,0,58,0) | 19.35 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=64,0,63,0,63,68,68,74,0,61,0) | 1.59 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=42,21,43,13,54,63,58,55,9,37,16) | 24.1 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 41.5 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=63,0,61,0,66,66,66,69,0,58,0) | 13.64 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=61,0,55,0,60,62,62,65,0,60,0) | 16.67 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=65,0,61,0,62,63,65,70,0,61,0) | 8.06 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=39,21,44,13,57,62,57,55,12,36,17) | 35.1 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=64,0,63,0,63,68,68,74,0,61,0) | 4.41 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=39,21,44,13,57,62,57,55,12,36,17) | 37.1 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=63,0,61,0,66,66,66,69,0,58,0) | 24.24 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=63,0,59,0,62,61,67,67,0,58,0) | 21.31 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=61,0,55,0,60,62,62,65,0,60,0) | 32.26 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=42,21,43,13,54,63,58,55,9,37,16) | 30.2 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 36.5 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=65,0,61,0,62,63,65,70,0,61,0) | 19.05 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=42,21,43,13,54,63,58,55,9,37,16) | 37.9 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=63,0,59,0,62,61,67,67,0,58,0) | 23.88 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=63,0,61,0,66,66,66,69,0,58,0) | 22.73 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=65,0,61,0,62,63,65,70,0,61,0) | 16.92 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 39.3 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=39,21,44,13,57,62,57,55,12,36,17) | 38.6 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=61,0,55,0,60,62,62,65,0,60,0) | 37.10 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=64,0,63,0,63,68,68,74,0,61,0) | 13.24 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=42,21,43,13,54,63,58,55,9,37,16) | 29.1 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=39,21,44,13,57,62,57,55,12,36,17) | 30.9 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=61,0,55,0,60,62,62,65,0,60,0) | 24.62 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=63,0,59,0,62,61,67,67,0,58,0) | 20.90 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=63,0,61,0,66,66,66,69,0,58,0) | 10.14 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 32.7 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=65,0,61,0,62,63,65,70,0,61,0) | 10.00 percentage of participants |
| CP-690,550 20 mg | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=64,0,63,0,63,68,68,74,0,61,0) | 4.05 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=42,21,43,13,54,63,58,55,9,37,16) | 11.1 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=63,0,61,0,66,66,66,69,0,58,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=63,0,59,0,62,61,67,67,0,58,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=61,0,55,0,60,62,62,65,0,60,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=64,0,63,0,63,68,68,74,0,61,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=65,0,61,0,62,63,65,70,0,61,0) | NA percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=39,21,44,13,57,62,57,55,12,36,17) | 0.0 percentage of participants |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 16.7 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=42,21,43,13,54,63,58,55,9,37,16) | 8.1 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=65,0,61,0,62,63,65,70,0,61,0) | 3.28 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=63,0,61,0,66,66,66,69,0,58,0) | 3.45 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=63,0,59,0,62,61,67,67,0,58,0) | 6.90 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=61,0,55,0,60,62,62,65,0,60,0) | 6.67 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=39,21,44,13,57,62,57,55,12,36,17) | 13.9 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 19.4 percentage of participants |
| Placebo | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=64,0,63,0,63,68,68,74,0,61,0) | 3.28 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 2 (n=64,0,63,0,63,68,68,74,0,61,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 24 (n=39,20,42,13,53,63,56,52,12,36,17) | 17.6 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 20 (n=39,21,44,13,57,62,57,55,12,36,17) | 17.6 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 16 (n=42,21,43,13,54,63,58,55,9,37,16) | 12.5 percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 12 (n=61,0,55,0,60,62,62,65,0,60,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 8 (n=63,0,59,0,62,61,67,67,0,58,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 6 (n=63,0,61,0,66,66,66,69,0,58,0) | NA percentage of participants |
| Placebo to CP-690,550 5 mg (R) | Percentage of Participants With Disease Remission Based on DAS28-3 (CRP) | Week 4 (n=65,0,61,0,62,63,65,70,0,61,0) | NA percentage of participants |
Secondary
Physician Global Assessment of Arthritis
Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Physician Global Assessment of Arthritis | Week 12 (n=63,0,59,0,64,66,65,70,0,61,0) | 33.65 mm | Standard Deviation 20.06 |
| CP-690,550 1 mg | Physician Global Assessment of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 37.38 mm | Standard Deviation 17.11 |
| CP-690,550 1 mg | Physician Global Assessment of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 35.71 mm | Standard Deviation 21.03 |
| CP-690,550 1 mg | Physician Global Assessment of Arthritis | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | 23.95 mm | Standard Deviation 16.25 |
| CP-690,550 1 mg | Physician Global Assessment of Arthritis | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | 49.49 mm | Standard Deviation 21.64 |
| CP-690,550 1 mg | Physician Global Assessment of Arthritis | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 20.44 mm | Standard Deviation 18.1 |
| CP-690,550 1 mg | Physician Global Assessment of Arthritis | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | 41.69 mm | Standard Deviation 21.31 |
| CP-690,550 1 mg | Physician Global Assessment of Arthritis | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 62.66 mm | Standard Deviation 16 |
| CP-690,550 1 mg | Physician Global Assessment of Arthritis | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | 18.90 mm | Standard Deviation 16.51 |
| CP-690,550 3 mg | Physician Global Assessment of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA mm | — |
| CP-690,550 3 mg | Physician Global Assessment of Arthritis | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | 44.19 mm | Standard Deviation 24.68 |
| CP-690,550 3 mg | Physician Global Assessment of Arthritis | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA mm | — |
| CP-690,550 3 mg | Physician Global Assessment of Arthritis | Week 12 (n=63,0,59,0,64,66,65,70,0,61,0) | NA mm | — |
| CP-690,550 3 mg | Physician Global Assessment of Arthritis | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA mm | — |
| CP-690,550 3 mg | Physician Global Assessment of Arthritis | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | 36.53 mm | Standard Deviation 21.17 |
| CP-690,550 3 mg | Physician Global Assessment of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
| CP-690,550 3 mg | Physician Global Assessment of Arthritis | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
| CP-690,550 3 mg | Physician Global Assessment of Arthritis | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 34.29 mm | Standard Deviation 16.64 |
| CP-690,550 5 mg | Physician Global Assessment of Arthritis | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 20.91 mm | Standard Deviation 18.21 |
| CP-690,550 5 mg | Physician Global Assessment of Arthritis | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 57.50 mm | Standard Deviation 18.47 |
| CP-690,550 5 mg | Physician Global Assessment of Arthritis | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | 41.07 mm | Standard Deviation 19.88 |
| CP-690,550 5 mg | Physician Global Assessment of Arthritis | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | 36.92 mm | Standard Deviation 21.2 |
| CP-690,550 5 mg | Physician Global Assessment of Arthritis | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | 20.26 mm | Standard Deviation 18.12 |
| CP-690,550 5 mg | Physician Global Assessment of Arthritis | Week 12 (n=63,0,59,0,64,66,65,70,0,61,0) | 26.17 mm | Standard Deviation 21.33 |
| CP-690,550 5 mg | Physician Global Assessment of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 26.60 mm | Standard Deviation 20.34 |
| CP-690,550 5 mg | Physician Global Assessment of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 31.51 mm | Standard Deviation 21.25 |
| CP-690,550 5 mg | Physician Global Assessment of Arthritis | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | 19.77 mm | Standard Deviation 19.74 |
| CP-690,550 10 mg | Physician Global Assessment of Arthritis | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | 33.31 mm | Standard Deviation 22.97 |
| CP-690,550 10 mg | Physician Global Assessment of Arthritis | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | 32.54 mm | Standard Deviation 24.26 |
| CP-690,550 10 mg | Physician Global Assessment of Arthritis | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA mm | — |
| CP-690,550 10 mg | Physician Global Assessment of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
| CP-690,550 10 mg | Physician Global Assessment of Arthritis | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
| CP-690,550 10 mg | Physician Global Assessment of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA mm | — |
| CP-690,550 10 mg | Physician Global Assessment of Arthritis | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 32.92 mm | Standard Deviation 25.15 |
| CP-690,550 10 mg | Physician Global Assessment of Arthritis | Week 12 (n=63,0,59,0,64,66,65,70,0,61,0) | NA mm | — |
| CP-690,550 10 mg | Physician Global Assessment of Arthritis | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA mm | — |
| CP-690,550 15 mg | Physician Global Assessment of Arthritis | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | 34.73 mm | Standard Deviation 17.4 |
| CP-690,550 15 mg | Physician Global Assessment of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 27.26 mm | Standard Deviation 19.97 |
| CP-690,550 15 mg | Physician Global Assessment of Arthritis | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | 23.67 mm | Standard Deviation 21.04 |
| CP-690,550 15 mg | Physician Global Assessment of Arthritis | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | 16.91 mm | Standard Deviation 14.67 |
| CP-690,550 15 mg | Physician Global Assessment of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 27.78 mm | Standard Deviation 18.4 |
| CP-690,550 15 mg | Physician Global Assessment of Arthritis | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | 42.29 mm | Standard Deviation 20.12 |
| CP-690,550 15 mg | Physician Global Assessment of Arthritis | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 56.51 mm | Standard Deviation 19 |
| CP-690,550 15 mg | Physician Global Assessment of Arthritis | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 20.65 mm | Standard Deviation 18.68 |
| CP-690,550 15 mg | Physician Global Assessment of Arthritis | Week 12 (n=63,0,59,0,64,66,65,70,0,61,0) | 24.77 mm | Standard Deviation 18.8 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | 21.25 mm | Standard Deviation 17.79 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | 42.85 mm | Standard Deviation 19.42 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | 33.56 mm | Standard Deviation 19.77 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 30.82 mm | Standard Deviation 19.95 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 28.01 mm | Standard Deviation 19.9 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 60.77 mm | Standard Deviation 16.75 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 12 (n=63,0,59,0,64,66,65,70,0,61,0) | 26.47 mm | Standard Deviation 19.69 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | 23.00 mm | Standard Deviation 18.6 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 24.05 mm | Standard Deviation 18.32 |
| Placebo | Physician Global Assessment of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 23.06 mm | Standard Deviation 17.18 |
| Placebo | Physician Global Assessment of Arthritis | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | 14.68 mm | Standard Deviation 13.07 |
| Placebo | Physician Global Assessment of Arthritis | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 60.51 mm | Standard Deviation 14.26 |
| Placebo | Physician Global Assessment of Arthritis | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | 19.31 mm | Standard Deviation 15.8 |
| Placebo | Physician Global Assessment of Arthritis | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | 35.99 mm | Standard Deviation 15.97 |
| Placebo | Physician Global Assessment of Arthritis | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 16.19 mm | Standard Deviation 12.41 |
| Placebo | Physician Global Assessment of Arthritis | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | 33.35 mm | Standard Deviation 19.24 |
| Placebo | Physician Global Assessment of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 27.08 mm | Standard Deviation 17.28 |
| Placebo | Physician Global Assessment of Arthritis | Week 12 (n=63,0,59,0,64,66,65,70,0,61,0) | 23.28 mm | Standard Deviation 17.89 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | 32.96 mm | Standard Deviation 22.38 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | 41.92 mm | Standard Deviation 22.3 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | 18.60 mm | Standard Deviation 15 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 27.70 mm | Standard Deviation 21.09 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 32.65 mm | Standard Deviation 23.41 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 12 (n=63,0,59,0,64,66,65,70,0,61,0) | 28.93 mm | Standard Deviation 23.44 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 58.75 mm | Standard Deviation 17.9 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 18.84 mm | Standard Deviation 18.42 |
| CP-690,550 20 mg | Physician Global Assessment of Arthritis | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | 14.49 mm | Standard Deviation 11.75 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | 48.42 mm | Standard Deviation 30 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 44.67 mm | Standard Deviation 25.31 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | 41.00 mm | Standard Deviation 31.58 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA mm | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 12 (n=63,0,59,0,64,66,65,70,0,61,0) | NA mm | — |
| Placebo | Physician Global Assessment of Arthritis | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | 20.67 mm | Standard Deviation 15.81 |
| Placebo | Physician Global Assessment of Arthritis | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | 26.22 mm | Standard Deviation 18.43 |
| Placebo | Physician Global Assessment of Arthritis | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 21.95 mm | Standard Deviation 18.03 |
| Placebo | Physician Global Assessment of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 37.85 mm | Standard Deviation 21.03 |
| Placebo | Physician Global Assessment of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 34.66 mm | Standard Deviation 21.39 |
| Placebo | Physician Global Assessment of Arthritis | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | 40.23 mm | Standard Deviation 19.43 |
| Placebo | Physician Global Assessment of Arthritis | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | 49.05 mm | Standard Deviation 18 |
| Placebo | Physician Global Assessment of Arthritis | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 58.30 mm | Standard Deviation 15.25 |
| Placebo | Physician Global Assessment of Arthritis | Week 12 (n=63,0,59,0,64,66,65,70,0,61,0) | 35.70 mm | Standard Deviation 24.86 |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 16 (n=42,21,44,13,58,66,61,55,12,37,16) | 27.44 mm | Standard Deviation 16.36 |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 12 (n=63,0,59,0,64,66,65,70,0,61,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 4 (n=68,0,65,0,67,70,72,75,0,66,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 24 (n=40,19,43,13,55,64,60,53,11,36,17) | 32.18 mm | Standard Deviation 19.03 |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA mm | — |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 33.94 mm | Standard Deviation 22.43 |
| Placebo to CP-690,550 5 mg (R) | Physician Global Assessment of Arthritis | Week 2 (n=67,0,68,0,68,73,73,79,0,66,0) | NA mm | — |
Secondary
Swollen Joints Count (SJC)
Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Swollen Joints Count (SJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | 8.31 swollen joints | Standard Deviation 8.41 |
| CP-690,550 1 mg | Swollen Joints Count (SJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 12.62 swollen joints | Standard Deviation 7.81 |
| CP-690,550 1 mg | Swollen Joints Count (SJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 9.85 swollen joints | Standard Deviation 7.74 |
| CP-690,550 1 mg | Swollen Joints Count (SJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 8.20 swollen joints | Standard Deviation 7.84 |
| CP-690,550 1 mg | Swollen Joints Count (SJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 4.95 swollen joints | Standard Deviation 7.82 |
| CP-690,550 1 mg | Swollen Joints Count (SJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 8.77 swollen joints | Standard Deviation 6.34 |
| CP-690,550 1 mg | Swollen Joints Count (SJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 16.51 swollen joints | Standard Deviation 8.24 |
| CP-690,550 1 mg | Swollen Joints Count (SJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 5.83 swollen joints | Standard Deviation 7.43 |
| CP-690,550 1 mg | Swollen Joints Count (SJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 4.10 swollen joints | Standard Deviation 4.83 |
| CP-690,550 3 mg | Swollen Joints Count (SJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA swollen joints | — |
| CP-690,550 3 mg | Swollen Joints Count (SJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 8.65 swollen joints | Standard Deviation 8.77 |
| CP-690,550 3 mg | Swollen Joints Count (SJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA swollen joints | — |
| CP-690,550 3 mg | Swollen Joints Count (SJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA swollen joints | — |
| CP-690,550 3 mg | Swollen Joints Count (SJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA swollen joints | — |
| CP-690,550 3 mg | Swollen Joints Count (SJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA swollen joints | — |
| CP-690,550 3 mg | Swollen Joints Count (SJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 8.90 swollen joints | Standard Deviation 7.55 |
| CP-690,550 3 mg | Swollen Joints Count (SJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA swollen joints | — |
| CP-690,550 3 mg | Swollen Joints Count (SJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 7.33 swollen joints | Standard Deviation 8.75 |
| CP-690,550 5 mg | Swollen Joints Count (SJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 6.63 swollen joints | Standard Deviation 7.63 |
| CP-690,550 5 mg | Swollen Joints Count (SJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 3.36 swollen joints | Standard Deviation 5.19 |
| CP-690,550 5 mg | Swollen Joints Count (SJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 3.49 swollen joints | Standard Deviation 3.78 |
| CP-690,550 5 mg | Swollen Joints Count (SJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 3.73 swollen joints | Standard Deviation 5.35 |
| CP-690,550 5 mg | Swollen Joints Count (SJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | 5.36 swollen joints | Standard Deviation 6.64 |
| CP-690,550 5 mg | Swollen Joints Count (SJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 15.68 swollen joints | Standard Deviation 8.56 |
| CP-690,550 5 mg | Swollen Joints Count (SJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 10.97 swollen joints | Standard Deviation 9.02 |
| CP-690,550 5 mg | Swollen Joints Count (SJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 8.58 swollen joints | Standard Deviation 8.2 |
| CP-690,550 5 mg | Swollen Joints Count (SJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 7.23 swollen joints | Standard Deviation 7.28 |
| CP-690,550 10 mg | Swollen Joints Count (SJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 10.00 swollen joints | Standard Deviation 10.51 |
| CP-690,550 10 mg | Swollen Joints Count (SJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA swollen joints | — |
| CP-690,550 10 mg | Swollen Joints Count (SJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA swollen joints | — |
| CP-690,550 10 mg | Swollen Joints Count (SJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA swollen joints | — |
| CP-690,550 10 mg | Swollen Joints Count (SJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA swollen joints | — |
| CP-690,550 10 mg | Swollen Joints Count (SJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 8.54 swollen joints | Standard Deviation 9.85 |
| CP-690,550 10 mg | Swollen Joints Count (SJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA swollen joints | — |
| CP-690,550 10 mg | Swollen Joints Count (SJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA swollen joints | — |
| CP-690,550 10 mg | Swollen Joints Count (SJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 7.00 swollen joints | Standard Deviation 7.14 |
| CP-690,550 15 mg | Swollen Joints Count (SJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 6.22 swollen joints | Standard Deviation 6 |
| CP-690,550 15 mg | Swollen Joints Count (SJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 5.35 swollen joints | Standard Deviation 5.03 |
| CP-690,550 15 mg | Swollen Joints Count (SJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 3.95 swollen joints | Standard Deviation 5.8 |
| CP-690,550 15 mg | Swollen Joints Count (SJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 3.84 swollen joints | Standard Deviation 4.4 |
| CP-690,550 15 mg | Swollen Joints Count (SJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | 6.13 swollen joints | Standard Deviation 6.82 |
| CP-690,550 15 mg | Swollen Joints Count (SJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 8.01 swollen joints | Standard Deviation 7.45 |
| CP-690,550 15 mg | Swollen Joints Count (SJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 3.71 swollen joints | Standard Deviation 4.33 |
| CP-690,550 15 mg | Swollen Joints Count (SJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 14.06 swollen joints | Standard Deviation 7.44 |
| CP-690,550 15 mg | Swollen Joints Count (SJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 9.51 swollen joints | Standard Deviation 6.3 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 4.21 swollen joints | Standard Deviation 5.59 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 14.74 swollen joints | Standard Deviation 7.46 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 4.41 swollen joints | Standard Deviation 6.86 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 7.53 swollen joints | Standard Deviation 6.98 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 10.14 swollen joints | Standard Deviation 7.92 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 7.10 swollen joints | Standard Deviation 7.62 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 6.78 swollen joints | Standard Deviation 7.43 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | 5.50 swollen joints | Standard Deviation 5.84 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 4.74 swollen joints | Standard Deviation 5.64 |
| Placebo | Swollen Joints Count (SJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 3.03 swollen joints | Standard Deviation 3.75 |
| Placebo | Swollen Joints Count (SJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | 4.85 swollen joints | Standard Deviation 6.04 |
| Placebo | Swollen Joints Count (SJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 10.07 swollen joints | Standard Deviation 7.29 |
| Placebo | Swollen Joints Count (SJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 7.85 swollen joints | Standard Deviation 6.7 |
| Placebo | Swollen Joints Count (SJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 4.26 swollen joints | Standard Deviation 5.4 |
| Placebo | Swollen Joints Count (SJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 6.60 swollen joints | Standard Deviation 6.31 |
| Placebo | Swollen Joints Count (SJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 3.27 swollen joints | Standard Deviation 4.02 |
| Placebo | Swollen Joints Count (SJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 15.33 swollen joints | Standard Deviation 7.02 |
| Placebo | Swollen Joints Count (SJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 6.01 swollen joints | Standard Deviation 6.22 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 3.58 swollen joints | Standard Deviation 3.54 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 7.66 swollen joints | Standard Deviation 7.43 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 15.21 swollen joints | Standard Deviation 8.04 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 2.89 swollen joints | Standard Deviation 2.97 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | 6.80 swollen joints | Standard Deviation 8.87 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 7.22 swollen joints | Standard Deviation 8.6 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 10.14 swollen joints | Standard Deviation 6.26 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 8.61 swollen joints | Standard Deviation 7.16 |
| CP-690,550 20 mg | Swollen Joints Count (SJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 3.31 swollen joints | Standard Deviation 4.19 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA swollen joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA swollen joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA swollen joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA swollen joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 11.25 swollen joints | Standard Deviation 9.81 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA swollen joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 14.50 swollen joints | Standard Deviation 12.99 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA swollen joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 12.25 swollen joints | Standard Deviation 8.25 |
| Placebo | Swollen Joints Count (SJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 8.16 swollen joints | Standard Deviation 8.02 |
| Placebo | Swollen Joints Count (SJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 11.11 swollen joints | Standard Deviation 8.58 |
| Placebo | Swollen Joints Count (SJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 15.72 swollen joints | Standard Deviation 8.83 |
| Placebo | Swollen Joints Count (SJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 10.39 swollen joints | Standard Deviation 9.24 |
| Placebo | Swollen Joints Count (SJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 4.11 swollen joints | Standard Deviation 3.9 |
| Placebo | Swollen Joints Count (SJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | 8.79 swollen joints | Standard Deviation 9.1 |
| Placebo | Swollen Joints Count (SJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 5.00 swollen joints | Standard Deviation 6.65 |
| Placebo | Swollen Joints Count (SJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 5.97 swollen joints | Standard Deviation 5.98 |
| Placebo | Swollen Joints Count (SJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 13.41 swollen joints | Standard Deviation 9.47 |
| Placebo to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 7.94 swollen joints | Standard Deviation 8.9 |
| Placebo to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 8.63 swollen joints | Standard Deviation 7.7 |
| Placebo to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 7.41 swollen joints | Standard Deviation 9.27 |
| Placebo to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA swollen joints | — |
| Placebo to CP-690,550 5 mg (R) | Swollen Joints Count (SJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA swollen joints | — |
Secondary
Tender Joints Count (TJC)
Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.
Time frame: Baseline, Week 2, 4, 6, 8, 12, 16, 20, 24/ET
Population: FAS included all randomized participants who received at least 1 dose of study treatment. Here N (number of participants analyzed) signifies participants evaluable for this measure and n signifies participants evaluable at specific time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 1 mg | Tender Joints Count (TJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 15.01 tender joints | Standard Deviation 11.19 |
| CP-690,550 1 mg | Tender Joints Count (TJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | 12.84 tender joints | Standard Deviation 12.79 |
| CP-690,550 1 mg | Tender Joints Count (TJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 8.08 tender joints | Standard Deviation 11.06 |
| CP-690,550 1 mg | Tender Joints Count (TJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 23.64 tender joints | Standard Deviation 11.6 |
| CP-690,550 1 mg | Tender Joints Count (TJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 8.07 tender joints | Standard Deviation 9.11 |
| CP-690,550 1 mg | Tender Joints Count (TJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 18.62 tender joints | Standard Deviation 12.09 |
| CP-690,550 1 mg | Tender Joints Count (TJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 7.45 tender joints | Standard Deviation 10.88 |
| CP-690,550 1 mg | Tender Joints Count (TJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 14.48 tender joints | Standard Deviation 12.18 |
| CP-690,550 1 mg | Tender Joints Count (TJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 14.24 tender joints | Standard Deviation 12.5 |
| CP-690,550 3 mg | Tender Joints Count (TJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 13.76 tender joints | Standard Deviation 12.02 |
| CP-690,550 3 mg | Tender Joints Count (TJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA tender joints | — |
| CP-690,550 3 mg | Tender Joints Count (TJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 14.80 tender joints | Standard Deviation 14.09 |
| CP-690,550 3 mg | Tender Joints Count (TJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA tender joints | — |
| CP-690,550 3 mg | Tender Joints Count (TJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA tender joints | — |
| CP-690,550 3 mg | Tender Joints Count (TJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA tender joints | — |
| CP-690,550 3 mg | Tender Joints Count (TJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA tender joints | — |
| CP-690,550 3 mg | Tender Joints Count (TJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA tender joints | — |
| CP-690,550 3 mg | Tender Joints Count (TJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 19.33 tender joints | Standard Deviation 15.7 |
| CP-690,550 5 mg | Tender Joints Count (TJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 22.79 tender joints | Standard Deviation 10.57 |
| CP-690,550 5 mg | Tender Joints Count (TJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 10.18 tender joints | Standard Deviation 10.3 |
| CP-690,550 5 mg | Tender Joints Count (TJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 11.12 tender joints | Standard Deviation 9.56 |
| CP-690,550 5 mg | Tender Joints Count (TJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 17.71 tender joints | Standard Deviation 11.87 |
| CP-690,550 5 mg | Tender Joints Count (TJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | 8.83 tender joints | Standard Deviation 9.61 |
| CP-690,550 5 mg | Tender Joints Count (TJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 6.02 tender joints | Standard Deviation 7.97 |
| CP-690,550 5 mg | Tender Joints Count (TJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 5.32 tender joints | Standard Deviation 6.35 |
| CP-690,550 5 mg | Tender Joints Count (TJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 12.80 tender joints | Standard Deviation 10.36 |
| CP-690,550 5 mg | Tender Joints Count (TJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 5.52 tender joints | Standard Deviation 5.65 |
| CP-690,550 10 mg | Tender Joints Count (TJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA tender joints | — |
| CP-690,550 10 mg | Tender Joints Count (TJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 15.00 tender joints | Standard Deviation 11.47 |
| CP-690,550 10 mg | Tender Joints Count (TJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 19.15 tender joints | Standard Deviation 16.42 |
| CP-690,550 10 mg | Tender Joints Count (TJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA tender joints | — |
| CP-690,550 10 mg | Tender Joints Count (TJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA tender joints | — |
| CP-690,550 10 mg | Tender Joints Count (TJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA tender joints | — |
| CP-690,550 10 mg | Tender Joints Count (TJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA tender joints | — |
| CP-690,550 10 mg | Tender Joints Count (TJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA tender joints | — |
| CP-690,550 10 mg | Tender Joints Count (TJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 13.92 tender joints | Standard Deviation 9.93 |
| CP-690,550 15 mg | Tender Joints Count (TJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 13.06 tender joints | Standard Deviation 11.59 |
| CP-690,550 15 mg | Tender Joints Count (TJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | 10.09 tender joints | Standard Deviation 11.65 |
| CP-690,550 15 mg | Tender Joints Count (TJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 21.46 tender joints | Standard Deviation 12.95 |
| CP-690,550 15 mg | Tender Joints Count (TJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 8.64 tender joints | Standard Deviation 12.25 |
| CP-690,550 15 mg | Tender Joints Count (TJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 7.16 tender joints | Standard Deviation 9.91 |
| CP-690,550 15 mg | Tender Joints Count (TJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 9.82 tender joints | Standard Deviation 11.08 |
| CP-690,550 15 mg | Tender Joints Count (TJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 6.85 tender joints | Standard Deviation 9.51 |
| CP-690,550 15 mg | Tender Joints Count (TJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 10.23 tender joints | Standard Deviation 10.44 |
| CP-690,550 15 mg | Tender Joints Count (TJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 15.56 tender joints | Standard Deviation 10.44 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 9.77 tender joints | Standard Deviation 12.49 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 24.84 tender joints | Standard Deviation 12.51 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 14.01 tender joints | Standard Deviation 14.73 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 13.55 tender joints | Standard Deviation 14.38 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 17.34 tender joints | Standard Deviation 12.13 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 12.22 tender joints | Standard Deviation 13.75 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | 10.88 tender joints | Standard Deviation 12.79 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 8.27 tender joints | Standard Deviation 11.32 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 8.20 tender joints | Standard Deviation 9.94 |
| Placebo | Tender Joints Count (TJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 8.39 tender joints | Standard Deviation 11.32 |
| Placebo | Tender Joints Count (TJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 6.37 tender joints | Standard Deviation 8.72 |
| Placebo | Tender Joints Count (TJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 23.68 tender joints | Standard Deviation 12.71 |
| Placebo | Tender Joints Count (TJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 11.51 tender joints | Standard Deviation 12.67 |
| Placebo | Tender Joints Count (TJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 13.00 tender joints | Standard Deviation 12.48 |
| Placebo | Tender Joints Count (TJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 16.32 tender joints | Standard Deviation 13.18 |
| Placebo | Tender Joints Count (TJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 9.49 tender joints | Standard Deviation 11.71 |
| Placebo | Tender Joints Count (TJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | 10.18 tender joints | Standard Deviation 12.65 |
| Placebo | Tender Joints Count (TJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 6.98 tender joints | Standard Deviation 9.96 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 11.15 tender joints | Standard Deviation 13.76 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 7.07 tender joints | Standard Deviation 8.86 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 6.51 tender joints | Standard Deviation 10.55 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 15.33 tender joints | Standard Deviation 12.59 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | 11.27 tender joints | Standard Deviation 13.68 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 5.87 tender joints | Standard Deviation 7.68 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 13.22 tender joints | Standard Deviation 13.25 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 23.11 tender joints | Standard Deviation 12.67 |
| CP-690,550 20 mg | Tender Joints Count (TJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 13.75 tender joints | Standard Deviation 13.08 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA tender joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA tender joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 21.67 tender joints | Standard Deviation 13.69 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA tender joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA tender joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 26.25 tender joints | Standard Deviation 19.07 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 23.00 tender joints | Standard Deviation 16.59 |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA tender joints | — |
| CP-690,550 20 mg to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA tender joints | — |
| Placebo | Tender Joints Count (TJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | 13.57 tender joints | Standard Deviation 14.16 |
| Placebo | Tender Joints Count (TJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 5.33 tender joints | Standard Deviation 5.74 |
| Placebo | Tender Joints Count (TJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | 21.59 tender joints | Standard Deviation 13.18 |
| Placebo | Tender Joints Count (TJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 7.62 tender joints | Standard Deviation 7.26 |
| Placebo | Tender Joints Count (TJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | 13.77 tender joints | Standard Deviation 14.84 |
| Placebo | Tender Joints Count (TJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | 16.17 tender joints | Standard Deviation 12.36 |
| Placebo | Tender Joints Count (TJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | 18.86 tender joints | Standard Deviation 13 |
| Placebo | Tender Joints Count (TJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | 14.74 tender joints | Standard Deviation 13.86 |
| Placebo | Tender Joints Count (TJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 8.51 tender joints | Standard Deviation 7.25 |
| Placebo to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 2 (n=68,0,68,0,68,73,73,79,0,66,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 4 (n=68,0,65,0,67,70,72,76,0,66,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Baseline (n=70,0,68,0,71,74,75,80,0,69,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 12 (n=64,0,59,0,64,66,66,70,0,61,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 8 (n=66,0,62,0,66,67,70,73,0,61,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 24 (n=40,20,44,13,55,64,60,53,12,36,17) | 15.88 tender joints | Standard Deviation 17.46 |
| Placebo to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 20 (n=39,21,44,13,57,66,59,55,12,37,17) | 15.24 tender joints | Standard Deviation 17.68 |
| Placebo to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 6 (n=66,0,65,0,69,71,72,74,0,62,0) | NA tender joints | — |
| Placebo to CP-690,550 5 mg (R) | Tender Joints Count (TJC) | Week 16 (n=42,21,45,13,58,66,61,55,12,37,16) | 15.56 tender joints | Standard Deviation 18.52 |